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ABSTRACT 
The preparation of two compounds designed to mimic the 
active site of Isopenicillin N Synthase (IPNS) is 
presented. Both compounds consist of two fragments from 
the enzyme linked by a lipophilic unit. 	The first 
contains a short linker unit namely 11-aminoundecanoic 
acid and the second contains a longer linker consisting of 
three of these units. 	The compounds were prepared by 
solid phase peptide synthesis and purified using a 
combination of gel permeation chromatography and Phenyl 
Sepharose hydrophobic interaction chromatography. 
These compounds have been examined in a two phase 
system of n-octane and aqueous buffer, containing the IPNS 
cofactors and tripeptide substrate. The postulated mimic 
would involve the lipophilic linker unit residing in the 
organic phase, thus holding the two peptides in close 
proximity in the aqueous phase. It was hoped that the 
addition of the Fe2+ cofactor might promote the adoption 
of a structure resembling that of the enzyme active site. 
Cyclisation of the penicillin precursors ACV and PCV has 
not been observed under the conditions investigated, 
however, the compound containing the short linker has been 
observed to bind iron. 
Work on immunological studies on IPNS fragments has 
resulted in the preparation of anti-sera to the N-terminal 
peptide IPNS(1-21). 	These anti-sera have been shown to 
bind to the peptides IPNS(1-21) and Cys-IPNS(1-21) in an 
ELISA test and have also been used to detect the native 
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ABBREVIATIONS 
7-ACA 7-aminocephalosporanic acid 
AcOH acetic acid 
LLD-ACV 6 -  (L-a-aminoadipyl) -L-cysteinyl-D-valine 
6-APA 6-arninopenicillanic acid 
Aua 11-aminoundecanoic acid 
B. Bacillus 
Bnpeoc 2, 2-bis(4 '-nitrophenyl)ethoxycarbonyl 
Boc tert-butyloxycarbonyl 




CD circular dichroisin 
CM carboxymethyl 
COSY correlation spectroscopy 
DAC deacetylcephalosporin C 
DAOC deacetoxycephalosporin C 
DBU 1, 8-diazabicyclo[5.4. O]undec-7-ene 
DCCC droplet counter current chromatography 
DCCI 1, 3-dicyclohexylcarbodiimide 
DCM dichioromethane 
DCV 2-[3-(3-trifluoromethyl-3H-diazirin-3-yl) 





DMA N, N-diinethylacetamide 
DMAP 4-dimethylaminopyridine 
DMF N, N-dixnethyl formainide 
DTE dithioerythritol 
DTT dithiothreitol 
ee enantiorneric excess 
ELISA enzyme-linked iinmunosorbent assay 
Enz. enzyme 
EPR electron paramagnetic resonance 
FAB fast atom bombardment 
Fmoc 9-fluorenylmethoxycarbonyl 
FTIR Fourier Transform infrared 
}IIC hydrophobic interaction chromatography 
HOBt l-hydroxybenzotriazole 
I-IPLC high performance liquid chromatography 
HRNS high resolution mass spectrometry 
IC 50 concentration producing 50% inhibition 
IgG inununoglobulin G 
IPNS Isopenicillin N Synthase 
IR infrared 
Mbh 4, 4-dixnethoxybenzhydryl 
MeOH methanol 
MOPS 4-inorpholinepropane sulphonic acid 
M.P. melting point 
N.D. not determined 
NNN N-methylmorpholine 
NNP N-methylpyrrol idinone 
n.m.r. nuclear magnetic resonance 
NOESY nuclear Overhauser enhancement spectroscopy 
0D450 optical density at 450 nm 
ONp p-nitrophenol ester 
PCV phenylacetyl-L-cysteinyl-D-val me 
Pen.G penicillin G 
Pen.V penicillin V 
Pmc 2,2,5,7, 8-pentamethylchroman-6-sulphonyl 
PVDF polyvinylidene difluoride 
R resin support 
ROESY rotating frame nuclear Overhauser enhancement 
spectroscopy 
r.t. room temperature 




sPPS solid phase peptide synthesis 
TBS tris-buffered saline 
TFA trifluoroacetic acid 
TFE trifluoroethanol 
TI-IF tetrahydrofuran 
Tris tris (hydroxyinethyl) aminomethane 
t.l.c. thin-layer chromatography 
TMS tetramethylsilane 
TOCSY total correlation spectroscopy 
trityl triphenylinethyl 
UV ultraviolet 
CHAPTER 1 : INIRODUCTION 
1.1 	BETA-LACTAM ANTIBIOTICS 
1. 1. 1 Introduction 
More than sixty years after the discovery of 
penicillin, Fleming's prediction remains applicable: "... 
we are not at the end of the penicillin story. Perhaps we 
are only just at the beginning" .1  
In 1929 Fleming2 observed the inhibition of bacterial 
growth by a contaminating mould (Penicillium notatum). 
The antibiotic (penicillin) was successfully isolated and 
characterised some ten years later by Florey and Chain3. 
Research into the large scale production and the 
chemistry of penicillins was stimulated by the Allied 
Forces' need for anti-infective agents in the Second World 
War. As a result it was established that the penicillins 
are a family of closely related natural products 
possessing in common the fused 3-lactam-thiazo1idine ring 
system (1). 
RCONH H H 
(1) 	H C 02H 
R = 	 Isopenicillin N 
R = 
	 Penicillin N 
R = C 6H 5CH 2 	benzylpenicillin (Pen. G) 
R = C 6H 5OCH 2 phenoxyxnethylpenicillin (Pen. V) 
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During the late 1950's the first of a iew class of 
3-lactain antibiotics, the cephalosporins (2), was isolated 
from a 	 species4. 	Cephalosporin C (2c) was 
shown to be related to the penicillins both structurally 
and biosynthetically. 
R1CONH H H 
NW 	R 
(2) 	C 02 
R 1 	 R 2 = H 	Deacetoxycephalosporin C 
R 1 R 2 = OH Deacetylcephalosporin C 
R 	 R 2 = OCOCH 3 	Cephalosporin C 
In 1959 the penicillin "nucleus", 6-aminopenicillanic 
acid (6-APA) (3) was isolated5 and found to be a versatile 
intermediate for the construction of a virtually limitless 
range of semisynthetic penicillins. 
NH H H 
CH 
(3) H CH 
2 
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A third class of j3-lactani antibiotics the cephamycins 
(4) produced by certain actinoinycetes, was discovered in 
19716. 




a) R 1 = CO,H R2 - OCOCH 3 	7-Methoxycephalosporin C 
1.1.2 Mode of Action 
3-Lactam antibiotics inhibit bacterial growth by 
selectively blocking the last step in bacterial cell wall 
biosynthesis7. 	This step is the cross linking of the 
peptidoglycan strands catalysed by glycopeptide 
transpeptidase. The amino group of the terminal glycine 
of one strand attacks the peptide bond between two D-
alanine residues of the other. A peptide bond is thus 
formed between the glycine and one of the D-alanine 
residues, the second D-alanine residue is released. The 
antibiotic acts by irreversibly binding to the 
peptidoglycan transpeptidase. 	Penicillin is extremely 
effective due to its close resemblance to acyl-D-Ala-D-Ala 
(5), the enzyme's natural substrate. The high reactivity 
of the j-lactam ring facilitates the formation of a 
covalent bond between a serine residue in the enzyme 
3 
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D-Ala-D-Ala 	 Penicillin 
1.1.3 Resistance 
Bacteria initially susceptible to j3-lactam antibiotics 
can suddenly or progressively develop resistance to them. 
The most significant factor in this resistance is the 
production of -lactaxnases, which catalyse the hydrolysis 
of the fi-lactam ring. 	Thus a continual supply of new 
3-lactam antibiotics is required. 
1.1.4 Antibiotic Production 
'Directed Biosynthesis' 
It was discovered in the late 1940's that unnatural 
penicillins could be prepared by the addition of the 
corresponding side-chain carboxylic acid to the 
fermentation medium. This method is however limited to 
Tnonosubstjtuted derivatives of acetic acid (aliphatic or 





The observation that 6-APA could be chemically 
acylated with phenylacetyl chloride to yield benzyl-
penicillin (ic) led to the synthesis of many new 
penicillins from 6-APA and acid chlorides. However direct 
production of 6-APA by fermentation is low yielding and 
the isolation is difficult. 6-APA is now readily produced 
on an industrial scale by chemical or enzymatic removal of 
the side-chain of benzyl or phenoxymethylpenicillin (ld). 
In cephalosporin semisynthesis the absence of an 
acylase capable of cleaving the aminoadipyl side-chain 
necessitates the use of chemical methods for the 
production of 7-aminocephalosporanic acid (7-ACA) from 
cephalosporin C. 
Total Synthesis 
The total synthesis of penicillin V (id) was achieved 
in 1959 by Sheehan and Henery-Logan8, and that of 
cephalosporin C (2c) in 1965 by Woodward9'10. These very 
elegant syntheses, however, compete poorly with 
fermentation methods as commercial routes to these 
antibiotics. 
Modified Biosynthesis 
In recent years research has turned towards the 
modification of the biosynthetic pathway. The development 
of the cell-free system allows the incorporation of 
unnatural substrates, whilst the application of cloning 
techniques can provide substantial amounts of the required 
enzymes. The use of site-directed mutagenesis offers the 
possibility of modifying the amino acid sequence within 
the binding site of the enzyme. By possible alteration of 
the substrate specificity in this manner the cell-free 
production of "unnatural" penicillins and cephalosporins 




1.2 	THE BIOSYNTHESIS OF PENICILLINS AND CEPHALOSPORINS 
Biosynthetic studies on penicillin began in the 1940's 
with early work demonstrating that both the penam and 
cepham nuclei are derived from the amino acids cysteine 
and valine. 	In 1960 the tripeptide -(L-a-aminoadipyl)- 
L-cysteinyl-D-valine (LLD-ACV) was isolated from P. 
chrysogenum by Arnstein and Morris11 and proposed to be 
the precursor of the penicillins ("tripeptide" theory). 
c_ S 
It was later identified as a metabolite of,cxcremonium. 
Work was however hampered by the inability to transport 
substrates into intact cells. 	Studies were directed 
towards determining which atoms of the amino acids were 
incorporated into the antibiotics and the stereocheinical 
fate of the various chiral and prochiral centres involved. 
In the late 1970's a cell-free system obtained by 
osmotic lysis of protoplasts from C. acremoniurn was 
developed. This discovery enabled subsequent elucidation 
of this unique biochemical mechanism for the formation of 
bicyclic ring systems. This work has been the subject of 
many excellent reviews'2'13'14. 
As a result of extensive research in this area the 
biosynthetic pathways to the penicillins and 
cephalosporins from the L-amino acid precursors have been 
elucidated (Scheme 1). Most of the biosynthetic reactions 
shown in the scheme have been demonstrated in cell-free 
systems, although some questions still remain concerning 
the exact role of some enzymes and intermediates involved. 
The first step in the biosynthesis of penicillins, 
cephalosporins and cephamycins is the formation of the 
tripeptide o-(L-a-aminoadipyl) -L-cysteinyl-D-valine (LLD-
ACV) (6). L-a-Aminoadipic acid and L-cysteine are first 
condensed to form the dipeptide L-a-aminoadipyl-L-
cysteine. The L-valine residue is then epimerised to the 
D-form during its incorporation into the tripeptide. The 
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enzyme in the common pathway is Isopenicillin N synthase 
(IPNS), which catalyses the conversion of the tripeptide 
LLD-ACV to isopenicillin N (la). 	This enzyme will be 
discussed in greater detail later. 
In the penicillin producing species isopenicillin N is 
the direct precursor of the naturally occurring 
penicillins (ic). 	The cx-aminoadipyl side-chain is 
exchanged with phenyl acetic acid activated in the form of 
phenylacetyl-CoA. In the absence of side-chain precursors 
6-APA (3) is produced. 
In the cephalosporin and cephamycin-producing 
microorganisms isopenicillin N is converted to penicillin 
N (lb) by isopenicillin N epimerase. 	This enzyme 
epimerises the L-a-aminodipyl side-chain to the D 
configuration. 	Penicillin N is then converted to 
deacetoxycephalosporin C (DAOC) (2a) by the deacetoxy- 
cephalosporin C synthase or expandase. 	This enzyme has 
been the subject of much research and was found to require 
oxygen, a-ketoglutarate, Fe2+ and ascorbate for activity. 
DAOC is then hydroxylated to give deacetylcephalosporin C 
(DAC) (2b). 	The enzyme involved in this step is DAOC 
hydroxylase or DAC synthase and has similar cofactor 
requirements of a-ketoglutarate, ascorbate, dithiothreitol 
(DTT) and Fe2+. 	Acetylation of DAC to cephalosporin C 
(2c) by the enzyme acetyl-CoA:deacetyl-cephalosporin C 
acyltransferase is the terminal reaction in the 
cephalosporin producing fungi. 
In the cephamycin producing actinornycetes the 
cephalosporin C is further modified to the 7-methoxy 
derivative (4a). 	The inethoxy group being derived from 
molecular oxygen and methionine. 
8 
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1.3 	ISOPENICILLIN N SYNTHASE 
1.3.1 Introduction 
Isopenicillin N synthase is an iron containing protein 
of molecular weight 38,000-40,000 daltons, which catalyses 
the conversion of the tripeptide 6-(L-a-axninoadipyl)-L-
cysteinyl-D-valine (6) to isopenicillin N (la). 
H H 
	 H
IPNS HNN H3NNS 






, 02, O 	HH 
ascorbate, 	 H 02H
1a (6) 	 DTT. 
+ 2H20 
Scheme 2. Conversion of ACV to isopenicillin N catalysed 
by IPNS. 
IPNS carries out this cyclisation in the presence of 
the cofactors, Fe2+1 molecular oxygen, ascorbate and a 
thiol group, e.g. dithiothreito]. (DTT). 	The enzyme 
consumes one molecule of 02 for the conversion of one 
molecule of tripeptide to isopenicillin N. The substrate 
ACV in turn loses four hydrogen atoms concurrent with the 
reduction of dioxygeri. 	The enzyme therefore acts as a 
dehydrogenase or desaturase. No loss or exchange of any 
other atoms are observed during the conversion. 	It 
appears that the conversion of ACV to isopenicillin N 
proceeds via the simplest process, i.e. the removal of 
only those hydrogens required to allow ring formation. 
The enzyme exists in two states, interconvertible by 
oxidation and reduction, assumed to be the disulphide and 
dithiol forms15. It is susceptible to pH changes and is 
effectively irreversibly inhibited below pH 6. 	Table 1 
shows the similarity in the characteristics of the enzymes 
from various species. 	In all cases similar cofactor 




Source Km Weight Cofactor Purification 
of Enzyme /uiN kDa p1 Requirements Inhibitors (folds) Refs. 
P. chrysogenum 013 39 5.5 0 1 	DTT, CO2+, Mn2+, 95 19 
Fe2+, ascorbate glutathiorie 
C. acreinonium 0.3 40 5.0 0 7 , 	DTT, Mn2+, 152 16 
Fe2 4', ascorbate a-aminoadipyl- 
cysteiriyl- 
dihydroval me 
S. lactarndurans 0.18 26.5 6.5 0 7 , 	DTT, 	Fe2+, CO2+, 79 25 
ascorbate Mn2+, glucose- 
6-phosphate 
S. clavuligerus 0.32 33 N.D. 0 71 	DTT, 	Fe2+, N-Ethyl-- 130 28 
ascorbate inaleiinide 
I. nidulans N.D. 37.4 N.D. N.D. N.D. N.D. 21 
'1avobacterium 0.08 38 N.D. 0 71 	DTE, 	Fe2+, Ni2+, 116.8 27 
ascorbate Co2+, Mn2+ 
Table 1. Characteristics of Isopenicillin N Synthases 
N.D. : not determined 
Km values for LLD-ACV 
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1.3.2 Cloning of the IPNS Gene 
The enzyme was first isolated from Cephalosporium 
acrernoniurn in 1984 by Pang et a116. The N-terminal amino 
acid sequence was determined and used to construct 
oligoriucleotide probes which were employed to clone the 
IPNS gene. The DNA sequence encoded a protein of Mr38416, 
which contained 336 amino acid residues17. This gene was 
inserted into Escherichia coli and was expressed as the 
major protein (- 20% of cell protein). 	The resulting 
recombinant protein, whilst undergoing slightly different 
N-terminal processing to that observed for the 





Sequence predicted from DNA sequence. 
Sequence determined from IPNS purified from Cephalosporium 
acremonium. 
Sequence determined from IPNS purified from Escherichia coli. 
Figure 1. N-terminal Sequences. 
To date the IPNS gene has been cloned and sequenced 
for eight microorganisms. Three of which are derived from 
eukaryotic 	filamentous 	fungi17i 20i 21, 	four 	from 
prokaryotic gram-positive actinomycetes2225 and recently 
one from a gram-negative unicellular prokaryotic 
bacterium26'27. The primary amino acid sequences of the 
11 
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IPNS proteins from the different species show a high 
degree of similarity. 	Figure 2 shows these sequences 
aligned to present maximum homology. In all seven of the 
reported sequences, greater than 60% of the nucleotide 
bases and 50% of the deduced amino acid residues are 
identical or have conservative replacements. 	These 
regions of sequence similarity are spread with no obvious 
pattern throughout the genes and proteins. 	It is 
therefore not possible to define those regions important 
for substrate binding or catalytic activity from sequence 
analogy alone. 
The primary amino acid sequence of IPNS shows no 
significant homology to other known enzyme sequences, thus 
implying that the IPNS proteins are unrelated to any 
previously characterised class of enzymes. 
12 
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sequences; open squares indicate positions of similar but not identical residues that are present at the same site in all 
seven sequences. Rectangular open boxes are drawn around amino acid residues that are conserved in streptornycete 
proteins; shaded boxes show residues that are conserved in fungal proteins. Arrowheads indicate the two cysteino 
residues present in all seven sequences. 
Figure 2. IPNS sequence alignment29. 
1.3.3 Evolutionary Relationships in IPNS Genes 
As discussed on Page 12, the amino acid sequences of 
the fungal and bacterial IPNS proteins share 55-60% 
identity. 	Such high homology between eukaryotic and 
prokaryotic proteins is rare and is generally attributed 
to relatively slow changes occurring in the genes during 
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evolution. In the case of IPNS this is deemed unlikely as 
the nucleotide sequence differences in the genes appear to 
be consistent with normal rates of evolutionary change and 
IPNS is a secondary metabolism gene, unnecessary for 
survival. 	Weigel et al.24 in 1988 suggested that an 
alternative explanation may be that the IPNS gene was 
transferred horizontally well after the divergence between 
eukaryotes and prokaryotes. This hypothesis was modified 
by Landan et al.30 in 1990 taking into account the new 
sequence data for the gram-negative unicellular bacteria 
ulavobacterium. 	This group proposed that a single 
transfer event occurred close to the divergence between 
the gram-positive and gram-negative bacteria estimated as 















II 	 I 
21-1.5 	 0.3 
(Billion years) 
Figure 3. Phylogenetic tree of IPNS29. 
1.3.4 The IPNS "Active Site Region" 
Studies by Baldwin15 and co-workers established in 
1985 that IPNS can exist in two interconvertib].e forms 
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presumed to be the cysteine disulphide and dithiol forms. 
This interconversion suggests that the cysteine residues 
may be in close proximity in the enzyme structure. 
Sulphydryl reacting reagents were shown to destroy the 
enzyme activity. 	In 1987 Samson et al. 31 used site- 
directed mutagenesis to probe the importance of the 
cysteine residues. 	The two cysteine residues in the 
Cephalosporium acrernoniurn sequence were replaced with 
serine residues. Replacement of Cys-106 or both Cys-106 
and Cys-255 was found to reduce specific activity by about 
97%. Mutation of Cys-255 alone reduced specific activity 
by about 50%. The Km values however showed little change 
indicating that the cysteine has little effect on binding 
the substrate. 	The group concluded that the cysteine 
residues are important but not essential for IPNS 
activity, with Cys-106 probably involved in iron binding. 
These two cysteine residues are located in regions 
which are identical or conserved in all IPNS proteins (see 
Figure 2) indicating the potential importance of these 
residues. 
The substrate binding domain of the enzyme was 
recently probed by Baldwin et ai.32,33  by a photoaffinity 
method. The IPNS was covalently labelled by laser-flash 
photolysis in the presence of a diazirinyl-containing 
substrate analogue of ACV. 	Tritium labelled 2-[3-(3- 
trifluoromethyl-3H-diazirin-3-yl)phenoxyl]acetyl-S-methyl-
oxycarbonylsulphenyl-L-cysteinyl-D-val me (DCV) (7) was 
used. 	Irradiation of DCV produces a highly reactive 
carbene (9) with the potential of reacting with any 
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Scheme 3. Cyclisation and irradiation of DCV (7). 
Tryptic digestion of the labelled enzyme, followed by 
separation and sequencing of the resulting fragments, 
identified two labelled regions. These regions were Asp-
40 to Arg-78 and Thr-237 to Arg-273. However, data from 
the sequences of overlapping fragments suggested that the 
important regions were Glu-59 to Arg-78 and Thr-237 to 
Arg-273. The point of [ 3H]DCV attachment to the Thr-237 
to Gly-256 fragment was found to be at Cys-255. 	This 
suggests that the Cys-255 residue is not involved directly 
in the catalytic events as these occur at the remote 
cysteinyl-valine end of the molecule, but may be involved 
in substrate binding. Cys-106 was found to be unlabelled, 
suggesting that it may be buried within the molecule at a 
site remote from the active site or may be tied up in the 
binding of the thiol group of ACV or of the Fe2+ cofactor. 
















Figure 4. IPNS binding site as derived by photo-affinity 
labelling. 
The coordination chemistry of the metal binding site 
of IPNS has been probed using spectroscopic 
techniques34'35. The combined use of EPR, Mössbauer and 
optical spectroscopies indicate that IPNS contains one 
Fe2+ molecule per enzyme monomer, with the Fe2+ in a high 
spin state. 	The iron environment was shown to be 
substantially altered by the binding of ACV, thought to 
bind to the iron, through its suiphydryl group. 	Using 
nitric oxide as an analogue for 02 the active site iron 
was demonstrated to have the ability to bind ACV and NO 
simultaneously. 	This work was extended using metal- 
reconstituted enzyme in which the Fe2+ centre was replaced 
by Cu2+ or CO2+.  In this way the different spectroscopic 
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properties of Fe2+, CO2+ and Cu2+ were exploited. Results 
from optical and EPR spectroscopies indicated a 
six-coordinate metal binding site in IPNS. The nature of 
the active site ligands was probed using 1H n.m.r and the 
involvement of three histidine ligands postulated. 	In 
conclusion these workers proposed a six-coordinate metal 
centre with three endogenous histidine ligands and sites 
for the thiolate of ACV, NO (or 02 by analogy) and 
solvent. 
His 




Figure 5. Iron coordination. 
Systematic modification of the three amino acids of 
the natural substrate (ACV) has been used to structurally 
probe the enzyme binding site36. 	This work will be 
described in detail in the following section. 
Relatively little is known about the secondary and 
tertiary structure of the enzyme. 	From CD and FTIR 
measurements Cooper37 has suggested that Cephalosporium 
IPNS consists of both cr-helix and a-sheet conformations. 
Computer analysis of the sequence using the Chou-Fasman 
method to determine regions of the protein which have the 
highest probability of existing in these conformations has 
been used to predict secondary structure. The results of 
this method suggests that the enzyme is an cx/13 protein, 
one which consists generally of alternating cr-helix and 
3-sheet regions. 	It is however important to note that 
these computer methods have a general predictive accuracy 
of about 70%. 
1.3.5 Mechanistic Experiments 
The precise manner by which the enzyme carries out the 
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oxidative bicyclisation of LLD-ACV to isopenicillin N has 
been the object of much experiment. 	Structural and 
isotopic analogues of ACV have provided a wealth of 
knowledge on mechanistic and binding constraints but much 
information remains to be elucidated. 
Early work was hampered by the problems of cell wall 
permeability with the use of intact cells. However, it 
was established from the use of valine (made chiral at C-3 
by specific labelling with 13C) that the C-S bond of the 
thiazolidine ring is formed with retention of 
stereochemistry38'39'40. 	It was also concluded that the 
3S hydrogen of cysteine was predominantly removed and 
hence the -lactam C-N bond formation also occurs with 
retention of configuration41'42. 
With the advent of cell free systems it became 
possible to use modified and labelled tripeptide 
precursors in mechanistic determination experiments. This 
work has been the subject of many excellent 
reviews36'43'44. 
The enzyme forms two new bonds hence raising the 
question of whether these bonds are formed in a stepwise 
or concerted manner. Attempts to answer this question by 
preparing or detecting possible intermediates failed. 
Baldwin et al.45 then turned to look at the kinetic 
isotope effects of deuterium on the reaction. 	Isotopic 
competition experiments were carried out in which IPNS was 
exposed to an approximately 1:1 mixture of labelled 
tripeptide (deuteriated at either the cysteine C-3 or the 
valine C-3 residue) and the unlabelled tripeptide. 	The 
enzyme discriminated between deuteriated and unlabelled 
precursor, with enrichment of deuteriated species in the 
pool of unreacted material only in the case when the Cys 
C-3 moiety was labelled. However, both the deuteriated 
substrates showed a significant deuterium isotope effect 
on Vmax (maximum velocity) when utilised as single 
substrates. These observations are listed in Table 2 and 
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13' '' 	RCH3 
o 	/4CH3 
C H 
R1 	R 2 Dv 	Dy/K 
H 	H 1 	 - 
H D 5.6±0.3 1.4 
D 	H 13±2 	1.0 
D D 18±2 - 
Dv = kH/kD 
Table 2. Kinetic isotope effects observed for the 
incubation of labelled substrates with IPNS. 
Reaction co-ordinate 
Figure 6. The energy profile for the conversion of ACV 
to isopenicillin N by IPNS. 
In 	conclusion, f rom this work it was suggested that 
the reaction proceeds stepwise, with the loss of the 
cysteine C(3) pro S hydrogen occurring first to generate 
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an enzyme bound inonocyclic intermediate (10), shown in 
Scheme 4. 
H3N t 	S;:\: HCH 
CO  0 
0' H %02H 
(6) 
HN 	N Ft IPNS 	 s_E - j5 	





Scheme 4. Cyclisation to an enzyme bound monocyclic 
intermediate. 
More recently the "shunt metabolite" (11) arising from 
a stereospecific oxidation at Cys C-3 and loss of the 
sulphur atom has been isolated and proposed to arise from 






CO 1 LNj CH3 
t02H 
(11) 
The formation of (14) and (15) from (12) and (13) 
respectively (Scheme 5) also provides evidence for an 
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Scheme 5. Evidence for the formation of an initial 
monocyclic enzyme bound intermediate. 
From work carried out with structural valinyl 
analogues of the tripeptide, all new products isolated are 
found to contain the -lactam ring in spite of variation 
in the second ring size. 
1.3.6 Modified Substrates 
By systematically modifying the three components of 
the tripeptide ACV, Baldwin et al.36 have developed a 
knowledge of the type of substrate tolerated by the 
enzyme. This work has also provided information on the 
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likely mechanism of the cyclisation carried out by the 
enzyme. 	The three amino acid components will be 
considered individually. 
a-Airtinoadipic Acid 
Examination of the aminoadipyl variants tested with 
the enzyme suggests that the minimal structural 
requirement for this part of the tripeptide is a 
six-carbon chain or equivalent chain, terminating in a 
carboxyl group49. 
The requirement of the carboxyl group suggests the 
possibility of the presence of a remote binding site for 
this group, e.g. via H-bonding interactions with lysine or 
arginine. 	However, the acceptance of both D and L 
stereochemistry suggests little influence on binding by 
the amino terminus. 	Both benzyl and phenoxymethyl 
derivatives are accepted and cyclised to penicillin G and 
penicillin V respectively although with low Vmax values50. 
L-Cysteine 
The cysteine moiety has been shown to tolerate very 
few structural modifications. 	Only three structural 
analogues (16), (17) and (18) have been accepted by the 
enzyme (Scheme 6). These analogues differ only slightly 
from the cysteine moiety itself. 	This is perhaps 
indicative of the crucial role played in the binding by 
this residue5 -. Peptides which do not contain the free SH 
fail to act as substrates. 
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/C H3  
C 02H 
HN 	NR'R2  
0' 
02H 
R'  = Me, 	R 2 = H, 	X = CH  
R 1 = H, R 2 = Me, X = CH  
R1 = OMe, R 2 = H, 	X = 0 
Scheme 6. Cysteine structural analogues cyclised by 
IPNS. 
D-Valine 
Modification of the D-valine moiety by other D-amino 
acids has been the most productive source of unusual 
enzymically synthesised -1actams as well as mechanistic 
insights. 	The only major constraint on this component 
appears to be the D configuration. 	Many tripeptides 
containing valine analogues have been prepared, this work 
has been recently reviewed36. 
The enzyme is observed to carry out the formation of 
the j3-lactam and thiazolidine rings with the simultaneous 
reduction of oxygen to two molecules of water. 
Considering also that kinetic isotope effects indicate a 
two step mechanism, the simplest working hypothesis is 
that the iron atom mediates two separate, 2-electron 
reductions of iron bound dioxygen by the substrate, shown 
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Scheme 7. Proposed catalytic cycle. 
The scheme postulates the existence of a ferryl 
species (oxo-iron (IV)) which mediates the second ring 
closure. If the cysteinyl sulphur atom is bound to the 
iron the first electron-transfer may be directly mediated 
through the iron-sulphur conductor. 	This proposed 
mechanism was probed by considering the four discrete 
reaction types characteristic of the ferryl species; 
insertion-homolysis for saturated side chains, [2+2w] 
cycloaddition, ene reactions and epoxide formation. The 
selectivity between the four modes of reaction depends on 
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the steric relationship between the ferryl centre and the 
side chain. 	When a-arninobutyrate was substituted for 
valine in the tripeptide (19) three products were obtained 
(20), (21) and (22) in the ratios shown52. 
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Scheme 8. Cyclisation of the a-aminobutyric acid analogue 
of the tripeptide by IPNS. 
The formation of the six membered ring was unexpected, 
but may however be accounted for if the enzyme mechanism 
responds to the strength of the C-H bond broken in the 
second ring closure, see Table 3. 
Residue Side-Chain D8,,/kcal mo1 1  
Valine Hf_H 98 
I D198=6 H 	-H  ,L 92 
a-Amino- Hr—H 98 
= 3 
butyrate j'I H L-H 95 
Table 3. Dissociation energies D198 of the C-H bonds. 
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The difference between the bond-dissociation energies 
of the vicinal C-H's in the aminobutyrate is lower than 
that for valine. If a hoinolytic or an equivalent type of 
mechanism was involved the production of the cepham system 
could become competitive with formation of a penam in the 
aininobutyrate system. 	Incubation of deuteriated amino- 
butyrates (23) and (24) produced the same monodeuteriated 
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Scheme 9. Cyclisation of deuteriated aminobutyric acid 
analogues of the tripeptide. 
In both cases the H was abstracted in preference to 
the D, to produce a free carbon radical. 	Rapid 
equilibration by rotation followed by slower ring closure 
would yield the same product (25) in each case. 	This 
radical hypothesis was tested using the cyclo- 
propylcarbinyl test54. 	Cyclopropylcarbinyl radicals are 




k1 = 108 s-i 
k2 = 10 3 si 
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Incubation of tripeptide (26) with IPNS indeed produced 
the two products (27) and (28) indicative of a radical 
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Scheme 10. Cyclisation of the cyclopropyl containing 
tripeptide analogue. 
With the use of numerous other tripeptide analogues 
the enzyme has been demonstrated to carry out 1,3-
shifts/oxo-ene reactions, [2+2r] cycloaddition/reductive 
elimination reactions, and epoxide formation/inverting 
displacement mechanisms in accordance with the nature of 
the D-valine replacement in the tripeptide substrate. All 
these mechanistic pathways are consistant with the 
proposed involvement of a ferryl species. 
It has been demonstrated that the IPNS enzyme has the 
ability to cyclise a variety of substrate analogues to a 
wide range of -lactam compounds, albeit at very low 
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rates. This broad substrate specificity demonstrated by 
the enzyme provides a basis for modifications leading to 
possible industrial production of new antibiotics. With 
the use of site directed in vitro inutagenesis of cloned 
IPNS genes it may be possible to alter the substrate 
specificity and/or the affinity of the enzyme for the 
different 3-lactam precursors. The substantial quantities 
of enzyme required should be available through expression 
of cloned IPNS genes. 
A chemical alternative to site directed mutagenesis is 
the use of solid phase peptide synthesis (SPPS)55. This 
technique allows the chemical synthesis and modification 
of peptides and small proteins. An unlimited number of 




1.4 	PROJECT AIM 
In recent years attention has focussed on the design 
of synthetic mimics of natural proteins and enzymes. SPPS 
has successfully been used in the construction of protein 
folding motif mnimetics, in particular helixes5659, and in 
the synthesis of an artificial hexneprotein60, possessing 
some catalytic activity. 
The tertiary structure of IPNS is unknown, however, 
substantial work has been carried out on the 
identification of those residues involved in the substrate 
and cofactor binding (see Pages 14-18). 	Although 
speculative we hoped to use this information to construct 
a synthetic model which might conceivably mimic the 
binding and activity observed in the active site of IPNS. 
IPNS is an enzyme of some 336 residues which falls 
outside the realms of satisfactory synthesis by SPPS. 
However, the vast majority of these residues must 
presumably be involved in maintaining the structure of the 
enzyme, and not be directly involved in the binding and 
the catalytic event. We chose to synthesise two peptide 
fragments of 29 and 25 residues, centred around Cys-106 
and Cys-255 respectively. 
In the design of a model system these two fragments 
must be linked together by some method but must still 
possess a limited degree of mobility. 	In order to 
accommodate these requirements we envisaged a model system 
in which the two peptide fragments were joined by a 
lipophilic linker. When introduced into a two phase 
system of organic solvent-aqueous buffer, the compound 
would be expected to traverse the interface with the 
linker in the organic layer and the peptide fragments in 
the aqueous layer. In this manner the peptides would be 
held in close proximity. The presence of the cofactors in 
the aqueous layer may promote the adoption of a structure 
similar to that found in the native enzyme. By changing 
the sequences of the peptides in the model system the 
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affinity for different precursor tripeptides might be 
modified. 	It may then be possible to direct the 
specificity of the system towards the turnover of certain 
penicillin precursors. 
The length of the linking unit used is important with 
respect to the degree of mobility available to the 
peptides and hence the range of structures which may be 
adopted. For this reason two systems were envisaged, one 
containing a short linker unit for which il-amino-




CHAPTER 2 : DISCUSSION 
2.1 	ENZYME MODEL 
2.1.1 Introduction 
The two peptide fragments IPNS(92-120) and IPNS(243-
267) were selected for synthesis. In the proposed model 
system the two peptides are to be linked together by a 
hydrophobic spacer. With two fragments there are four 
possible ways in which they may be linked together, as 
shown in Figure 7. 
Peptide 1 	 Amine 	• Q © 
Peptide 2 	Q--LI1 	Carboxyl I LII 
Linker 
Figure 7. Peptide alignment. 
Discussion 
From a synthetic viewpoint, systems A and B are the 
most easily accessible. 	The first peptide may be 
synthesised in a stepwise manner from the C to N terminus 
onto a solid support (resin) using SPPS. The linking unit 
may then be coupled onto the amino end of the resin-bound 
peptide and the second peptide then synthesised directly 








Peptide 2 -Linker-Peptide 1 
 Cleave from 
the resin 
Peptide 2 -Linker-Peptide i 	+ 
Scheme 11. Stepwise synthesis of two peptides 
incorporating a linking unit. 
Systems C and D however necessitate the use of 
fragment coupling, as in these cases the linking unit 
joins two carboxylic acid or two amino functions. 	To 
avoid undesirable side reactions during the coupling step 
it would be necessary to synthesise and purify the two 
peptide fragments separately with all side-chain 
functionality protected. 	The use of protected peptide 
fragments may also lead to problems of low solubility. In 
addition selective or graded protection of the terminal 
functionality would also be required due to the presence 
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of three carboxyl or three amino groups in any one 
coupling step, see Figure 8. 
\ 
protect 	1) couple 	
protect/  couple 






Figure S. Fragment coupling to incorporate the linking 
unit. 
A further problem associated with fragment 
condensation is racemisation of the C-terminal amino acid 
during activation. This would be a problem in the above 
case where the peptide fragments are linked to the spacer 
by their C-termini but not in the case where they are 
joined by their N-termini, as the linking unit could be 
activated in this case. 	In cases A and B the 
incorporation of a relatively short linker would hold the 
two peptides in an antiparallel arrangement, i.e. the 
amino terminal of one aligned with the carboxyl terminal 
of the other. Figure 9. 
4~h 	organic phase 
aqueous phase 
Figure 9. Antiparallel alignment of the fragments with a 
short linking unit. 
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If a longer linker were used the peptides should have 
increased mobility and may be capable of adopting both 







Figure 10. Parallel and antiparallel alignments allowed 
by a long linking unit. 
This route using the long linker was adopted as an 
alternative approach to the fragment condensation method 
for systems C and D. 
2.1.2 The Linking Unit 
The properties required for the linking unit are: 
It must be sufficiently lipophilic in character to 
reside in the organic layer and therefore not 
interfere with the peptide fragments. 
The unit and the covalent bonds to the peptide must be 
stable to the conditions of peptide synthesis, in 
particular the final acid cleavage. 
The possession of an amide function at one end and a 
carboxylic acid function at the other would facilitate 
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its incorporation during synthesis. 
11-Aininoundecanoic acid and its triiner were identified 
as suitable candidates for linkers and their use was 
further investigated. 
2.1.3 Solid Phase Peptide Synthesis (SPPS) 
The peptides described were prepared by SPPS based on 
the method introduced by Merrifield55. 	Only a brief 
outline of the method is given, further information may be 
obtained in the many reviews available61'62'63. 	More 
detail on the procedure used is outlined in the 
experimental section. An orthogonal protection strategy 
was employed based on the 9-fluorenylinethoxycarbonyl 
(Fmoc)64 a-amino protecting group. This base-labile amino 
protection was used in conjunction with the p-alkoxybenzyl 
alcohol polystyrene resin65 and acid-labile side-chain 
protecting groups. After assembly of the peptide chain 
the side-chain protecting groups were removed by treatment 
with TFA, a process which also cleaves the peptide from 
the resin. 
JH TFA— CH_,CH3 C
CH3CN NH 	__O IS_,cH  \\/ 
0 	
C O2 
CH3 \,I"CH3  - 	 I I 
CO NH 
CH 	(C H2)3 
H 'CHj-ç-NH-CH-ç-NH-CH-C- 
a H2 	 2 
TFA 
Figure 11. Fmoc based SPPS. 
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The addition of the first amino acid to the resin was 
carried out manually. All subsequent manipulations during 
the chain assembly process were carried out automatically 
on a peptide synthesiser. 	Each amino acid was double 
coupled to ensure maximum coupling efficiency, firstly as 
its preformed symmetrical anhydride and subsequently in 
the form of its preformed l-hydroxybenzotriazole active 
ester. Amino acid activation was in both cases mediated 
by diisopropylcarbodiimide (DIC). 	The Fmoc group was 
cleaved using four sequential deprotections with 20% 
piperidine in DMF. 	All syntheses were monitored as 
discussed in the following section. 
2.1.4 Peptide Synthesis Monitoring 
The use of the Fmoc group for the semi-permanent 
protection of the amino acids provides the opportunity to 
monitor the efficiency of the synthesis using a system 
based on Til/ absorbance. Such a monitoring system has been 
developed in our laboratory66. 	Aliquots of the Fmoc 
deprotection solutions are taken, diluted and passed 
through a UV detector linked to an integrator. The peak 
areas thus observed give a semi-quantitative measure 
(approximately ± 5%) of the extent of the previous 
coupling. 	Although once the Fmoc group is removed the 
coupling cannot be improved upon, the monitoring is useful 
for the identification of problem areas and couplings 
which may then be optimised in subsequent syntheses. 
Initially the monitoring of the IPNS peptide fragment 
syntheses were carried out at 314 nm, however in certain 
sequences deprotection peak areas greater than 100% were 
observed (see Figures 18 and 20). 	It is known that 
cleavage of the Fmoc group results in the generation of 
dibenzofulvene (82) which then forms an adduct (84) with 
the piperidine67, see Scheme 12. 
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Finoc-piperidine adduct 
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Scheme 12. Finoc cleavage. 
The UV spectra of the dibenzofulvene and the 
piperidine adduct were required to establish the relative 
contribution of each to the overall absorbance at 314 nm. 
Dibenzofulvene may be isolated but on standing either in 
solution or as a solid it rapidly forms an insoluble 
polymer. To avoid the need for purification this compound 
was prepared by flash vacuum pyrolysis of 9-fluorenyl-
methyl acetate (80) and used immediately. The extinction 
coefficient of dibenzofulvene (82) at 314 nm is 1700 dm 3  
mo1 1 cm. Some twenty times greater than that of the 
adduct (84) (81 dm 3 mol' CM-1). 	If dibenzofulvene were 
therefore present in the solution its contribution to the 
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nfl' 
Wavelength (nm) 
Figure 12. UV absorbance spectra. 
At 302 nm however an isosbestic point occurs and hence 
any dibenzofulvene present does not over contribute to the 
observed absorbance, resulting in more consistant 
monitoring. Synthesis monitoring at 302 nm, while greatly 
reducing the magnitude of the peaks over 100% did not 
completely eradicate the problem. The presence of some 
dibenzofulvene is not the sole cause of this problem. 
Other factors such as the dilution of the deprotection 
solutions and possible trapping of unreacted Fmoc-amino 
acid by the resin require investigation. 
An alternative base-labile Naprotecting group is the 
2, 2-bis(4 '-nitrophenyl)ethoxycarbonyl (Bnpeoc) group68. 
Discussion 
NO2 	 NO2 
4: P_ 
Synthesis monitoring using this group may be carried 
out at 405 nm. 	At this wavelength the extinction 
coefficients of the 1,1-bis(41-nitrophenyl)ethene (83) and 
the corresponding piperidine adduct (85) are equivalent. 
This protecting group may prove to be more suitable for 
synthesis monitoring. 
2.1.5 The Preparation of the System Containing the Short 
Linker 
The model systems, either with the short or long 
linkers were prepared using a 3-step approach as outlined 
in Scheme 11 (see page 33). 
Synthesis of the first peptide on the resin. 
Addition of the linker to the resin-bound peptide. 
Synthesis of the second peptide onto the linker. 
All amino acid sequences and numbering quoted 
correspond to the Cephalosporiurn acrernonium gene coding17. 


















solid phase methodology. 	The chain assembly proceeded 
smoothly and the deprotection monitoring indicated the 
absence of any notably poor couplings. 	This was later 
corroborated by the HPLC analysis of the crude peptide 
(Figure 14a). One third of the resin-bound material (33) 
was removed from the bulk material to assess the quality 
of the peptide. 	A number of small scale cleavage 
reactions were carried out over varying time periods in 
order to achieve a balance between complete removal of all 
protecting groups and acid degradation of the free 
peptide, Figure 13. 
2 hours 	 4 hours 
Figure 13. HPLC analysis of the TFA deprotection of 
IPNS(92-120), 1-5 hours. 
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Optimum cleavage time was judged to be 5 hours after 
which no further enhancement of the major peak was 
observed. 	Degradation of the product became apparent 
after 8 hours. The remainder of the resin removed from 
the reaction vessel was then successfully cleaved after 5 
hours. 	The crude peptide obtained was purified using 
standard procedures of gel filtration and semi-preparative 
HPLC, after removal of the cysteine protection with 
tributyiphosphine. 	The amino acid analysis values 
obtained for proline and cysteine were 5.86 and 0.16 
respectively whereas those required were 5 and 1 
respectively. 	It would appear that the cysteine is 
degraded to a product which co-elutes with proline, thus 
explaining the low cysteine and high proline values. This 
phenomenon was often observed with the cysteine containing 
IPNS fragments. The presence of the cysteine was verified 
by an Elimans test and the peptide was further 
characterised by FAB mass spectrometry and sequencing by 
Edman degradation. 
Step 2. The Introduction of the Linker 
Having demonstrated the authenticity of the 
resin-bound peptide the coupling of the linker was 
investigated. 	The amino function of the linking unit, 
11-aininoundecanoic acid was first coupled with 
N- (9-fluorenylmethoxycarbonyloxy) succinimide 	to 	give 
FrnocAuaOH (61). 	The Finoc derivatisation of the linker 
served both as an a-amino protection and as a handle for 
the determination of the coupling efficiency of the linker 
to the resin-bound peptide. Two activating methods were 
investigated for the coupling of the FmocAuaOH (61) to the 
resin-bound IPNS(92-120) (34). The carboxylic group was 
activated either as the diphenyiphosphinic mixed anhydride 
or the HOBt ester. The mixed anhydride method was found 
to be superior in that a higher percentage of the 
aminoundecanoic acid derivative was coupled. 	The crude 
42 
Discussion 
products after acid cleavage from the resin are shown in 
Figure 14. 	Unreacted amino functions were capped with 
acetic anhydride to avoid deletion peptides being 
synthesised lacking the linker unit, thus simplifying 
purification. 
\ 7 0 
a) crude peptide 	b) DIC/HOBt 	C) Ph 2 PO 2 POPh 2 
IPNS (92-120) coupling coupling 
Figure 14. HPLC analysis of the coupling of the linker 
to IPNS (92-120) 
Step 3. The Synthesis of IPNS(243-267) onto the Linker. 
H-Asp-I le-Gln-Ala-Asp-Asp-Thr-Gly-Phe-Leu-Ile-Asn-Cys-Gly-




Prior to the synthesis of IPNS residues 243-267 onto 
the resin-bound linker (38), the sequence was synthesised 
directly onto the p-alkoxybenzyl alcohol resin. 	The 
synthesis proceeded relatively smoothly however a drop in 
coupling efficiency for the coupling of Asn(254) to 
Cys(255) and a general decline in the coupling 
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efficiencies over the synthesis were observed. Cleavage 
from the resin produced a crude material containing a 
major peak but also a substantial number of impurities. 
The material was purified by gel filtration chromatography 
and semi-preparative reverse phase HPLC. 	Problems were 
however encountered during manipulation apparently due to 
the rather low solubility of the material in aqueous 
media. 	Characterisation by amino acid analysis and FAB 
mass spectroscopy showed the major component of the crude 
mixture to be the desired peptide IPNS(243-267) (37). 
The sequence was then synthesised onto the resin-bound 
Finoc Aua-IPNS(92-120) (38) to give IPNS(243-267)-Aua-IPNS 
(92-120) (43). 	Asn(254) was triple coupled to minimise 
the drop at this point. The synthesis of residues 243-267 
again showed the same general decline in coupling 
efficiency. 	Small scale sample cleavages over 1 to 5 
hours indicated that optimum cleavage time was 2.5 hours. 
Purification of the compound (43) was carried out with 
the cysteine protection intact (42), to avoid complication 
from the thiols (i.e. dilnerisation or cyclisation). 
Initial purification was achieved using gel permeation 
chromatography (Figure 15) which allowed the removal of 
low molecular weight truncated sequences (including the 
capped IPNS(92-120) Figure 15d) and scavengers from the 
cleavage mixture. Surprisingly, a small fraction (Figure 
15b) containing the desired peptide (42) eluted before the 
main fraction and gave broad peaks on HPLC. This may have 
been due to aggregation of material on the column due to 
the presence of the lipophilic linker. 
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b) fraction (35-43) 
a) crude peptide 
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C) fraction (44-49) 
d) fraction (50-54) 	e) fraction (55-66) 
Figure 15. HPLC analysis of the fractions obtained after 
gel filtration of IPNS(243-267) (t-butylthio)-
Aua-IPNS(92-120) (t-butylthio) (42). 
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Further purification of the peptide proved difficult. 
The material (42) was poorly soluble in aqueous media and 
then only at extreme pH's, i.e. below 2 and above 10, see 
Table 8, experimental section. The addition of organic 
solvents and denaturing agents such as urea were however 
found to enhance the solubility. 
The use of semi-preparative reverse phase HPLC 
resulted in significant loss of material (65-80%). This 
was almost certainly due to the affinity of the alkyl 
linker for the column reverse phase material, both C. and 
C18. 	Other methods of purification were therefore 
investigated. 
Droplet counter current chromatography (DCCC) is a 
well established technique for the purification of natural 
products69 and peptides70, which involves the use of 
partially miscible organic-aqueous solvent systems. 
Purification is effected by the partitioning of compounds 
between droplets of a mobile phase passing through a 
column of liquid stationary phase. Since both phases are 
liquid loss of material is minimal. 	Of the systems 
investigated, n-BuOH/AcOH/H 20 (4:1:5) was found to result 
in the most efficient partitioning of the crude peptide 
mixture. 	Partial purification of the peptide (42) was 
achieved but separations were time-consuming and UV 
monitoring of the eluent unsatisfactory, with no clearly 
defined peaks being observed. 
Traditionally ion exchange chromatography has proven 
to be a powerful tool for the purification of peptides and 
proteins. The separation is based on the relative ionic 
charge of the mixture components and is therefore ideally 
suited to peptides containing amino acids with charged 
side-chain functions. Compound (42) has an overall charge 
of -7 and a calculated p1 of 7.7. Anion exchange columns 
were therefore investigated at pH 8.7. Elution from ion 
exchange columns is normally effected by salt or pH 
gradients with aqueous buffer systems. 	Purification of 
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compound (42) in purely aqueous systems was found to be 
unsatisfactory due to its poor solubility. 
Ion exchange columns have been reported as being run 
in buffer systems containing acetonitrile71 or urea72. 
Partial purification of the peptide (42) was achieved on a 
DEAE Sepharose anion exchange column eluting with a 7M 
urea based buffer. 	Collected fractions were dialysed 
against urea solutions of decreasing concentration and 
eluted through gel permeation columns to remove the urea. 
Total removal of the urea was very difficult and 
accompanied by significant loss of peptide. 	Similar 
attempts with cation exchange columns failed due to 
insufficient binding to the columns. 
A further technique employed in the purification of 
proteins is hydrophobic interaction chromatography (HIC). 
Separation is based on the varying hydrophobic 
interactions of substances with an uncharged bed material 
containing hydrophobic groups. 	Elution is effected by 
changing the factors which influence hydrophobic binding 
such as, ionic strength, temperature, pH, detergents and 
polarity lowering agents such as ethylene glycol. A major 
drawback of this technique is the frequent loss of 
material on the column. In view of the strong hydrophobic 
interactions encountered in the reverse phase HPLC (C8 , 
C18), a less hydrophobic bed material, Phenyl Sepharose 
was selected. Using an acetonitrile gradient (containing 
0.1% TFA), the peptide was eluted from the column with 
virtually quantitative recovery of material. 	Selective 
combination of fractions led to the isolation of the 
required peptide (42) as a single peak as shown by 
analytical HPLC, Figure 16a. The removal of the cysteine 
protection resulted in broadening around the base of the 
peak corresponding to the desired peptide (43) as observed 
by analytical HPLC, Figure 16b. This effect may be due to 






Bu 3P/H 20/TFE 
\I 
a) 	 b) 
Figure 16. HPLC of the Pheny]. Sepharose HIC purified 
peptide. 
Characterisation of the product by FAB mass 
spectrometry (nominal (Figure 17) and accurate mass), 
amino acid analysis, Elimans testing and sequencing of the 
first ten residues confirmed the identity of the isolated 
product as the desired compound (43). 
C 2 	2N 6 808 5S 3 
M 6375 
M 2+ 3187 
lem 	Wrl 	40N 	 low 	 2.?.?.? 
 
Figure 17. FAB mass spectrum of IPNS(243-267)-Aua-IPNS 
(92-120) (43) 
Having established that this modified peptide (43) 
could be successfully purified in reasonable quantities 
the synthesis was undertaken again. 	Examination of the 
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synthesis monitoring graphs and HPLC traces of the 
intermediate compounds was used to identify areas of the 
synthesis which might be improved upon. 
The conditions for the synthesis of residues 92-120 
(36) had resulted in an acceptable product and were 
therefore unchanged. 	From various studies it had been 
observed that the final coupling percentage achieved, for 
the coupling of FmocAuaOH(61) onto the resin bound 
peptide, was dependent upon the extent of the initial 
coupling. 	A subsequent recoupling resulted in an 
improvement of 3-5% on the first and a third coupling 
produced no further enhancement. The coupling of (61) was 
therefore increased from 75 to 95% by using a ten fold 
excess of the activated species rather than five, thus 
maximising the extent of the initial coupling. 	This 
effect may be a result of hindrance to the incoming 
activated species by the FmocAuaOH already bound to the 
peptide. 
The synthesis of residues 243-267 (37) onto the linker 
had proceeded somewhat less than satisfactorily at the 
first attempt, possibly due to aggregation problems 
associated with the linker unit. In order to force the 
coupling reactions closer to completion the second 
synthesis was carried out with the following 
modifications: 
A reduced scale of 0.1 ininole and hence ten equivalents 
of activated amino acid in each coupling. 
Triple coupling cycles were employed, the third 
coupling being a further DIC/HOBt activation. 
coupling reactions were carried out in a 1:1 mixture 
of DMF/1,4-dioxan, thus lowering the dielectric 
constant of the solvent. 
The Fmoc deprotection monitoring and analytical HPLC 
analysis of the crude product indicated that the synthesis 
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Figure 18. Comparison of the syntheses monitoring and 




2.1.6 The Preparation of the System Containing the Long 
Linker 
H-Asp-Ile-Gln-Ala-Asp-Asp-Thr-Gly-Phe-Leu-Ile-Asn-Cys-Gly-
Ser-Tyr-Met-Ala-His-Ile-Thr-Asp-Asp-Tyr-Tyr-NH (CH2) 1  000NH-
(CH2) ØCONH (CH 2) 1 000-Tyr-Tyr-Leu-Pro-Ile-Pro-Gly-Lys-Lys-
Al a-Val -Glu-Ser-Phe-Cys-Tyr-Leu-Asn-Pro-Ser-Phe-Ser-Pro-Asp-
His-Pro-Arg-Ile-Lys-OH (48) 
The incorporation of a tri-aminoundecanoic acid linker 
can be accomplished by two routes: 
1. The aininoundecanoic acid units may be introduced in a 













 Couple FmocAuaOH 
Fmoc-Aua-Aua-Aua-Peptide i 
Scheme 13. Stepwise incorporation of the triamino-
undecanoic acid linker. 
This route has the disadvantage that incomplete 
coupling reactions of each FmocAuaOH followed by 
capping steps will result in truncated sequences 
containing one, two and three capped aininoundecanoic 
acid units, thus complicating purification. 
2. The preparation of the complete linking unit and its 





Couple Fmoc(Aua) 30H 
Fmoc-Aua-Aua-Aua-Peptide 1 
Scheme 14. Incorporation of the long linker in a single 
coupling step. 
The use of one coupling step in place of three should 
result in increased coupling efficiency. This method also 
precludes the formation of truncated sequences with 
varying lengths of lipophilic derivatisation and was 
therefore chosen. 
Preparation of the Linker 
Fmoc[NH(CH 2 ) 10C0]30H (67) 
The aminoundecanoic acid trimer was prepared using a 
stepwise solid phase approach. Synthesis in this manner 
allowed the use of vast excesses of reagents to improve 
yields in the chemical steps. All excess reagents were 
washed away and possible solubility problems were also 
avoided. 	Coupling, capping and deprotection steps were 
executed as described for SPPS using manual synthesis in a 
"bubbler" reaction vessel63. 
The coupling of FmocAuaOH(61) was investigated using 
diphenyiphosphinic mixed anhydride, acid chloride and DIC/ 
HOBt active ester activation procedures. 	The coupling 
reactions in all cases were found to be slow, typically 
requiring an overnight coupling with four equivalents of 
the activated species. The use of the diphenylphosphinic 
mixed anhydride was found to be superior both for coupling 
directly onto the resin and onto the resin bound Aua. 
Acid cleavage of the trimer from the resin gave a 
satisfactory recovery of crude material (67). Solubility 
of this compound was found to be poor in a range of 
solvents. Acceptable solubility was however exhibited in 
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N-methylpyrrolidinone (NMP) which was employed to elute 
the crude product through an LH-20 gel permeation column. 
Good separation of the desired trimer from the capped 
monomer and dimer was achieved due to the significant mass 
difference. Unfortunately, a high degree of Fmoc cleavage 
was also observed. 
The synthesis was repeated omitting the intermediate 
capping steps so that the main impurities would be H-AuaOH 
and H-Aua-AuaOH. Previous coupling studies had shown that 
recoupling with FmocAuaOH(61) resulted in a maximum of 5% 
coupling and hence coupling of FmocAuaoH to uncapped 
Aua- R (63) would produce only a minor amount of 
FmocAua-Aua-R. 	These uncapped monomer and dimer 
impurities were efficiently removed from the desired 
product Fmoc(Aua)30H (67) by eluting the crude mixture 
through a silica flash column with a CHC1 3/MeOH/AcOH 
9:1:0.5 solvent system. 
Coupling to the Resin-Bound Peptide 
IPNS(92-120) (36) was synthesised using the improved 
conditions described for IPNS(243-267), (Page 49), but 
with the Fmoc deprotections also performed in a 1:1 
mixture of DMF/1,4-dioxan in order to keep the solvent 
conditions constant. 	30% Piperidine in DMF was used as 
the Fmoc deprotection in the mixed solvent system was 
slower. However, 2,5-diketopiperazine (DKP) formation was 
observed after the deprotection of the second residue, 
presumably catalysed by the additional base, see Figure 
20. Consequently, in subsequent syntheses 20% piperidine 
in DMF was employed for the Fmoc deprotection. The poor 
solubility of Finoc(Aua)30H(67) was a limiting factor in 
its coupling to the resin-bound peptide (34). 	The 
observed couplings in DMF, DMA, NNP and mixtures of the 
solvents were poor as a result of the low concentrations 
of the solutions containing the activated species. 
Solvent selection for coupling reactions in SPPS is 
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limited by the requirements for highly concentrated 
solutions of the activated components, efficient swelling 
of the resin and for inertness towards the reagents. 
Anhydrous lithium bromide in tetrahydrofuran has been 
reported to solubilize hydrophobic and side-chain 
protected peptides73 and also to disaggregate protected 
resin-bound peptides74. 	Compound (67) exhibited 
solubility up to 50 mg ml 1 in this system resulting in 
sufficiently concentrated solutions for coupling. 	The 
solvent system also swells the polystyrene resin very 
effectively. 	An overall coupling efficiency of 84% was 
achieved using two consecutive couplings each with five 
equivalents of activated species. 	A third coupling 
produced no further change. 
A small sample of resin was removed from the reaction 
vessel and the derivatised peptide was successfully 
cleaved from the resin. Analytical HPLC analysis (Figure 
19b) showed no peak corresponding to IPNS(92-120) Figure 
19a and together with the appearance of peaks with 
increased retention times, indicating increased 
lipophilicity, the results were encouraging. 
a) IPNS(92-120) b) 	(Aua) 3-IPNS(92-120) 




As the addition of the linker to the first peptide had 
been achieved the third phase of the assembly was 
initiated. 	The first residue of the second peptide, 
tyrosine (267) was coupled manually in order to ensure 
complete coupling using extended coupling times and Kaiser 
monitoring. The remaining residues of IPNS(243-267) were 
introduced using the automated cycles previously described 
and the conditions described for the second synthesis of 
(43). 	The synthesis monitoring (Figure 20) showed a 
gradual decline in coupling efficiencies, greater than 
that observed for the syntheses with the short linker. 
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Acid cleavage of the crude material from the resin was 
encouraging, see Figure 21. 
Figure 21. HPLC analysis of the crude IPNS(243-268) 
(t-butylthio)-(Aua) 3-IPNS(92-120) (t-butylthio) 
(47) 
Again purification by gel permeation chromatography 
removed the relatively low molecular weight truncated 
sequences, amounting to 60% of the weight of the crude 
material, see Figure 22a. 	A second pass through the 
column improved the product quality but resulted in the 
loss of approximately 50% of the material. 
Purification by Phenyl Sepharose HIC proved 
unsatisfactory. The desired peptide (47) was eluted from 
the column over a wide gradient range. Furthermore the 
increased lipophilicity of the compound also resulted in 
30% of the material being retained on the column. In an 
attempt to reduce the lipophilic nature of the material 
the cysteine t-butylthio protecting groups were cleaved to 
give the free peptide (48). 	Removal of these groups 
increased the proportion of the major peak observed by 
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reverse phase HPLC, (Figure 22b). In contrast a similar 
removal of the cysteine protecting groups from the crude 




Bu 3P/H 20/TFE 
a) After gel filtration 
	 b) After t-butylthio 
removal 
Figure 22. HPLC analysis of the t-butylthio cleavage 
from the semi-purified (47). 
A small sample was further purified by semi-
preparative reverse phase HPLC (11% recovery), to a single 
peak on HPLC (Figure 23) in order to verify that the major 
peak observed was the desired product (48). 
Characterisation by FAB mass spectrometry, amino acid 
analysis, Ellmans testing and sequencing of the first 10 
N-terminal residues confirmed the identity of the isolated 
product. 
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Figure 23. HPLC and FAB mass spectral analysis of the 
purified product (48) 
Due to the substantial loss of material encountered 
during the purification and the relatively small amount of 
crude material available without further synthesis, 
compound (48) was used in a semi-purified form (i.e. after 
gel filtration and cysteine deprotection). The impurities 
present in the mixture were not considered a serious 
problem for subsequent studies. 
2.1.7 Spectroscopic Studies 
The absorbance, fluorescence and circular dichroism 
spectra of peptides and proteins depend upon the 
environment and mobility of their chromophores. 	These 
spectra for the two compounds (43), with the short linker, 
and (48), with the long linker, were examined. 
Absorbance 
Peptides and proteins absorb and re-emit light in the 
UV range of the spectrum. This absorbance is caused by 
the amide bonds, the aromatic side-chains and to a small 
extent by disulphide bonds. 	Metal binding to proteins 




The ultraviolet spectrum of IPNS has previously been 
recorded in 0.1 mM MOPS buffer, pH 7.1. The spectrum was 






enzyme plus 5 mM ACV 
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Figure 24. UV spectrum of IPNS34. 
The absorbance spectrum of IPNS(243-267)-Aua-IPNS 
(92-120) (43) was recorded in 50 mM MOPS pH 8.0, as the 
compound was insoluble at pH 7.1, (Figure 25a). 	The 
peptide showed a strong absorbance at 276 nm, 
corresponding to the tyrosine residues and a second 
feature in the region 300-360 run. This absorbance may be 
due to light scattering by aggregates. The addition of 
ferrous sulphate to the sample resulted in the appearance 
of a new weak band with a maximum at 550 run Figure 25b, 
not seen in a peptide free control sample. 	This new 
absorbance may be caused by charge transfer between the 
Fe2+ and the peptide. Addition of one equivalent of Fe2+ 
resulted in a band at 550 nm with £ = 300 dm 3 mol 	cm 1 
while the addition of two equivalents resulted in a band 
with £ = 500 din 3 mol' cm 1 , further addition of Fe2+ 
produced no subsequent increase in the observed E value. 
This suggests that the compound may bind two Fe2+ 
molecules. 	Rubredoxin75, an iron containing protein, 
exhibits absorbance maxima at 380 and 490 nut when bound to 
Plant-type ferredoxins75 also exhibit absorbance 
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spectra with maxima at 280, 330, 420 and 460 nm. These 
bands in the visible region decrease by about 50% on 
reduction of the iron. 	Lactoferrin76 which binds Fe 
through tyrosine, aspartic acid and histidine ligands 
shows a maximum at 466 nm. By comparison the position of 
the band observed for (43) suggests that this compound may 
bind iron through sulphur or oxygen ligands. 
The ultraviolet spectra of the individual peptide 
sequences 92-120 (36) and 243-267 (37) showed no 
additional bands in the visible region on the addition of 
ferrous sulphate. A sloping baseline was observed between 
300 and 500 nm in each case, presumably due to 
aggregation. 	The absorbance observed between 400 and 
700 run, with maximum at 550 run, for (43) appears to result 
from a cooperative effect between the two peptides. 
The addition of ACV to the peptide produced a small 
increase in absorbance in the 300 nm region both in the 
presence of and absence of Fe2+,  Figure 26. This change 
is similar to that observed for IPNS, Figure 24. 
IPNS(243-267)-(Aua) 3-IPNS(92-120) (48) was found to be 
insufficiently soluble at pH 8 for meaningful comparison. 
The UV spectrum was recorded revealing the tyrosine 
absorbance at 276 nm and a sloping baseline from 300 to 
400 nm. 	Addition of ferrous sulphate increased the 
absorbance between 300 and 400 nm but produced no obvious 
effect above 400 nm. The increased lipophilicity of this 
compound was demonstrated by the lower solubility and 
increased aggregation observed in comparison to (43). 
In conclusion the UV absorbance in the presence of 
Fe2+ indicated that (43) but not seemingly (48) binds 
iron. The inability of (48) to bind iron may be due to 
masking of the ligands by the alkyl chain. This might not 
be a problem as in the envisaged model system the alkyl 
chain should be removed from interference with the 
peptides by its affinity for the organic phase. 
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a) i) peptide plus one equivalent of Fe2+,  ii) peptide plus 





b) i) peptide alone, ii) peptide plus one equivalent of ACV, 
iii) peptide plus two equivalents of ACV, iv) peptide 
plus two equivalents of ACV and one equivalent of Fe 2+ 





Fluorescence emission of peptides and proteins 
originates from the aromatic amino acids. 	Fluorescence 
emission is observed when excited electrons return from 
the first excited state to the ground state. 	As some 
energy is always lost by non-radiative processes such as 
vibrational transitions, the energy of the light emitted 
is always less than that of the absorbed light. 	The 
observed fluorescence depends predominantly on the local 
environment of the chroinophores. The fluorescence maximum 
for tyrosine is 303 nm and changes in emission are 
predominantly seen as changes in intensity at this 
wavelength. 
The fluorescence spectrum of IPNS(243-267)-Aua-IPNS 
(92-120) (43) which contains six tyrosine residues 
was recorded in 50 mM NH 4OAc, pH 80. 	The tyrosine 
chromophores were excited at 280 nm and the emission 
intensity at 303 nm was recorded with sequential addition 
of ferrous sulphate. The tyrosine emission at 303 nm was 
observed to decrease from 60 to 25 with the addition of 
ferrous sulphate, (see Figure 27a). Addition of ferrous 
sulphate to the buffer alone produced no effect. 	The 
change in the tyrosine fluorescence emission on the 
addition of Fe 2+ suggests that the peptide does bind iron. 
From this type of experiment it is however not possible to 
say whether the iron is bound by the tyrosine or a residue 
close to one or more of the tyrosine residues, e.g. 
binding of the Fe2+ to Cys106 or Cys255 may affect the 
fluorescence of Tyr107 or 258 respectively. 	It is also 
possible that binding iron may cause a change in the 
structure of or induce structure in the peptide, hence 
changing the environment of one or more tyrosine residues. 
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Equivalents of FeSO 4 added 
IPNS(243-267)-Aua-IPNS(92-120) (43) 
IPNS(243-267)-(Aua) 3-IPNS(92-120) (48) 
Figure 27. Fluorescence spectra. 
In the case of IPNS(243-267)-(Aua) 3-IPNS(92-120) (48), 
the addition of ferrous sulphate increased the tyrosine 
fluorescence emission intensity from 15 to 40 (Figure 
27b). 	This compound again appears to behave in a 
different manner to (43). 	The addition of Fe2+ again 
changes the tyrosine fluorescence suggesting binding may 
be occurring. The fact that the fluorescence increases in 
this case may be a result of a different starting 
conformation of the compound rather than a different means 
of binding. 	In both cases continual addition of iron 
produced a change in the emission intensity with no 
evidence for levelling off as would be expected when 
maximum binding is reached. 
Circular Dichroism 
When a chromophore is part of an asymmetric structure, 
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or when it is immobilised within an asymmetric 
environment, left- and right-handed circularly polarised 
light are absorbed to different extents. This phenomenon 
is called circular dichroism (CD). 	For peptides and 
proteins CD spectra in the amide region (170-250 nm) may 
be used to estimate the secondary structure content. 
The CD spectra of IPNS(243-267)-Aua-IPNS(92-120) (43) 
were recorded in 20 mN Tris HC1 pH 8.0 and a 1:1 mixture 
of this buffer and trifluoroethanol. 	In each case an 
FeSO 4 solution was added and any structural changes noted. 
Similar spectra were recorded for IPNS(243-267)-(Aua) 3-
IPNS(92-120) (48) but using methanol rather than TFE. The 
results obtained are shown in Figures 28 and 29 and the 




% Structure Content 
a-helix a-sheet Remainder 
43 Tris buffer 0 7±0.59% 46±1.1% 47±1.0% 
43 Tris buffer 2 of tt if 
43 Tris buffer 4 If it 
43 Tris + TFE 0 14±0.97% 41±1.9% 45±1.6% 
43 Tris + TFE 2 15±1.9% 55±1.9% 30±3.3% 
48 Tris buffer 0 1±1.7% 67±1.8% 32±3.1% 
48 Tris buffer 2 0±3.3 x 67±1.6% 33±1.6% 
l0% 
48 Tris + MeOH 0 8±1.5% 52±2.1% 40±2.6% 
48 Tris + MeOH 4 4±1.8% 52±1.9% 43±3.2% 
Table 4. Structure content from CD analysis. 
Discussion 
The compound with the short linker (43) was found to 
display more a-helical content with respect to the 
compound with the long linker (48). 	This result is in 
agreement with the insolubility of compound (48) seemingly 
due to aggregation and 13-sheet formation. 
In the presence of 50% TFE compound (43) displayed a 
substantial increase in a-helical content. However in all 
cases the addition of Fe2+ unfortunately produced 
virtually no effect on the structure content. Again these 
results must be considered in the context of the solvent 
in which the spectra were recorded. These CD spectra were 
recorded in either purely aqueous or miscible 
organic-aqueous systems. This must be compared with the 
proposed mimic system in which a two phase organic-aqueous 
system is used. Any effect on the structure caused by 
interference by the linker would presumably be removed to 
a greater extent in the two phase system. This would be 
expected to be important especially in the case of the 
compound with the long linker (48) where this long 
lipophilic unit appears to have a substantial effect on 
the behaviour of the compound. 
-10000 
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A further technique which may have been useful in 
observing iron binding is n.m.r. 	Unfortunately this 
technique could not be applied due to the relatively high 
concentration (- 1 mM) of compound required in an aqueous 
system and the poor solubility of the compounds. 
2.1.8 Studies on the Possible Mimicking of the Enzyme 
The cyclisation of a variety of ACV analogues by IPNS 
has been studied and hence cyclisation and assay 
conditions are well established. 	For the proposed two 
phase system the cyclisation conditions described by 
Jensen et al.77 (Tris HC1 buffer (pH 7.0) 50 inN, ascorbic 
acid 2.8 inN, and FeSO 4 45 M) were used as the aqueous 
layer and n-octane was used as the organic layer. Two 
penicillin precursor peptides were investigated. 	These 
were the natural substrate &-(L-a-aminoadipyl)-L-
cysteinyl-D-valine (ACV) and the benzylpenicillin or 
penicillin G precursor, bis-phenylacetyl-L-cysteinyl-D- 
valine (PCV). 	HPLC assays were derived based on the 
published assay conditions77'78'79. 	Biological assays 
using B. calidolactis and B. licheniformis were also 
carried out. 
HPLC Assay for ACV Cyclisation 
The published incubation conditions for the enzyme 
were initially followed and subsequently repeated 
increasing the temperature to 40°C. 	With the knowledge 
that the enzyme is thought to bind the Fe2+ via three 
histidine ligands and the fact that compounds (43) and 
(48) contain only two histidine residues, L-histidine was 
added to some reactions. 	The retention time of an 
authentic sample of the desired cyclisation product, 
isopenicillin N, was established to be 15 mins. In some 
reactions a peak was observed at this position, however in 
these instances the peak was also observed in the absence 
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of the 3-lactaxn precursor and/or compound (43) or (48). 
New solutions were prepared and different columns and HPLC 
systems were investigated, but this peak still appeared 
sporadically. 	The peak appeared to originate from the 
buffer solution and could not be consistently eradicated. 
The appearance of this peak complicated the identification 
of possible cyclisation products. 	The results are 
tabulated in the experimental section, Table 14. 
HPLC Assay for PCV Cyclisation 
Bis-phenylacetyl-L-cysteinyl-D-valine 	(PCV) 	was 
incubated under analogous conditions to those described 
for ACV. The optimal peak separation of the cofactors, 
starting material and desired product, was found to result 
in retention times for the PCV monomer and Penicillin G of 
18.5 mm. (37 mm) and 22.0 mm. (44 mm) respectively. The 
cyclisation reactions were carried out with no evidence 
for a cyclisation product observed. 	The results are 
tabulated in the experimental section, Table 15. 
Biological Assays 
The reactions were assayed using a B. calidolactis 
hole-plate assay in which the presence of a 3-1actam is 
indicated by a zone of inhibition of the organism growth. 
No inhibition was observed for the reactions with ACV, 
down to the limit of detection at 15 ng. 
The absence of the amino side-chain function in PCV 
enabled the use of larger amounts of material with 
subsequent concentration of the 'products' for the assay. 
The B. calidolactis is also more sensitive to penicillin G 
in comparison to isopenicillin N. No inhibition of growth 
was however observed. 
A f3-lactarnase induction assay was carried out in which 
the reactions were incubated on a B. lichenitormis plate 
which was subsequently flooded with nitrocephin solution. 
This screen detects the presence of -1actam compounds, as 
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in the presence of a t3-lactam the organism produces an 
inducible 13-lactamase. 	The 3-lactamase is detected by 
flooding the plate with nitrocephin which on hydrolysis 
produces a red colouration. This assay was employed to 
investigate the possibility that the tripeptides may have 
undergone a single cyclisation to a monocyclic -lactaxn 
system. Unfortunately no -1actamase was detected. 
Having established that under these conditions 
compounds (43) and (48) do not cyclise penicillin 
precursors a competitive assay was devised to investigate 
whether any iron or substrate binding may be observed. 
The reactions with ACV were incubated to allow binding to 
the compound (43) or (48) and then incubated a further 
hour in the presence of IPNS. The control reaction with 
IPNS in the absence of compounds (43) and (48) established 
that under these conditions IPNS does cyclise the 
tripeptide ACV to isopenicillin N. 
In the absence of compounds (43) and (48) cyclisation 
of the ACV by IPNS produced a zone of inhibition of 30 mm 
diameter. 	In the presence of (48) this was reduced to 
20 mm and in the presence of (43) only a trace of 
inhibition was observed, see Figure 30. 	Compounds (43) 
and (48) and in particular IPNS(243-267)-Aua-IPNS(92-120) 
(43) appear to interfere with the action of the enzyme. 
This may be the result of many different factors, e.g. the 
peptides may preferentially bind the cofactors or the 
substrate or the peptides may in fact bind to the enzyme. 
Concluding Remarks 
Under the conditions investigated no cyclisation of 
the penicillin precursors was observed. 	These peptides 
however display interesting properties. In particular 
IPNS(243-267)-Aua-IPNS(92-120) (43) by some unknown 
mechanism, virtually completely inhibits the enzyme IPNS. 
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1) IPNS alone, 2) IPNS + (43), 	3) IPNS + (48), 
4) IPNS alone. 
Figure 30. B. Calidolactis hole plate assay for the 
cyclisation of ACV by IPNS in the presence 





When the body is challenged by a foreign substance an 
immune response is initiated in order to locate, 
neutralise and eliminate the foreign substance. 	One 
mechanism of immunity results in the secretion of proteins 
(antibodies) which bind specifically to the foreign 
molecules. This type of immunity is increased by repeated 
exposure. Many small chemicals (haptens) including 
peptides can be used to raise antibodies if they are 
coupled to a large protein (carrier). When the sequence 
of a protein is known, anti-peptide antibodies can be 
prepared, targetting the particular region of the protein 
from which the peptide sequence is taken. 
However, the major disadvantage associated with anti-
peptide antibodies is that they may not recognise the 
native protein. In order to achieve recognition between 
the anti-peptide antibodies and the native protein the 
peptide sequences must be located on the surface of the 
protein. There are no strict rules concerning the choice 
of the peptide sequences, however, the following 
guidelines have been developed. 	Sequences containing a 
high percentage of hydrophilic residues are likely to be 
exposed on the protein surface. The presence of proline 
residues in synthetic peptides has been suggested, as 
3-turns often form portions of known epitopes. Carboxyl 
and amino terminal sequences are often exposed and often 
provide good targets. 
If anti-peptide antibodies are prepared which 
recognise the native protein those antibodies may be used 
to detect the presence of the protein. 	In the case of 
IPNS a use for such antibodies could be envisaged in the 
detection of the enzyme in e.g. soil sample fermentations. 
Structural similarity between the IPNS enzymes from 
different species could also be probed by determining 
whether antibodies raised to the sequence of one species 
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recognised the native enzyme from another species. 
Two sequences from IPNS were selected for synthesis 
and subsequent immunology. 	The N-terminal sequence 
consisting of residues 1 to 21 (53) and a highly conserved 
sequence, residues 268-291 (58), were prepared. 
2.2.2 The N-Terminal Sequence IPNS(1-21) 
H-Met-Gly-Ser-Val -Pro-Val-Pro-Val -Ala-Asn-Val -Pro-Arg-
Ile-Asp-Val-Ser-PrO-LeU-Phe-G1Y-OH (53) 
IPNS(1-21) (53) was synthesised using standard Fmoc 
based SPPS. 	The synthesis proceeded smoothly with the 
synthesis monitoring showing no indication of a drop in 
the coupling efficiency. 	Acid cleavage of the crude 
material from the resin resulted in a very clean product 
with one major impurity (10% weight). This impurity was 
isolated during purification by semi-preparative reverse 
phase HPLC and was found to exhibit an amino acid analysis 
consistent with the required sequence. 	FAB mass 
spectrometry however showed a molecular ion at 2134 
corresponding to [MH+_18]. The impurity was postulated to 
be the result of an asparagine side-chain dehydration to 
the cyano derivative, as the side-chain amide was 
unprotected during the synthesis. 	The major peak was 
isolated by semi-preparative reverse phase HPLC and its 
identity as the desired peptide (53) confirmed by full 
characterisation. 
Towards the end of the synthesis one third of the 
resin was removed after the coupling of Ser(3). 	This 
resin-bound peptide (49) was used to investigate the 
coupling of the final two residues, Met(l) and Gly(2) as a 
dipeptide. 
The use of X-Gly and X-Pro dipeptides has been 
employed in SPPS in order to minimise the number of 
chemical steps80. 	C-terminal glycine and proline 
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fragments are chosen to minimise racemisation of the 
fragments during activation. The coupling of amino acids 
as dipeptides also has the advantage of ensuring the 
introduction of equivalent amounts of both residues. 
Glycine in particular has been observed on occasion to be 
incorporated into the growing peptide as a Gly-Gly unit81. 
Dipeptide couplings have also been shown to proceed 6 to 
15 times faster than the corresponding monomers82. 
Dipeptide coupling in SPPS was investigated using the 
IPNS(1-21) system. 	FmocMetGlyOH (69) was prepared and 
coupled to the resin-bound IPNS(3-21) (50). 	The two 
methods of activation investigated, a DIC activated HOBt 
ester and a diphenyiphosphinic mixed anhydride each 
produced quantitative couplings. After cleavage from the 
resin the crude peptide in each case was comparable on 
analytical HPLC (Figure 31), mass spectrum and amino acid 
analysis, to that obtained by total stepwise synthesis, 
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A second use of dipeptide couplings in SPPS is in the 
avoidance of DKP formation, commonly observed for alkyl 
esters of dipeptides83, Scheme 15. 
011C  ollo 
CH 
NH 
I 	1 + RÔH 
HNN '-%.0"0
CH 
Scheme 15. Diketopiperazine formation. 
This undesirable reaction is particularly pronounced 
for glycine and proline containing dipeptides. 	In the 
case of glycine the absence of a side-chain sterically 
favours the cyclisation, while for proline the cyclic 
side-chain lies in the plane of the DKP molecule and is 
hence out of the way during ring closure. 	The fused 
structure of proline also causes the peptide to bend back 
upon itself thus promoting attack on the ester bond by the 
amine. DKP formation is of particular importance in SPPS 
where the peptide is attached to the polymer support via 
an ester linkage. When the amino group of a resin-bound 
C-terminal dipeptide is deprotected the dipeptide may 
undergo DKP formation and be eliminated from the resin. 
The process is usually only a minor side reaction, 
however, if the coupling of the third residue is for some 
reason hindered or slow, or if proline or glycine are 
involved as either of the resin-bound amino acids, 
significant DKP formation may be observed. In general DKP 
formation at this point may be minimised by creating 
favourable conditions for the coupling of the third 
residue, such as the use of a highly reactive derivative 
76 
Discussion 
in high concentration. 	The dipeptide-resin stage may 
however be avoided by coupling the second and third 
residues as a dipeptide unit84'85. 
The first three C-terminal residues of IPNS(1-21) were 
used as a test system for preliminary work on dipeptide 
coupling, using diphenyiphosphinic anhydride92 activation, 
to avoid DKP formation. Synthesis of FmocLeuPheGlyOH (77) 
by both stepwise synthesis and the use of an FmocPheGlyOH 
(71) dipeptide resulted in significant loss of material. 
The use of an FmocLeuPheOH (73) dipeptide however resulted 
in quantitative recovery of the tripeptide suggesting that 
previous loss of material may have occurred as a result of 
DKP formation, see Table 5. 
Synthetic Route % Yield 
FmocLeu + Phe + Gly 60 
FmocLeu + PheGly 40 
FmocLeuPhe + Gly 100 
Table 5. Synthesis of FmocLeuPheGlyOH (77). 
DKP formation was found to be much more pronounced 
when proline was used as the C-terminal amino acid, 
complete loss of the dipeptide PhePro from the resin was 
observed, see Table 6. 
Synthetic Route % Yield 
FmocLeu + Phe + Pro 
FmocLeuPhe + Pro 
0 
95 
Table 6. Synthesis of FniocLeuPheProOH (78). 
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The tripeptide FmocLeuProGlyOH (79) was successfully 
prepared using both stepwise synthesis and a coupling of 
FmocLeuProOH (75) to the resin-bound glycine. 	DKP 
formation appears to be more pronounced for proline bonded 
directly to the resin rather than in position two. 
In examining the coupling of these dipeptides the 
diphenyiphosphinic anhydride activation was compared to 
DIC mediated HOBt activation. 	The diphenylphosphinic 
anhydride in general produced a higher level of coupling. 
The activation of dipeptides or larger peptide 
fragments however may lead to significant levels of 
















Scheme 16. Dipeptide racemisation via oxazolone formation 
The degree of racemisation observed is dependant on 
the C-terminal amino acid and on the coupling procedure 
employed. The extent of racemisation encountered in the 
dipeptide couplings was determined using a reverse phase 
HPLC assay capable of separating the di and tripeptide 
diastereojsomers. The results are summarised in Table 12 
in the experimental section. 
HOBt has been reported to suppress racemisation, this 
was corroborated by the negligible amount of racemisation 
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observed for the HOBt mediated coupling of FmocLeuPheOH to 
glycine and proline resins. Diphenylphosphinic anhydride 
coupling however resulted in an increased level of 
racemisation. 	This may be a result of the appreciable 
levels of base required for the coupling. The level of 
racemisation was found to increase with the addition of 
the base DMAP and with the lowering of the temperature. 
By lowering the temperature the coupling rate is lowered 
and perhaps the probability of oxazolone formation by the 
activated dipeptide increased. 	A higher level of 
racemisation was also observed during the coupling of the 
dipeptide onto a proline resin than with a glycine resin. 
The increased steric hindrance of coupling to proline may 
account for this. 
Conclusion 
Diphenyiphosphinic anhydride has shown itself to be an 
efficient coupling reagent. However if it is to be used 
in fragment coupling further work is required on the 
suppression of racemisation, when peptide fragments with 
C-terminal amino acids other than glycine and praline are 
involved. 
N.rn.r. of IPNS Residues 1-21 
The synthesis of IPNS(l-2l) (53) was carried out with 
a view to the production of antibodies specific to the 
sequence. The sequence was also examined for the presence 
of secondary structure using two-dimensional n.m.r. 
The proton n.m.r. of IPNS(1-21) (53) was recorded in 
90% H 20, 10% D 20. The amino acid residues were assigned 
by the method of Wuthrich86, using one-dimensional and 
COSY and TOCSY two-dimensional spectra. The NH-aCH cross 
peak assignments are shown in Figure 32. 
A "walk" along the amide backbone of the peptide and 
hence sequencing of the peptide was achieved using a 







All ROESY and NOESY long range cross peaks were assigned 
to coupling within a residue or between adjacent residues. 
No cross peaks corresponding to secondary structure were 
observed, indicating that in the aqueous environment the 
peptide adopts a random coil conformation. 
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Figure 32. The NH-cCH region of the TOCSY spectrum 
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Figure 33. A superimposition of the NH-aCH regions of 




N-Cysteinyl IPNS(1-21) (55) 
As discussed previously (Page 73), in order to raise 
antibodies to a peptide the peptide must first be coupled 
to a carrier protein. A common method of coupling is via 
the suiphydryl side-chain of cysteine. 	NcX_cysteinyl 
IPNS(1-21) (55) was therefore prepared by coupling FmocCys 
(t-butylthio)OH to resin-bound IPNS(1-21) (52). The Finoc 
group was cleaved and the peptide readily released from 
the resin and the side-chain protection removed by acid 
treatment. After purification to give a single peak on 
HPLC by semi-preparative reverse phase HPLC the cysteine 
side-chain protection was successfully removed. 
Polyclonal Antibodies 
The Cys-IPNS(1-21) (55) was conjugated to bovine serum 
albumin (BSA) and anti-sera against the conjugate were 
raised in seven rabbits. These anti-sera were studied in 
ELISA tests and on Western blots96. 
Enzyme-Linked Immunosorbent Assay (ELISA) 
An ELISA test was used to determine the concentration 
of peptide giving 50% inhibition of the response to each 
anti-serum (IC50). 	In this way a semi-quantitative 
measure of the affinity of the anti-serum for the peptides 
may be obtained, the higher the affinity for the peptide 
the less peptide required to bind the antibody and hence 
the lower the IC50. The procedure used in the ELISA tests 
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Figure 34. Schematic representation of an ELISA. 
The microtitre plates were first coated with 
IPNS(1-21)cys-ovalbuiain conjugate (antigen) and non- 
specific binding sites saturated with ovalbuinin. 	The 
anti-serum under test was incubated prior to addition to 
the plates with known concentrations of either IPNS(1-21) 
(53) or CysIPNS(1-21) (55) thus removing a proportion of 
the antibodies specific to these peptides. On addition to 
the plates specific antibodies remaining in the serum bind 
to the antigen on the plate wall. After washing to remove 
unbound antibodies, anti-rabbit antibodies chemically 
linked to biotin were added. 	These biotinylated 
anti-rabbit IgG bound to any bound antibody and were 
detected by the addition of streptavidin-alkaline 
phosphatase, followed by p-riitrophenyl phosphate. 	The 
enzyme labelled streptavidin binds strongly to biotin and 
the complex may be detected by the addition of the enzyme 
substrate p-nitrophenol phosphate which produces a yellow 
colouration. The intensity of the colour which develops 
is proportional to the amount of enzyme-linked 
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antiglobulin that is bound, which in turn is proportional 
to the amount of bound antibody. The optical density at 
405 nm (0D405) was measured and used to determine the IC 50
values for the anti-sera. The values are shown in Table 
17, experimental section. Anti-sera 6233, 6796 and 6454 
were found to display low IC., values, indicating good 
affinity for the peptides. 
By following the same procedure but omitting the 
incubation of the anti-serum with the peptides prior to 
addition to the plates a measure of the anti-serum titre 
may be obtained. This value corresponds to the dilution 
of anti-serum giving a four-fold higher response compared 
to the non-specific binding control and thus gives an 
indication of the affinity and amount of antibodies 
present. Anti-serum 6454 was found to have a titre value 
of 1 280 000, much greater than the other anti-sera. 
Western Blotting 
The anti-sera were used to probe Western blots of 
antigen from IPNS-producing strains. The bound rabbit IgG 
was detected using biotinylated anti-rabbit IgG and 
streptavidin-gold and silver enhancer. A major band was 
detected at 40 kDa, i.e. the region where the IPNS enzyme 
would be expected, and four minor bands at approximately 
30 kDa, see Figure 35. The intensity of these bands was 
proportional to the anti-IPNS titre measured in the ELISA, 
with anti-serum 6454 giving the best staining. 	These 
results show that under the conditions of a Western blot 
the antibodies raised to the N-terminal peptide IPNS(1-21) 
(53), recognise and bind to the native enzyme IPNS. These 
antibodies may therefore be employed in the detection of 
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2.2.3 IPNS Residues (268-291) 
H-Pro-Ala-Pro-Ile-His-Arg-Val-LYS-Trp-Val-ASfl-G1UG1U-Arg-
Gln-Ser-Leu-Pro-Phe-Phe-Val-Asfl-LeU-Gly-OH (58) 
The second sequence synthesised for use in 
immunological studies was IPNS(268-291) (58). 	This is a 
stretch of twenty-four amino acid residues constituting 
one of the most highly conserved regions in the primary 
amino acid sequence of IPNS. The sequence also contains a 
relatively high amount of proline and hydrophilic 
residues, making it a suitable candidate for immunological 
work. 
The sequence was synthesised using the standard SPPS 
cycles, one half of the resin (56) was removed on 
completion of the synthesis and FmocCys(t-butylthio) was 
coupled to the remaining half. 	Both peptides were 
successfully cleaved and purified by a combination of gel 
filtration and semi-preparative reverse phase HPLC. 
Analysis of each peptide confirmed 	& 	identity. 	The 
immunological studies on these peptides are currently in 
progress. 
N.m.r. of IPNS(268-291) 
The possible adoption of secondary structure by the 
peptide (58) was examined using two-dimensional n.m.r. 
The proton n.m.r. of IPNS(268-291) (58) was recorded in 
90% H 20, 10% D 20. 	The spectra were analysed and fully 
assigned by the procedures outlined for IPNS(1-21) (53). 
The NH-aCH cross peak assignments are shown in Figure 36. 
Sequencing of the peptide was again achieved by a 
"walk" along the amide backbone (Figure 37). All NOESY 
and ROESY cross peaks were assigned with no evidence 
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Figure 37. A superimposition of the NH-aCH regions 
of the TOCSY and ROESY spectra for 
IPNS(268-291) (58). 
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2.3 	CONCLUDING REMARKS 
The efficacy of SPPS for the synthesis of these 
peptides containing large lipophilic units has been 
clearly demonstrated. 	This technique has enabled the 
preparation of these compounds with the incorporation of 
unnatural amino acids to produce modified systems 
unattainable by molecular biology techniques. 	The 
importance of a monitoring system for the synthesis was 
illustrated by the ability to optimise synthesis 
conditions based on the coupling efficiencies observed by 
the Fmoc cleavage monitoring. 	The use of dipeptide 
coupling in SPPS to avoid Gly-Gly and DKP formation has 
been demonstrated. Diphenylphosphinic anhydride has been 
shown to be an extremely efficient activating reagent for 
the coupling of both the lipophilic linkers and dipeptides 
not prone to racemisation. 
Preliminary immunological work on the sequence 
IPNS(1-21) has provided promising results for future work 
in this area. Antibodies to this sequence have been shown 
to recognise the peptide in ELISA tests. More importantly 
these antibodies recognised and bound to the native enzyme 
IPNS on a Western blot. 
Furthermore, following the synthesis of the peptides 
containing lipophilic modification, HIC has been shown to 
be effective in their purification, exploiting the 
lipophilic nature of the compound. The choice of solvent 
and the use of mixed organic/aqueous systems has been 
demonstrated to be crucial in the handling of these 
compounds. 
Spectroscopic studies have indicated that the 
IPNS(243-267)-Aua-IPNS(92-120) (43), binds iron. However, 
the failure of the peptides to cyclise penicillin 
precursors although disappointing was not unexpected. 
More importantly the conception of the two phase system 
appears to be viable as demonstrated by the high 
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solubility of the compounds in the system. This type of 
modified peptide and two phase system may well find future 
application in the mimicking of more well established 
enzyme mechanisms, protein conformation and perhaps 
receptor binding pockets. 
CHAPTER 3 : EXPERIMENTAL 
3.1 NOTES 
All amino acids were purchased from the SAS group of 
companies and unless otherwise stated were of the 
L-configuration. 	Melting points were recorded in open 
capilliaries on a BUchi 510 melting point apparatus and 
are uncorrected. Optical rotations were measured on an 
AA1000 polarimeter using a 10 cm cell in the solvents 
indicated in the text. Thin layer chromatography (t.l.c.) 
was carried out on commercially available plastic sheets 
pre-coated with silica gel 60 F254 (Merck) in the 
following systems: (A) CHC1 3/MeOH (9:1), (B) n-hexane/ 
ethyl acetate 	(7:3), 	(C) 	CHC1 3  /MeOH/AcOH 	(9:1:0.5), 
(D) n-BuOH/AcOH/H 20 (3:1:1), (E) CHC1 31  (F) ethyl acetate. 
Visualisation of the compounds was achieved by ultraviolet 
absorption at 254 nm and ninhydrin for free amino groups. 
Infrared spectra were recorded on a Perkin Elmer 781 
double beam spectrophotometer in the solvent indicated or 
by KBr disc technique. 	Polystyrene (1603 cm-1) was 
employed as the standard. 	Ultraviolet spectra were 
recorded on a Varian Cary 210 spectrophotometer in the 
solvent indicated. 	High and low resolution fast atom 
bombardment (FAB) spectra were measured on a Kratos MS50TC 
machine. Proton nuclear magnetic resonance (n.m.r.) were 
recorded on a Jeol FX-60 (60 MHz), a Bruker WP80 (80 MHz) 
or a WP200 (200 MHz) in the solvent stated, using 
tetramethylsilane (TMS) as the external standard (6 = 
0.00). Phosphorus-31 n.in.r. were recorded on a Jeol FX-90 
(36.3 MHz) machine and the chemical shifts recorded 
relative to an external 85% aqueous phosphoric acid 
standard, assigned to zero. Carbon-13 n.in.r. spectra were 
recorded on a Bruker WP200 machine operating at 50.3 MHz. 
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The solvents used are indicated in the text and chemical 
shifts were measured relative to TNS assigned to zero. 
Elemental analyses were performed on a Carlo Erba 
elemental analyser (model 1106). 	All solvents were 
distilled before use and the following were dried using 
the reagents given in parenthesis when required: benzene 
(sodium wire), dichloromethane (calcium hydride), diethyl 
ether (sodium wire), ethanol (magnesium iodine), 
tetrahydrofuran (sodium, benzophenone). 
3.2 SOLID PHASE PEPTIDE SYNTHESIS 
The peptides described, unless otherwise stated, were 
synthesised on an Applied Biosystems 430A automated 
peptide synthesiser. The synthesiser was fitted with a 
monitoring system consisting of either an Applied 
Biosystems 757 absorbance detector and a Hewlett Packard 
HP 3396A integrator or an Applied Biosystems 759A 
absorbance detector and a Spectra Physics Chrom Jet 
integrator. 	The dimethylformamide (DMF) and 1,4-dioxan 
used were peptide synthesis grade, supplied by Rathburn 
Chemicals. 	All amino acids were purchased from 
Novabiochem and Raylo (FmocArg(Pmc)OH), and unless 
otherwise stated were of the L-configuration. Amino acid 
analysis was carried out on an LKB 4151 amino acid 
analyser following sealed Carius tube hydrolysis with 
constant boiling hydrochloric acid at 110°C for 12-36 
hours. High performance liquid chromatography (HPLC) was 
carried out using either a Waters system: 2 x 600A pumps, 
a U6K injector, a 680 automatic gradient controller and a 
model 441 ultraviolet detector; or one of two Applied 
Biosystems systems: A) 2 x 1406A solvent delivery systems, 
a 1480A injector/mixer and a 1783A detector/programmer, B) 
2 x 400 solvent delivery systems, a 491 injector/mixer and 
a 783A detector/programmer. 	Analytical and semi- 
preparative separations were accomplished using the 
conditions and columns described in the text. 	Peptide 
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sequencing was performed by Welmet on an Applied 
Biosystems 477A protein sequencer. Proton n.m.r. spectra 
were recorded on a Varian VXR 5000 (600 MHz) machine in a 
9:1 H 2 0/D 2 0 mixture. Fluorescence spectra were recorded 
on a Perkin Elmer LS-5 luminescence spectrophotometer. 
Circular dichroisin (CD) spectra were performed on a JASCO 
J600 spectropolaritneter. 
An orthogonal synthesis strategy was adopted in which 
the base-labile 9-fluorenylmethoxycarboflyl (Fmoc) group 
was employed for Na-amino protection. 	This is 
complimented by the use of acid-labile side-chain 
protection and an acid-labile peptide-resin linkage 
provided by the p-alkoxybenzyl alcohol group (Wang). The 
side chain protecting groups used were as follows: t-butyl 
(But) ethers for serine, threonine and tyrosine; But 
esters for aspartic and glutainic acid; t-butoxycarbonyl 
(Boc) for lysine; 4,4'-dimethoxybenzhydryl (Mbh) or no 
protection for asparagine and glutainine; r-triphenylinethyl 
(trityl) or ir-t-butoxymethyl (Bum) for histidine and 
2,2,5,7, 8-pentamethylchroman-6-sulphonyl 	(Pmc) 	for 
arginine. A non-acid-labile cysteine protecting group was 
used: t-butylthio. 
The first amino acid was coupled to the resin outwith 
the synthesiser and the resin substitution determined by 
UV analysis of the Fmoc deprotection for an aliquot. 
The syntheses were monitored in a semi-quantitative 
manner by passing the deprotection solution through a UV 
detector (314 or 302 nm). 
Most residues were double coupled, firstly as a 
symmetrical anhydride and secondly as a l-hydroxybenzo-
triazole (HOBt) active ester. Exceptions were asparagine, 
arginine, glutamine and histidine which were coupled twice 
via their HOBt esters and glycine which was single coupled 
as a symmetrical anhydride. 
Deprotection, activation, coupling and capping were 




The resin was capped with 1 ml of 0.5 N acetic 
anhydride in DMF and 1 ml of 0.5 N pyridine in DMF for 2 
minutes, drained and washed twice then capped a second 
time for 4 minutes. 
2. Wash: 
The resin was washed 5 times with DMF. 
3. Deprotection: 
The resin was deprotected with 20% piperidine in DMF 
for 5, 3, 3 and 1 minutes. 	After each deprotection an 
aliquot of the solution was removed, diluted and passed 
through a UV detector connected to an integrator. 	A 
semi-quantitative measure of the previous coupling 
efficiency was thus obtained. The resin was drained and 
washed twice between each consecutive deprotection. 
4. Wash: 
The resin was washed 5 times. 
5. Coupling: 
The resin was coupled for 30 minutes with the 
diisopropylcarbodiixnide (DIC) activated symmetrical 
anhydride of the amino acid. 	The amino acid was 
preactivated for 15 minutes prior to addition to the 
resin. The resin was washed and drained twice. 
A second coupling (recoupling) was performed in the 
form of a DIC activated HOBt ester of the amino acid, 
preactivated for 20 minutes. This coupling was also 
for a period of 30 minutes. 
6. Wash: 
The resin was washed 4 times. 
These cycles were repeated throughout the synthesis, 
with the appropriate 'end cycle' added, depending on the 
requirement for a free N-terminal or Fmoc derivatised 
peptide. 
The substitution and resin loading of Fmoc derivatised 
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peptides were quantitatively determined in the following 
manner. A small sample of the resin was dried and a known 
amount deprotected in a 10 ml solution of 20% piperidine 
in DMF. 	The UV absorbance of the solution was then 
measured and a computer programme then used to calculate 
the substitution and loading87. 	This method was used 
throughout the described work to determine the 
substitution and loading values quoted. 
3.3 EXPERIMENTAL 
Coutlina the C-Terminal Amino Acid onto the p-Alkoxybenzyl 
Alcohol Resin 
The first amino acid was coupled to the resin outwith 
the synthesiser using one of the following coupling 
procedures. 
Diphenyiphosphinic Anhydride Coupling (Ph 2PO 2POPh 2 ) 
The Fmoc-amino acid (6.3 mmol) was dissolved in DMF 
(30 ml) and diphenyiphosphinic anhydride (2.6 g, 6.3 mmol) 
and N-methylmorpholine (NMM) (0.7 ml, 6.3 mmol) were 
added. The solution was activated in an ultrasonic bath 
for 5 minutes before addition to the p-alkoxybenzyl 
alcohol resin (2.0 g, 1.6 mmol) previously swollen in DMF 
(15 ml). 	4-Dimethylaminopyridine (DMAP) (9.2 mg, 0.08 
mmol), NMM (0.7 ml, 6.3 mmol) and 2,6-lutidine (1.4 ml, 
12.6 mmol) were added and the resin sonicated for 3 hours. 
The resin was filtered and washed well with DMF, DCN and 
1,4-dioxan. The resin substitution and percentage loading 
was then determined. 
Diisopropylcarbodiiinide Coupling 
The Fmoc-ainino acid (15.6 mmol) was dissolved in DMF 
(50 nil) and diisopropylcarbodiiniide (DIC) (1.22 ml, 7.8 
mmol) was added. 	The solution was sonicated for 10 
minutes, then added to the p-alkoxybenzyl alcohol resin 
(2.0 g, 156 mmol), previously swollen in DMF (4 ml). DMAP 
(9.0 mg, 0.08 mmol) was added and the resin sonicated for 
Experimental 
3 hours. The resin was then filtered, washed well and the 
substitution was determined. 
Resin 
Compound Amino Coupling Substitution Resin 
Number Acid Method inmol/g Loading 
29a Gly 1 0.543 81 
b Gly 1 0.544 83 
c Gly 1 0.592 91 
d Gly * 2 0.570 90 
e Gly 2 0.364 52 
30 Tyr(But) 2 0.518 86 
31a Pro 1 0.473 72 
b Pro 1 0.460 69 
32a Lys(Boc) 1 0.508 85 
b Lys(Boc)* 2 0.438 72 
* Required two couplings. 
Table (7). Summary of the Fmoc-amino acid derivatised 
p-alkoxybenzyl alcohol resins used. 
Resin Capping 
After coupling the first amino acid to the resin, 
unreacted hydroxyl groups were capped in the following 
manner. 
The resin (1.0 g) was swollen in DCM (50 ml) and 
cooled to 0°C on a salt/ice bath. Pyridine (0.5 nil) and 
Experimental 
benzoyl chloride (0.5 ml) were added and the resin stirred 
for 30 minutes at room temperature. 	The resin was 
filtered and excess reagents removed by washing with DCM. 
Isopenicillin N Synthase Residues (92-120) 




The synthesis was carried out using the functionalised 
resin FmocLys(Boc)-(OCH 2C6H 4OR) (32b) on a 0.5 mmol scale. 
The arginine, aspartic acid, cysteine, glutamic acid, 
lysine, serine and tyrosine were protected as previously 
indicated. 	The asparagine and histidine were protected 
with Mbh and trityl respectively. 	The couplings were 
carried out in DMF using a double coupling cycle (2 
equivalents) and the Fmoc deprotections monitored at 
314 nm. One third (0.17 mmol) of the resin was removed 
after the coupling of Glu(103) due to the excessive 
swelling of the resin. The final Fmoc group was left on 
the resin-bound peptide (3 3) (substitution 0.176 mmol/g), 
two thirds of which was stored for later use. The Fmoc 
was removed from the remaining resin by treatment with 20% 
piperidine in DMF for 20 minutes. The peptide was then 
cleaved from the resin (570 mg) and the side-chain 
protection removed (with the exception of the cysteine 
protection). This was achieved by treatment with TFA/H 20/ 
anisole/ethyl methyl sulphide (95:5:5:5; 50 ml), with 
sonication at room temperature. 	5 hours was found to be 
the optimum time. The resin was removed by filtration and 
washed with TFA (1 ml) and CHC1 3 (8 ml). The washings and 
filtrate were combined, concentrated in vacuo and the 
crude peptide (328 mg) was precipitated with diethyl 
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ether. 	The peptide was then dissolved in 30% aqueous 
acetic acid and applied to a Sephadex G25 column (90 x 
2.5 cm). The column was eluted with 30% acetic acid at 30 
ml h' with simultaneous monitoring at 254 and 277 nm. 
The peptide was eluted in fractions 20-31 (200-310 ml). 
These fractions were combined and lyophilised to yield a 
white fluffy solid (308 mg, 	94%). 	The cysteine 
t-butylthio protecting group was then removed. 	The 
cysteine-protected peptide (35) (40 mg, 0.01 mmol) was 
dissolved in TFE (6 ml), H 20 (0.4 ml) and Bu 3P (36 Al, 
0.01 mniol) was added. The reaction was sonicated for 2 
hours after which the solvent was removed in vacuo. The 
peptide (30.3 mg, 76%) was obtained by filtration and 
washing well with diethyl ether. 
The peptide was purified by semi-preparative HPLC on 
an Aquapore C1. reverse phase column (250 x 10 mm, 20 Am). 
A linear gradient of H 20/CH 3CN (0.1% TFA) 20-60%B over 20 
mm. was employed at a flow rate of 5 nil minl and UV 
monitoring at 214 nm. 	Removal of the solvents by 
lyophilisation gave the title compound (36), (15.0 mg, 
50%); amino acid analysis: Asx 2 1.96, Ser 3 2.61, G1x 1 
1. 11, Pro 	5.86, Gly1 1.02, Ala, 1.00, Cys1 0.16, Val, 
1.03, Ile 2 1.92, Leu 2 1.98, Tyr3 2.91, Phe 2 2.00, His1 
1.09, Lys 3 2.97, Arg 1 1.00; m/z (FAB) 3367.9 (Mt), 1683.1 
(M2+), HRMS C159H237N 38041S 1 requires 3367.73814, found 
3367.73799 	< 1 ppm; HPLC (Aquapore C18, 220 x 4.6 mm, 
7 m; A = H 20, B = CH3CN, 0.1% TFA, 10-90% B over 25 
mm.), Rt = 14.2 mm., 56.5% B; Elimans test88: requires 
3.8 x 10 	mnol dnr 3, found 3.8 x lO 	mol dm-3; the 




Isopenicillin N Synthase Residues (243-267) 
IPNS(243-267) 	(37) 
H-Asp- lie-Gin-Al a-Asp-Asp-Thr-Gly-Phe-Leu-I le-Asn-Cys-
Gly-Ser-Tyr-Met-Al a-His-Il e-Thr-Asp-Asp-Tyr-Tyr-OH 
The synthesis was carried out using the functionalised 
resin Fmoc Tyr(But)_(OCH2C6H4OR)  (30) on a 0.5 mmol scale. 
The aspartic acid, cysteine, serine, threonine and 
tyrosine side-chains were protected as previously 
described. The asparagine and glutamine were unprotected 
and the histidine protected by the trityl group. 	All 
couplings were carried out in DMF, employing a double 
coupling cycle with Fmoc deprotection monitoring at 
314 nm. The peptide was cleaved from the resin (200 mg), 
with simultaneous removal of the acid-labile side-chain 
protection by treatment with TFA/H20/anisole/ethyl methyl 
sulphide (95:5:3:3, 2.5 ml). 	The reaction was sonicated 
at room temperature for 2 hours. 	The resin was then 
removed by filtration, washing with TFA (0.5 ml) and CHC1 3 
(3 ml). 	The combined washings and filtrate were 
concentrated in vacuo and the resulting residue was 
dissolved in CHC1 3 (2 ml) and added dropwise to glacial 
acetic acid. The acetic acid was then diluted to 30% with 
water and applied to a Sephadex G50 (fine) column (91 x 
2.5 cm). The column was eluted with 30% aqueous acetic 
acid at 26 ml h 1 , monitoring at 254 and 277 nm. 	The 
desired peptide was eluted in fractions 20-30 (173-
260 ml), which were combined and lyophilised to yield the 
peptide (106 mg). The cysteine side-chain protection was 
removed by Bu 3P treatment. The peptide (80 mg, 30 mol) 
was 	suspended in TFE (5 ml), H 2  0 (1.2 ml) and Bu 3P 
(0.3 ml, 1 inmol) was added and the solution was sonicated 
for 1.5 hours. The solvent was removed in vacuo and the 
resulting white solid was washed with diethyl ether. The 
peptide was purified further by semi-preparative HPLC on 
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an Aquapore C18 reverse phase column (250 x 10 mm, 20 pm). 
A linear gradient of H 20/CH 3CN (0.1% TFA) 25-55% B over 16 
mm. was employed at a flow rate of 5 ml Injfll, UV 229 nm. 
Removal of solvents in vacuo gave the title peptide (37) 
(1.3 mg, 2%); amino acid analysis: Asx 6 5.98, Thr 2 1.82, 
Seri  0.91, G1x1 1.06, G1y 2 2.04, Ala 2 2.00, Cys1 0.45, 
Met., 1.00, Ile 3 2.83, Leu1 1.03, Tyr3 2.94, Phe1 1.05, 
His1 1.01; m/z (FAB) 2840.4, HPNS C 124H 178N 29044S 2 
requires 2842.20564, found 2842.20559 	< 1 ppm; HPLC 
(Aquapore C18, 220 x 4.6 mm, 7 Lm; A = H 20, B = CH 3CN 0.1% 
TFA, 10-90% B over 25 mm.), Rt = 14 mm., 57% B. 
11- (9' -Fluorenylmethoxycarbonylamino)undecaflOyl-
Isopenicillin N Synthase (92-120) (t-Butylthio) 
Fmoc Aua-IPNS(92-120) (t-butylthio) (39) 
1. DIC/HOBt Method 
The Fmoc group was removed from the resin-bound 
IPNS(92-120) (33) by treatment with 20% piperidine in DMF 
to give the free amino resin-bound IPNS(92-120) (34). 
FmocNH(CH 2 ) 10CO 2H (61) (18.6 mg, 0.044 mmol) and HOBt 
(6.0 mg, 0.044 mmol) were dissolved in DMF (2 ml) and DIC 
(7 il, 0.044 mmol) was added. 	The solution was stirred 
for 5 minutes then added to the resin-bound IPNS(92-120) 
(34) (50 mg, 8.8 mol). 	The resin was agitated in an 
ultrasonic bath overnight. The resin was filtered, washed 
well with DMF/DCM and diethyl ether and dried to give the 
resin-bound peptide FmocAua-IPNS(92-120) (39) (41.1 mg). 
The resin substitution was determined by small scale Fmoc 
cleavage to be 0.104 mmol/g, 59% loading. 	The Fmoc 
derivatised peptide was cleaved from the resin and the 
side-chain protection was simultaneously removed by mild 
acid treatment: the resin (30 mg) was sonicated for 5 
hours in TFA/H 20/anisole/ethyl methyl sulphide (95:5:5:5, 
5 ml). The resin was removed by filtration, washing with 
TFA (1 ml) and CHC1 3 (3 ml). The filtrate and washings 
were combined and the solvent was removed in vacuo. 
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Precipitation with diethyl ether gave the title compound 
(39) (16.3 mg); m/z (FAB) 3832.3 (M-29); HPLC (Aquapore 
C81 220 x 4.6 mm, 7 Am; A = H 20, B = CH 3CN, 0.1% TFA, 
10-90% B over 25 mm.), Rt = 17.2 mm, 68% B. 
2. DiphenyiphosphiniC Anhydride Method 
Small Scale 
FmocNH (CH 2 ) 100O 2H 	(61) 	(18.6 	mg, 	0.044 mmol), 
Ph 2PO 2POPh 2 (76) (18.0 mg, 0.044 mmol) and NMM (5 zl, 
0.044 mmol) were dissolved in DMF (2 ml). 	The solution 
was stirred at room temperature for 5 minutes then added 
to the resin-bound IPNS(92-120) (34) obtained by the Fmoc 
removal from (33) 	(50 mg, 8.8 	tmo1). 	N1IM (5 Al t 
0.044 mmol) and 2,6-lutidine (10 Al t 0.088 mmol) were 
added and the reaction was sonicated overnight. The resin 
was filtered, washed well with DMF, DCN and diethyl ether 
to give, after drying 43.2 mg of resin-bound Fmoc 
Aua-IPNS(92-120) (38). 	The measured substitution was 
0.162 mmol/g, 95% loading. The Fmoc derivatised peptide 
was cleaved from the resin (26 mg) as described above to 
give the crude peptide (39) 18.1 mg; m/z (FAB) 3833.3 
(M-28); HPLC (Aquapore C8, 220 x 4.6 mm, 7 nun; A = H 20, B 
= CiI 3CN, 0.1% TFA, 10-90% B over 25 mm.), Rt = 17.2 mm., 
68% B. 
Large Scale 
FmocNH(CH 2 ) 10CO 2H 	(61) 	(0.54 	g, 	1.28 	mmol), 
Ph 2PO 2POPh 2 (0.52 g, 1.28 mmol) and NMN (0.14 ml, 1.28 
mmol) were dissolved in DMF (50 ml). 	The solution was 
agitated in an ultrasonic bath for 5 minutes then added to 
the resin-bound free amino IPNS(92-120) (34) (1.45 g, 0.26 
mmol). NMN (0.14 ml, 1.28 mmol) and 2,6-lutidine (0.3 ml, 
2.55 mmol) were added and the reaction was sonicated 
overnight. The resin was filtered and washed well with 
DMF and DCM. 	A small sample was removed, washed with 
diethyl ether and dried. 	The resin substitution was 
determined by the Fmoc cleavage from this sample and found 
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to be 0.125 mmol/g, 72% loading. 	The coupling was 
repeated and a new substitution of 0.131 mmol/g, 75% 
loading obtained. Unreacted amine was capped by swelling 
the resin in DMF (15 ml) and adding 0.5 M acetic anhydride 
in DMF (1 ml) and 0.5 N pyridine in DMF (1 ml). The resin 
was sonicated for 10 minutes, filtered and washed 
extensively with DMF followed by DCM. Resin-bound Fmoc 
Aua-IPNS(92-120) (38) 1.5 g was obtained. 
Isopenicillin N Synthase (243-267)-11-aminoundecanoyl-
Isopenicillin N Synthase (92-120) 
IPNS(243-267)-Aua-IPNS(92-120) (43) Synthesis 1 
H-Asp-Ile-Gln-Ala-Asp-Asp-Thr-G1y-Phe-LeU-Ile--ASflCYS 
Gly-Ser-Tyr-Met-Ala-His-Ile-Thr-ASP-ASP-TYr-TYr-NH (CH2) - 
cO-Tyr-Tyr-Leu-Pro-Ile-Pro-Gly-Lys-Lys-A1 a-Val-Glu-Ser-Phe-
Cys-Tyr-Leu-Asn-Pro-Ser-Phe-Ser-PrO-ASP-Hi s-Pro-Arg-I 1 e-Lys-
OH 
The synthesis of IPNS(243-267) (37) was carried out in 
a stepwise manner onto the functionalised resin FmocAua-
IPNS(92-120)-(OCH 2C 6H 4OR) (38) on a 0.17 minol scale. The 
side-chain protection used was as described for the 
synthesis of (37), but with the asparagine and glutamine 
residues unprotected. All couplings were carried out in 
DMF, with a double couple cycle (5 equivalents) and Fmoc 
deprotection monitoring at 314 nm. The asparagine residue 
(254) was triple coupled. The peptide was cleaved from 
the resin and the side-chain protecting groups (with the 
exception of the cysteine protection) were simultaneously 
removed by TFA treatment. 	The resin bound peptide 
(200 mg) was sonicated in the presence of TFA/H 20/ 
anisole/ethyl methyl sulphide (95:5:2.5:2.5, 2.2 ml) for 
2.5 hours. 	A timed deprotection study was previously 
carried out to determine the optimum time for cleavage. 
The resin was removed by filtration and washed with TFA 
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(0.5 ml) and CHC1 3 (3 ml). The solvent was removed from 
the combined washings and filtrate to give an orange 
residue. The crude cysteine protected peptide (42) was 
precipitated as a white powder (147 mg) with diethyl 
ether, dissolved in 30% aqueous acetic acid and applied to 
a Sephadex G50 (fine) column (99 x 2.5 cm). The column 
was eluted with 30% acetic acid at 29 ml h 1, monitoring 
the eluent at 254 and 280 nm. The required peptide eluted 
in two peaks the fractions from which were combined 
separately and the solvent was removed by lyophilisation. 
Fractions 35-43 (254-312 ml) contained 26.6 mg, 18% with 
the desired peptide (42) as the major component, while 
fractions 44-49 (313-355 ml) gave 61.0 mg, 42% with a 




solvent pH conc. insoluble 
partially 
soluble soluble 
0.025 M NH 4 HCO 3 5-8 2 mg/nil 
of 	 go 8.5-9.5 of / 
of 	 If 10-10.5 to / 
0.5 H NH 4 HCO 3 10-10.5 it j 
30% AcOH 2.0 10 mg/ml / 
H 2 0/CH 3 CN 	1:2 7 2 mg/ml 
H0/CH 3 CN 1:2 , 0.1% TFA 2 2 mg/nil j 
0.025 M NH 4OAc + 10% v/v MeOH 6.5 of j 
go 	 + 	if of 	CH 3 	C IS II j 
go + 20% v/v CH3CN 11 of /  
0.025 H NH 4OAc + 10% v/v CH 3 CN 9.0 / 
+ 15% of is It / 
of 	 + 	20% "of of is /  
is + 10% v/v MeOH it of j  
to 	 + 	20% "it  9.0 if j 
of 	 + 20% v/v isopropanol is it 
it + 	20% v/v 1,4-dioxan to If j  
0.2 M NH 4OAc + 20% CH3CN of of / 
2Murea of / 
4Murea If / 
6Murea is 
8Murea it / 
0.025 M NH 4OAc + 20% 8 M urea v/v 9.0 to 
0.6 M NH 4OAc + 20% 8 H urea v/v of of j 
0.05 M Tris HC1, 7 M urea 8.7 10 mg/nil / 
0.05 H Tris HCl, 7 M urea, 	0.2 M NaCl 8.7 10 mg/nil / 
1% v/v Triton in 0.3 H NH 4OAc 3 mg/ml / 
1% v/v octyl-fi-D-glucopyranoside It J 
in 0.3 M NH 4OAc 
Table 8. Solubility of Cysteine Protected IPNS(243-267)-Aua-IPNS(92-120) (42) 
LIU11 LaJ_ 
Purification of IPNS(243-267)-Aua-IPNS(92-120) (43) 
Gel Permeation Chromatography 
A Sephadex G50 (fine) column (99 x 2.5 cm) was used as 
described in the text. 
Semi-preparative Reverse Phase HPLC 
Aquapore C18, 250 x 10 iran, 20 Am 
The cysteine-protected peptide (42) (44 mg) was 
dissolved in H20/CH 3CN 1:1, containing 0.1% TFA (9 ml) and 
applied to the column. A linear gradient of 30-70% B over 
20 minutes was used, where A = H20, B = CH 3CN, 0.1% TFA. 
A flow rate of 5 ml min-' was employed, monitoring at 214 
nm. All the material eluted was collected and the solvent 
was removed by lyophilisation. 	The total recovery of 
material was 9.4 mg, 21%, of which 2.1 mg, 5% was the 
t-butylthio derivative of title compound (42); amino acid 
analysis: Asx 8 8.03, Thr2 1.85, Ser 4 3.45, Glx2 2.28, Pro, 
5.60, G1y 3 3.26, Ala, 3.17, Cys2 1.38, Va1 1 1.08, Met1 
0.98, lie 5 4.92, Leu 3 3.05, Tyr, 5.82, Phe 3 3.08, His2  
2.12, Lys 3 3.08, Arg 1 0.86; HPLC (Aquapore C18, 220 x 4.6 
mm, 7 m; A = H20, B = CH 3CN, 0.1% TFA, 10-90% B over 25 
minutes), Rt = 16 Thin., 64% B. 
Aquapore C8, 100 x 10 mm, 20 Am 
The cysteine-protected peptide (42) (55 mg) was 
dissolved in a 1:1 mixture of H20/CH 3CN containing 0.1% 
TFA and applied to the column. A flow rate of 5 ml min' 
was used with a linear gradient of 25-50% B over 10 
minutes, where A = H20, B = CH 3CN, containing 0.1% TFA. 
All material eluted was collected and the solvent was 
removed by lyophilisation. The t-butylthio derivative of 
title compound (42) was collected in fraction 2 (8.8 mg, 
16%), however, a significant amount of impurities remained 
due to poor resolution, total recovery 21.4 mg, 39%. 
Aquapore Cl ., 250 x 10 mm, 20 Am 
The cysteine protection was removed by sonication of 
peptide (42) (100 mg, 0.02 minol) in TFE (6 ml), H20 
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(0.5 ml) and Bu 3P (50 gil, 0.2 mmol) for 45 minutes. 	The 
solvent was removed in vacuo and the residue was dissolved 
in 10% acetic acid (3 ml). The peptide was eluted through 
a Sephadex GlO column (30 x 1.5 cm), with 10% aqueous 
acetic acid at 30 ml h 1. 	The peptide was eluted in 
fractions 4-12 (30-90 ml). These fractions were combined 
and lyophilised to yield the free peptide (78.4 mg, 79%). 
The crude peptide (30.2 mg) was dissolved in a 1:1 mixture 
of 1120/ CH 3CN containing 0.1% TFA and applied to the 
column. A linear gradient of 30-70% B over 20 mm. was 
employed, where A = 11 20, B = CH 3CN, 0.1% TFA. A flow rate 
of 5 ml min-' was used, monitoring at 214 nm. 	All 
material eluted from the column was collected and the 
solvent was removed by lyophilisation. The title compound 
(43) gave a single peak on HPLC (6.2 mg, 20%), with a 
total recovery of material from the column of 10.7 mg, 
35%; HPLC (Aquapore C 181 220 x 46 mm, 7pm; A = H 20, B = 
CH 3CN, 0.1% TFA, 10-90% B over 25 minutes), Rt = 12.2 mm, 
59.5% B; Ellmans test88: requires 3.5 x 10 	mol dm-3  
found 2.8 x 10 	mol dm-3; amino acid analysis: Asx 8 7.51, 
Thr 2 1.73, Ser 4 3.44, G1x 2 2.22, Pro, 6.60, Gly 3 3.03, 
Ala 3 3.01, Cys 2 0.37, Va11 1.09, Met, 1.06, Ile, 4.81, 
Leu 3 2.99, Tyr 6 5.98, Phe 3 2.95, His 2 2.08, Lys3 3.05, 
Arg 1 0.93. 
3. DroiDlet Counter Current Chromatocraphy1DCCC 
The partitioning of the crude peptide (42) in the 
following two phase systems suitable for DCCC was examined 
by HPLC: 
n-BuOH/AcOH/H 2 0 	 (4:1:5) 
C 6H 6/CHC1 3/MeOH/HC1 	 (11:5:10:4) 
C 6H 6/CHC1 3/MeOH/0.2 M NH 4OAc pH 10 (11:5:10:4) 
n-BuOH/0.2 M NH 4OAc pH 10 	 (1:1) 
n-BuOH/TFA:H 20 	 (1:0.01:1) 
The n-BuOH/AcOH/H 2  0 (4:1:5) system was found to show a 
significant partitioning of the desired peptide into the 
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lower layer with the truncated sequences remaining in the 
upper phase. 
The DCCC apparatus consisted of 288 glass columns 
mounted vertically with internal diameter 2.7 mm. 	The 
solvent mixture was equilibrated in a separating funnel 
and the lower (aqueous) phase was then loaded into the 
required units of the glass columns (288) as the 
stationary phase. 	The sample of peptide (46.2 mg) was 
dissolved in a 1:1 mixture (15 ml) of the stationary and 
mobile phases and pumped into the system. 	The upper 
(organic) phase was then aspirated through the system at 7 
ml h 1. 	The eluent was monitored at 277 and 254 nm, 
collecting 4 ml fractions. No peptide could be detected 
in the eluent. 	The mobile and stationary phases were 
recovered from the system and the solvent was removed in 
vacuo. A significant partitioning of the product into the 
aqueous (stationary) phase was observed. A total recovery 
of peptide was achieved: mobile phase 28.4 mg, stationary 
phase 26.7 mg. 
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Asx 8 7.57 5.95 
Thr 2 1.70 1.17 
Ser 4 3.39 3.09 
Glu 2 2.26 1.88 
Pro 5 5.31 5.23 
Gly 3 3.34 2.46 
Ala 3 3.24 2.54 
Cys 2 1.78 1.53 
Val 1 1.14 1.05 
Met 1 1.12 0.54 
Ile 5 4.71 3.69 
Leu 3 3.05 2.49 
Tyr 6 5.58 4.28 
Phe 3 3.07 2.60 
His 2 2.06 2.07 
Lys 3 3.07 3.08 
Arg 1 0.92 1.00 
The procedure was repeated, reversing the phases, i.e. 
with the lower (aqueous) phase mobile and the upper 
(organic) phase stationary. 192 columns were used with a 
pump speed of 10 ml h 1. Cysteine-protected peptide (42) 
(40 mg) was used. As in the previous case no peptide was 
observed by the UV monitoring of the eluent. 	However, 
pooling of the fractions and removal of the solvent in 
vacuo showed the peptide to be slowly and continually 
eluted from the system. 
Fractions 1-74 (11.6 mg), 75-123 (9.5 mg), 124-156 
(9.0 mg), recovered stationary phase (18.0 mg), recovered 
mobile phase (1.7 mg). 
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4. Anion Exchange Chromatography 
The crude cysteine-protected peptide (42) was loaded 
onto a DEAE Sepharose column (50 x 2.5 cm). 	The 
column was eluted with 7 M urea containing 50 inN Tris 
HC1 pH 8.7, at a flow rate of 33 ml h 1. Two linear 
gradients of NaCl were run, 0-0.3 N followed by 
0.3-0.5 N. The column eluent was monitored at 254 and 
276 nm. 	Analytical HPLC analysis of the fractions 
collected revealed significant improvement in the 
purity of the required peptide in fractions 57 and 58 
(627-638 ml). 	Fractions 57 and 58 were combined and 
desalted by passage through a Sephadex G50 (fine) 
column (100 x 2.5 cm), eluting with 30% aqueous acetic 
acid at 29 ml h', with monitoring at 254 and 276 nm. 
Semi-purified peptide (42) (13.7 mg) was obtained 
after removal of the solvent by lyophilisation; amino 
acid analysis: Asx 8 8.53, Thr 2 1.91, Ser 4 3.61, G1x 2 
2.53, Pro  4.79, G1y 3 3.32, Ala 3 3.25, Cys 2 1.01, Val, 
1.16, Met, 1.08, lie 5 5.08, Leu 3 3.18, Tyr 6 5.98, Phe 3 
3.22, His  2.18, Lys 3 2.88, Arg 1 0.95. 
The crude peptide (cysteine protected) (42) was 
charged onto a DEAE Sepharose column (45 x 2.5 cm). 
The column was eluted with 7 M urea containing 50 mN 
Tris HC1 pH 8.3, at a flow rate of 33 ml h 1. Three 
linear gradients of NaCl were run 0-0.1 N, 0.1-0.2 N 
and finally 0.2-1.0 N. The required peptide was found 
to elute in fractions 93 and 94 (767-776 ml). 	The 
fractions were combined and desalted as described 
above using a Sephadex G25 column (91 x 2.5 cm) at a 
flow rate of 30 ml h 1. 	Partially purified peptide 
(42) (21.5 mg) was obtained. 
5. Cation Exchange Chromatography 
(a) Fractions 56 and 59 from the anion exchange column 
4(a) were dialysed against 7 M urea containing 50 mN 
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NH 4OAc, pH 6.5 then loaded onto a CM Sepharose CL-6B 
column (35 x 1.5 cm). The column was eluted with 7 N 
urea containing 50 inN NH 4OAc, pH 6.5. The peptide was 
observed to elute in the column dead volume. The pH 
was adjusted to 5.5, however no binding of the peptide 
to the column was observed. 
(b) Prior to use the 7 M urea was deionised using a 
Bio-Rex MSZ 501(D) column (1 x 50 cm). 
The peptide (30 mg) was dissolved in the starting 
buffer and loaded onto a SP Sephadex column (1.5 x 40 
cm). The column was eluted with 7 M urea containing 
50 InN NH 4OAc, pH 6.3. The peptide was found to elute 
with the column dead volume. 
The procedure was repeated after lowering the 
ionic strength and pH: 7 M urea containing 10 mN 
NH 4OAc at pH 6.0. 	No binding of the peptide was 
observed. 
6. Hydrophobic Interaction Chromatography (HIC) 
The crude (cysteine protected) peptide (42) (15 mg) 
was dissolved in 25% CH 3CN/H 20 containing 0.1% TFA (1.5 
ml) and loaded onto a Phenyl Sepharose CL-4B column (24 x 
1.5 cm). The column was eluted sequentially with linear 
gradients of CH 3CN, 25-50%, and 50-100%. The column was 
run at 28 ml h 1, monitoring the eluent at 254 and 276 nm. 
The desired peptide was eluted in fractions 36-39 
(336-364 ml). The fractions were combined and the solvent 
was removed in vacuo to give the peptide (42) as a white 
fluffy solid (3.4 mg, 23%), total recovery from the column 
(14.9 mg, 99%) ; amino acid analysis: Asx 8 8.34, Thr 2 1.89, 
Ser 4 3.56, G1x 2 2.31, Pro  5.63, Gly 3 3.26, Ala 3 3.13, 
Cys 2 0.88, Val, 1.07, Met1 0.91, lie 5 4.84, Leu 3 3.08, 
Tyr 6 5.88, Phe 3 3. 10, His 	2. 13, Lys 3 3.02, Arg., 0.94; 
HPLC (Aquapore C18, 220 x 4.6 mm, 7 it m; A = H 20, B = 
CH 3CN, 0.1% TFA, 10-90% over 25 mm.), Rt = 18.2 mm., 70% 
B. The cysteine protection was removed by treatment with 
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Bu 3P. The peptide (42) (10.1 mg, 1.6 izmol) was dissolved 
in TFE (1 ml), H 2  0 (0.4 ml) and Bu 3P (0.21 ml, 0.063 mmol) 
was added. 	The solution was sonicated for 1 hour, 
followed by removal of the solvent in vacuo. 	The 
resulting residue was dissolved in 30% aqueous acetic acid 
and loaded onto a Sephadex G25 column (51 x 1.5 cm). The 
column was eluted with 30% acetic acid at a flow rate of 
20 ml h, monitoring at 254 and 277 nm. 	The peptide 
eluted in fractions 6-8 (40-53 ml), which were combined 
and the solvent was removed by lyophilisation to give the 
title peptide (43) (7.0 mg, 19%); amino acid analysis: 
Asx 8 7.83, Thr 2 1. 79, Ser 4 3.60, G1x 2 2.20, Pro 	4.89, 
G1y 3 3.50, Ala 3 3.16, Cys 2 0.70, Val, 1.08, Met, 0.80, 
lie 5 4.65, Leu 3 3. 00, Tyr 6 5.61, Phe 3 3.00, His 	2.13, 
Lys 3 2.91, Arg1 0.85; Elimans test88: requires 3.9 x 10 
mmol dm 3, found 4.1 x 10 ininol dm-3; m/z (FAB) 6368, 
3186.8 (M2+); HPLC (Aquapore C181 220 x 4.6 mm, 7 m; A = 
H 20, B = CH3CN, 0.1% TFA, 10-90% B over 25 mm.), Rt = 
11.7 mm., 57.5% B. 
IPNS(243-267)-Aua-IPNS(92-].20) (43) Synthesis 2 
The complete synthesis of (43) was repeated with some 
modification. 
The synthesis of IPNS(92-120)-(OCH 2C 6H 4OR) (34) was 
carried out using the functionalised resin, Fmoc 
Lys (Boc)-(OCH 2C8H 4OR) (32a) on a 0.5 mmol scale. 	The 
amino acid side-chain functionality was protected as 
described for (36) with the exception of asparagine and 
histidine, for which no protection and Bum were used 
respectively. The synthesis was carried out following the 
procedure described for (36), removing one third 
(0.17 mmol) of resin after the coupling of Ser (113). The 
measured resin substitution at the end of the synthesis 
was found to be 0.159 mmol/g, 74% loading. The synthesis 
was assessed by TFA cleavage of a small sample of (34) to 
give the free cysteine-protected peptide (35); amino acid 
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analysis: Asx 2 2.26, Ser 3 2.60, G1x 1 1.06, Pro  5.74, G1y 1 
0.96, Alai  1.06, Cys 1 0.34, Val, 1.29, lie 2 1.77, Leu 2 
1.83, Tyr 3 2.57, Phe 2 2.17, His, 1.17, Lys3 2.89, Arg1 
1.06; m/z (FAB) 3451.1; HPLC (Aquapore C8, 220 x 4.6 mm, 
7 m; A = H 20, B = CH 3CN, 0.1% TFA, 10-90% B over 25 
mm.), Rt = 13.6 mm., 54% B. 	The cysteine t-butylthio 
protection was then removed to give compound (36) ; m/z 
(FAB) 3363.4; HPLC (Aquapore C8, 220 x 4.6 mm, 7 m; A = 
H 20, B = CH 3CN, 0.1% TFA, 10-90% B over 25 mm.), Rt = 
12.2 mm., 51% B. 
11- (9' -Fluorenylmethoxycarbonylamino) undecanoic 	acid 
(61) was coupled to the resin-bound peptide (34) via the 
diphenylphosphinic mixed anhydride. The procedure 2(b), 
described for (39) was employed using a ten fold excess of 
FmocAuaOH (61) to peptide in each coupling. 	A single 
coupling overnight resulted in a substitution of 
0.102 mmol/g, 89%, which was subsequently increased to 
0.108 mmol/g, 94% by a second coupling. A third coupling 
resulted in no further increase in substitution, and the 
resin (38) was then capped with acetic anhydride. A small 
sample of resin (38) was deprotected and cleaved to give 
the cysteine-protected Aua-IPNS(92-120) (40) for analysis; 
amino acid analysis: Asx 2 2.22, Ser 3 2.44, G1x 1 1.15, Pro  
6.15, Gly1 0.87, Ala, 1.09, Cys1 0.22, Val, 1.11, Ile 2 
1.76, Leu 2 1.81, Tyr 3 2.87, Phe 2 2.20, His, 1.04, Lys 3 
2.76, Arg 1 1.09; m/z (FAB) 3638.2; HPLC (Aquapore Cl ., 220 
x 4.6 mm, 7 m; A = H 20, B = CH 3CN, 0.1% TFA, 10-90% B 
over 25 mm.), Rt = 14.2 mm., 57% B. 
The cysteine t-butylthio protection was then removed 
to give the fully deprotected Aua-IPNS(92-100) (41); m/z 
(FAB) 3545.9; HPLC (Aquapore C18, 220 x 4.6 mm, 7 Am; A = 
H 20, B = CH 3CN, 0.1% TFA, 10-90% B over 25 nun.), Rt = 
13.1 mm., 54% B. 
The synthesis of IPNS(243-267) (37) onto (38) was 
carried out as described for (43) on a 0.1 mmol scale. 
All amino acids were triple coupled (10 equivalents) in a 
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1:1 mixture of DMF/1,4-diOxafl. 	The peptide was cleaved 
from the resin and eluted through a Sephadex G50 (fine) 
column as described for (43) Synthesis 1. Purification to 
single peak analytical HPLC was achieved using 
semi-preparative reverse phase HPLC on a Vydac C18 column 
(280 x 25 mm). The peptide (100 mg) was dissolved in a 
1:1 mixture of H 20/CH 3CN containing 0.1% TFA (6 ml) and 
applied to the column. A linear gradient of 20-65% B over 
25 minutes was used, where A = H 20, B = CH 3CN, 0.1% TFA. 
A flow rate of 10 ml jfl1 with simultaneous monitoring at 
229 nm was employed. 	Removal of the solvent by 
lyophilisation resulted in the isolation of the required 
cysteine-protected peptide (42) (13.5 mg, 13.5%), total 
recovery from the column, 70 mg, 70%. 	The cysteine 
protection was removed by Bu 3P treatment. The peptide 
(23.7 mg, 3.7 mol) was dissolved in TFE (2.5 ml), H 20 
(1.0 ml) and 0.3 N BU 3P(0.5 ml, 0.15 mmol) was added. 
The solution was sonicated for 45 minutes and the solvent 
then removed in vacuo. The residue was dissolved in 30% 
aqueous acetic acid and loaded onto a Sephadex GlO column 
(52 x 1.5 cm). The column was eluted with 30% acetic acid 
at a flow rate of 20 ml h 1 to elute the desired peptide 
in fractions 8-10 (53-67 ml). The solvents were removed 
by lyophilisation to give the title compound (43) (20.1 
mg, 84%); amino acid analysis: Asx 8 7.74, Thr 2 1.61, Ser 4 
3.00, G1x 2 2.13, Pro 5 6.65, G1y 3 3.00, Ala 3 3. 09, Cys 2 
0.70, Val, 1.09, Met, 0.96, lie 5 4.61, Leu 3 2.96, Tyr 6 
6.52, Phe 3 3.00, His 2 2.00, Lys3 2.87, Arg1 1.00; Elinians 
test88: requires 3.5 x 10 	mol dm-3, found 9.4 x 10 	mol 
dm-3; m/z (FAB) 6375.0 (Mt), 3171.3 (M 2 +), HRNS 
C294H433N 68085S 3 requires 6375.09105, found 6375.09097 
1 ppm; HPLC (Aquapore C18, 100 x 4.6 mm, 7 pm; A = H 20, B 
= CH 3CN, 0.1% TFA, 10-90% B over 25 mm.), Rt = 12.0 mm., 
50.5% B. 	The first ten N-terminal amino acid residues 
(243-252) were sequenced by Edman degradation and found to 
be in agreement with the required sequence. 
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Isopenicillin N synthase(243_267)_(11_am 0 deTb0Yl) 3 
Isopenicillin N Synthase (92-120) 
IpNS(243-267)-(Aua) 3-IPNS(92120) (48) 
H-Asp-Il e-Gln-Al a_Asp_ASPThrG1Y-Phe Leu-I le-Asn-CyS-G1Y 
2) 1 - 




The resin-bound Fmoc-IPNS(92120) (33) was synthesised 
using the functioflalised resin mocLys(BOC)(OCH2C6H4OR) 
(32a) on a 0.5 mmol scale. 	The amino acid side chains 
were protected as described for the synthesis of (36), 
except for asparagine which was used unprotected. 	All 
couplings were carried out in a 1:1 mixture of DMF/1,4-
dioxan using a double coupling cycle (2 equivalents). 
Intermediate Fmoc deprotectionS were achieved using 30% 
piperidine in a 1:1 mixture of DMF/1,4-diOXan, monitoring 
at 314 nm. 	The N-terminal Fmoc group was not cleaved 
until required except that a small scale Fmoc cleavage was 
employed to determine the final resin substitution, which 
was found to be 0.072 mmol/g. Subsequently the Fmoc group 
was cleaved from this material (33) by treatment with 20% 
piperidine in DMF for 20 minutes to give free amino resin- 
bound IPNS(92-l20) (34). 	Fmoc[NH(CH2 ) 10C0]30H (67) 
(570 mg, 0.72 mmol) and Ph2PO2POPh 2  (295 mg, 0.72 mmol) 
were dissolved in anhydrous 2M LiBr/THF (15 ml). 	NHM 
(80 zl, 0.72 mmol) was added and the solution sonicated 
for 5 minutes. 	The activated Finoc(Aua) 30H solution was 
then added to the above amine (34) (2.0 g, 0.144 mmol). 
NMM (80 4, 0.72 mmol) and 2,6-lutidine 
(160 4, 
1.44 mmol) were added and the reaction agitated in an 
ultrasonic bath overnight. 	The resin was filtered and 
washed well with fresh 2N LiBr/THF and DMF. A small scale 
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quantitative Fmoc cleavage was carried out to determine 
the substitution which was found to be 0.036 mmol/g, 53% 
coupling. 	The coupling was repeated and a new 
substitution of 0.057 mmol/g, 84% was achieved. A third 
coupling resulted in no further increase in loading. The 
remaining unreacted amino function was capped by swelling 
the resin in DMF and sonicating in the presence of 0.5 N 
acetic anhydride in DMF (1 ml) and 0.5 14 pyridine in DMF 
(1 ml) for 10 minutes. The resin was filtered and excess 
reagents removed by washing with DMF and 1,4-dioxan. The 
Fmoc group was removed from a small sample of the 
resin-bound Fmoc(Aua 3 )-IPNS(92120) (44) by treatment with 
20% piperidine in DMF for 20 minutes to give (Aua) 
IPNS(92_120)_(OCH 2 C 6 H 40R) (45). The (Aua) 3 derivatised 
peptide was then cleaved with simultaneous removal of the 
acid-labile side-chain protection to give (Aua) 
IPNS(92_l20)(tbUtYlth]0) (46); amino acid analysis: 
Asx 2 2.47, Ser 3 2.82, G1x1 1.06, Pro 5 6.59, G1y1 
0.82, 
Ala i  0.94, Cys1 0.53, Val, 1.06, lie
2 2.41, Leu 2 1.82, 
Tyr 3 2.71, Phe 2  2.35, His, 1.24, Lys, 3.29, Arg1 
1.53; 
I-IPLC (Aquapore C1 , 220 x 4.6 nun, 7 m; A = H20, B = 
CH 3CN, 0.1% TFA, 10-90% B over 25 mm.), Rt = 17.0 mm., 
67% B. 
The Fmoc group was cleaved from Fmnoc(Aua) 3-IPNS(92-
120)-(OCH 2 C 6 H 4OR) (44) by treatment with 20% piperidine in 
DMF. 	The first residue, tyrosine (267), was coupled to 
the resin-bound peptide outwith the synthesiser. 	Fmoc 
Tyr(But)OH (662 mg, 1.44 mnmol) and DIC (113 jtl, 0.72 nunol) 
were dissolved in DMF (15 ml) and the reaction was 
sonicated for 15 minutes. The solution was added to the 
resin-bound peptide (2.0 g, 0.114 mmol) and sonicated 
overnight. 	The resin was filtered and excess reagents 
removed by washing with DMF and 1,4-dioxan. The coupling 
was repeated once more to give quantitative coupling. The 
remaining residues of IPNS(243-267) were coupled using the 
automated peptide synthesiser on a 0.1 mnmnol scale. 	All 
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couplings were carried out in a 1:1 mixture of 
DMF/1,4-dioxafl. 	Tyr (266) and Asp (265) were triple 
coupled, double coupling cycles were then employed up to 
Ser (257) which along with all subsequent residues was 
triple coupled. A ten fold excess of amino acid was used 
in each coupling. The asparagine and glutamine residues 
were used with free side-chain amides, the histidine 
imidazole was protected with trityl and all other side-
chain functionalities requiring masking were protected as 
described previously. 	The Finoc deprotections were 
monitored at 302 ma. The peptide was cleaved from the 
resin and the side-chain protecting groups (with the 
exception of the cysteine t-butylthio) were simultaneously 
removed by mild acid treatment. The resin-bound peptide 
(170 mg) was sonicated for 4 hours in the presence of 
TFA/H 20/anisole/ethYl methyl sulphide (95:5:3:3, 4.5 ml). 
The resin was removed by filtration, and washed with TFA 
(1 ml) and CHC1 3 (5 ml). The washings and filtrate were 
combined and reduced in vacuo. 	The cysteine protected 
peptide (47) (85 mg) was precipitated from the residue by 
the addition of diethyl ether. The crude peptide was then 
dissolved in 30% aqueous acetic acid and charged onto a 
Sephadex G50 (fine) column (90 x 2.5 cm). The column was 
eluted with 30% acetic acid at a flow rate of 29 ml h 1 , 
monitoring the eluent at 254 and 276 nm. 	The desired 
peptide (47) was eluted in fractions 14-18 (135-174 ml) 
and 19-22 (184-213 ml). The fractions were combined and 
the solvent removed by lyophilisation and found to contain 
(9.6 mg, 11%) and (20.7 mg, 24%), respectively of peptide 
material. 	The cysteine protection was cleaved by Bu 3P 
treatment. The material (15 mg, 2 mol) was dissolved in 
TFE (1.1 ml), H 20 (0.4 ml) and Bu 3P (300 pl, 0.1 mmol) was 
added and the solution sonicated for 1 hour. The solvent 
was removed in vacuo and the resulting residue dissolved 
in a 1:1 mixture of H 20/CH 3CN containing 0.1% TFA. The 
peptide was purified by semi-preparative reverse phase 
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HPLC, using a Vydac C,8 reverse phase column (280 x 
25 mm). A linear gradient of 20-60% B over 40 minutes, A 
= H 20, B = CH 3CN, 0.1% TFA was employed at a flow rate of 
10 ml min, monitoring at 229 nm. The removal of the 
solvents by lyophilisatiOn gave the title compound (48) 
(1.7 mg, 11%); amino acid analysis: Asx 8 7.95, Thr 2 1.71, 
Ser 4 3.15, G1x 2 2.31, Pro  5.33, G1y 3 3.12, Ala 3 3.05, 
Cys 2 0.84, Val, 1.05, Met, 0.98, lie 5 5. 08, Leu 3 3.15, 
Tyr 6 5.96, Phe 3 3.19, His 2 2. 14, Lys 3 3. 19, Arg 1 1.12; 
Elimans test88: requires 2.8 x l0 	mol dm
-3, found 3.0 x 
10 5 mol dm-3; m/z (FAB) 6740 (M+), 3370.6 
(M2+), HRMS 
C316H475N,0087S 3 requires 6741.41566, found 6741.41598 
1 ppm; HPLC (Aquapore C,8, 220 x 4.6 mm, 7 pm; A = H 20, B 
= CH 3CN, 0.1% TFA, 10-90% over 25 mm.), Rt = 17.4 main, 
67% B. The first ten N-terminal amino acid residues were 
sequenced by Edman degradation and found to be in 
agreement with the required sequence. 




The synthesis was carried out using the functionaliSed 
resin Fmoc Gly-(OCH 2C 6H 40R) (29a) on a 0.5 mmol scale. 
The arginine, aspartic acid and serine side-chain 
functionalitieS were protected as indicated previously. 
The asparagine side-chain amide was unprotected. 
Couplings were carried out in DMF, using a double coupling 
cycle (2 equivalents) and the Fmoc deprotection was 
monitored at 314 nm. One third (0.17 mmol) of the resin 
(49) was removed after the coupling of FmocSerOH (residue 
3) for studies on the coupling of the final two amino 
acids as a dipeptide. A further 0.17 mmol of resin was 
removed before the final Fmoc deprotection (51) for use in 
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the preparation of the Na_cysteinyl peptide. The peptide 
was cleaved from the resin and the side-chain protection 
removed by treatment with TFA/H 20/thioanisole/ethYl methyl 
sulphide (95:5:5:5, 35 ml) sonicating at room temperature 
for 1.5 hours. 	The resin was removed by filtration, 
washing with TFA (1 ml). The washings and filtrate were 
combined and concentrated in vacuo. 	The crude peptide 
(0.3 g) was precipitated from the residue by the addition 
of diethyl ether. The peptide was then dissolved in 30% 
aqueous acetic acid and applied to a Sephadex G25 column 
(90 x 2.5 cm). The column was eluted with 30% acetic acid 
at 30 ml h, monitoring at 254 and 277 nm. The required 
product was eluted in fractions 27-35 (270-350 ml), which 
were lyophilised to give 226 mg of a white fluffy solid. 
The peptide (131 mg) was further purified by 
semi-preparative HPLC on an Aquapore C. reverse phase 
column (250 x 10 mm, 20 sin). A linear gradient of 20-50% 
B over 15 minutes, where A = H 20, B = CH 3CN, both 
containing 0.1% TFA was used, with a flow rate of 5 ml 
min-' and UV monitoring at 229 nm. Solvents were removed 
by lyophilisation to give the title peptide (53) (69.1 mg, 
53%); amino acid analysis: Asx 2 2.15, Ser 2 1.79, Pro, 
3.94, G1y 2 1.95, Ala, 1.00, Va1 5 4.96, Met, 0.93, lie 1 
1.04, Leu1 1.08, Phe1 1.11, Arg1 1.06; m/z (FAB) 2151.1, 
HRNS C98H160N 25027S requires 2152.16689, found 2152.16688 
< 1 ppm; HPLC (Aquapore Cl ,,, 220 x 4.6 mum, 7 Am; A = 
H 20, B = CH 3CN, 0.1% TFA, 10-90% over 25 mm.), Rt = 12.8 
mm, 53% B. The peptide was fully sequenced by automated 




6H [600 MHz, 90% H 2 0, 10% D 2 01 
Amino Acid NH aCH H's yH's Others 
Ala(9) 8.32 4.28 1.32 
Arg(13) 8.38 4.27 1.72,1.77 1.59,1.72 63.16 
NH 6.64,7.15 
Asn(10) 8.39 4.64 2.67,2.73 NH 6.86,7.55 
Asp(15) 8.54 4.69 2.75,2.89 
Gly(2) 8.73 4.02 
Gly(21) 8.14 3.90 
Ile(14) 8.10 4.14 1.80 CM 2 	1.39,1.53 6 	0.81 
CM 3 0.84 
Leu(19) 8.09 4.16 1.44 1.35 60.77,0.83 
Met(1) - 4.15 2.15,2.18 2.61,2.62 £ CH 3 	2.09 
Phe(20) 7.97 4.63 2.98,3.16 2,6 H 	7.22 
3,5 H 7.32 
4H 	7.26 
Pro(12) 4.35 1.82 1.99 3.64,3.83 
Pro(18) 4.35 1.82 1.99 3.64,3.83 
Pro(S) 4.39 1.78 1.93 3.64,3.83 
Pro(7) 4.39 1.78 1.95 3.68,3.78 
Ser(3) 8.35 4.46 3.79 
Ser(17) 8.29 4.80 3.79 
Val(4) 8.16 4.42 2.03 0.90,0.95 
Val(6) 8.15 4.34 2.27 0.94 
Val(8) 8.15 4.01 2.01 0.92 
Val(16) 8.03 4.12 2.05 0.86 
Val(11) 7.97 4.37 2.02 0.92,0.88 
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ROESY cross peak coordinates and assignments 
8.73 Gly(2) NH 4.15 Met (1) aCH 
8.54 Asp(15) NH 4.14 Ile(14) aCH 
8.39 Asn(10) NH 4.28 Ala(9) aCH 
8.35 Ser(3) NH 4.02 Gly(2) aCH 
8.32 Ala(9) NH 4.01 Val(8) aCH 
8.29 Ser(17) NH 4.12 Val(16) aCH 
8.38 Arg(13) NH 4.35 Pro(12) aCH 
8.16 Val(4) NH 3.79 Ser(3) 3CH 
8.15 Val(6) NH 4.37 Pro(5) aCH 
8.15 Val(8) NH 4.37 Pro(7) aCH 
8.16 Val(4) NH 4.46 Ser(3) aCH 
8.03 Val(16) NH 4.69 Asp(15) aCH 
8.10 Ile(14) NH 4.27 Arg(13) aCH 
7.97 Val(11) NH 4.64 Asn(10) aCH 
8.09 Leu(19) NH 4.37 Pro(18) aCH 
7.96 Phe(20) NH 4.16 Leu(19) aCH 
8.14 Gly(21) NH 4.63 Phe(20) aCH 
7.26 Phe(20) 4H 2.98 Phe(20) OICH 
7.26 Phe(20) 4H 3.16 Phe(20) OCH 
8.54 Asp(15) NH 0.84 Ile(14) yCH 3 
8.54 Asp(15) NH 1.80 Ile(14) 13CH 2  
8.39 Asn(10) NH 1.32 Ala(9) 3CH 3 
8.32 Ala(9) NH 2.01 Val(8) jICH 
8.29 Ser(17) NH 2.05 Val(16) OCH 
8.32 Ala(9) NH 0.92 Val(8) -yCH 
8.29 Ser(17) NH 0.86 Val(16) -yCH 
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IPNS(1-21) (53) Synthesis by a Dipeptide Coupling onto 
IPNS(3-2l)-(OCH 2CH4OR) (50) 
A small scale Fmoc deprotection of the resin-bound 
peptide (49) was used to measure the resin substitution, 
which was found to be 0.180 mmol/g. The Fmoc group was 
then cleaved from the resin-bound peptide (49) with 20% 
piperidine in DMF to give the free amino resin-bound 
peptide (50). Residues 1 and 2 were then coupled as a 
dipeptide onto (50). 
(a) DIC/HOBt Activation 
FmocMetGlyOH (69) (35.8 mg, 0.09 mmol) and HOBt (12.2 
mg, 0.09 mmol) were dissolved in DMF (2 ml). DIC (14 pl, 
0.09 mmol) was added and the solution was sonicated for 
ten minutes. The activated dipeptide was then added to 
the resin-bound peptide (50) (100 mg, 0.02 mmol) and the 
reaction was sonicated overnight. The resin was filtered, 
washed well with DMF, DCM and ether, and dried. 	Fmoc 
deprotection showed the substitution to be 0.188 mmol/g, 
indicating that quantitative coupling had been achieved. 
The Fmoc group was removed by sonication of the resin in 
20% piperidine in DMF (5 ml) for 20 mm., followed by 
extensive washing of the resin with DMF and DCM. Cleavage 
from the resin and simultaneous side-chain protection 
cleavage was achieved by 1.5 hour sonication in TFA/H 20/ 
thioanisole/ethyl methyl sulphide (95:5:5:5, 25 ml). The 
resin was removed by filtration and washed with TFA (5 
ml). The TFA was removed from the filtrate in vacuo and 
the peptide (42 mg) obtained by ether precipitation. The 
crude peptide (35 mg) was dissolved in 30% aqueous acetic 
acid and charged onto a G15 Sephadex column (85 x 1.5 cm). 
The column was eluted with 30% aqueous acetic acid at a 
flow rate of 26 ml h 1, monitoring at 254 nm. The peptide 
was eluted in fractions 7-10 (61-87 ml). The solvent was 
removed by lyophilisation to give the crude peptide (53) 
(17 mg, 49%). 	The peptide was further purified by 
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semi-preparative HPLC using an Aquapore C. reverse phase 
column (100 x 10 mm, 20pm). A linear gradient of 20-50% 
B over 15 minutes, where A = H 20, B = CH 3CN, containing 
0.1% TFA was employed at a flow rate of 5 ml min-' and UV 
monitoring at 229 nm. 	The solvent was removed by 
lyophilisation to give the title compound (53) (7.8 mg, 
49%); amino acid analysis: Asx 2 2.08, Ser 2 1.78, Pro  
3.38, G1y 2 1.95, Ala, 1.04, Va1 5 4.63, Met, 0.96, Ile, 
1.02, Leu 1 1.06, Phe1 1.04, Arg1 1.00; in/z (FAB) 2152 
(M+), HRMS C98H160N 2502 ,S 1 requires 2152.16689, found 
2152.16688 :. < 1 ppm; HPLC (Aquapore C8, 100 x 4.6 mm, 7 
/Lm; A = H 20, B = CH 3CN, 0.1% TFA, 10-90% B over 25 mm.), 
Rt = 12.2 mm., 50.5% B. 
(b) Diphenylphosphinic Anhydride Activation 
FmocMetGlyOH (69) (37.8 mg, 0.09 mmol), Ph 2PO 2POPh 2 
(36.9 mg, 0.09 mmol) and NMM (0.01 ml, 0.09 mmol) were 
dissolved in DMF (2 ml) and sonicated for 5 minutes. This 
solution was then added to the resin-bound peptide (50) 
(100 mg, 0.02 iniiiol) with NMN (0.01 ml, 0.09 mmol) and 
2,6-lutidine (0.02 ml, 0.18 mmol). 	The resin was 
sonicated overnight, washed and dried as described 
previously. The substitution was determined to be 0.169 
mmol/g (quantitative). 	The crude peptide (43.5 mg) was 
obtained in an analogous method to that described for the 
DIC/HOBt activation (a). 	Purification was also carried 
out using the previously described procedures; gel 
filtration (30.2 mg, 69%) and semi-preparative HPLC gave 
the title compound (53) (16.1 mg, 54%); 	amino acid 
analysis: ASX 2 2.06, Ser 2 1.71, Pro  3.50, G1y 2 2.02, Ala, 
1. 08, Val 5 4.76, Met1 1.00, Ile, 1.03, Leu1 1.06, Phe1 
1.04, Arg1 0.95; m/z 2152 (M+), HRNS C98H180N 25027S 1 
requires 2152.16689, found 2152.16688 	< 1 ppm; HPLC 
(Aquapore C8, 100 x 4.6 mm, 7 pm; A = H 20, B = CH 3CN, 0.1% 
TFA, 10-90% B over 25 mm.), Rt = 12.2 mm., 50.5% B. 
122 
Experimental 
N-Cysteinv1-Isotenici11in N Synthase (1-21) 
Cys-IPNS(1-21) (55) 
H-Cys-Met-Gly-Ser-Val -Pro-Val -Pro-Val -Ala-Asn-Val-Pro-
Arg-I le-Asp-Val -Ser-Pro-Leu-Phe-Gly-OH 
The Fmoc group was removed from the resin-bound 
peptide (51) (0.5 g, 0.09 mmol) by treatment with 20% 
piperidine in DMF (5 ml) for 20 minutes to give the free 
amino resin-bound peptide (52). 	The resin was then 
filtered and washed well with DMF. 	The symmetrical 
anhydride of FmocCys(t-butylthio)OH was formed by 
dissolving FmocCys(t-butylthio)OH (0.4 g, 0.9 mmol) in DMF 
(3 ml), in the presence of DIC (70 jul, 0.45 mmol). 	The 
solution was sonicated for 15 minutes after which it was 
added to the peptide-resin (52) (0.5 g, 0.09 mmol), and 
sonicated for 2 hours. 	The coupling was monitored by 
qualitative ninhydrin tests. The resin was filtered and 
washed well with DMF and 1,4-dioxan. The Fmoc group was 
then removed as before with 20% piperidine/DMF, followed 
by extensive washing of the resin with DMF and 1,4-dioxan. 
The peptide was cleaved from the resin and the acid-labile 
side-chain protection was removed by a 2.5 hour treatment 
of the resin (460 mg) with TFA/H 20/anisole/ethyl methyl 
sulphide (95:5:4:4, 7 ml). 	The resin was removed by 
filtration and washed with TFA (1 ml) and CHC1 3 (5 ml). 
The combined washings and filtrate were concentrated in 
vacuo. The resulting residue was dissolved in 30% aqueous 
acetic acid and charged onto a Sephadex G50 (fine) column 
(91 x 2.5 cm). The column was eluted with 30% acetic acid 
at 26 ml h 1 , monitoring at 254 and 277 nm. The desired 
product was eluted in fractions 28-34 (250-300 ml), the 
solvent was removed by lyophilisation to give the peptide 
(54) (165.6 mg). 	An aliquot, (86 mg), was then further 
purified by semi-preparative HPLC, using an Aquapore C. 
(100 x 10 mm, 20 Lm) reverse phase column. 	A linear 
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gradient of 15-45% B over 16 minutes was employed, where A 
= H 20, B = CH 3CN, containing 0.1% TFA. A flow rate of 5 
ml min-' and UV monitoring at 229 ma were used. 	The 
solvents were removed by lyophilisation to give the 
t-butylthio derivatised peptide (54) (35 mg, 41%); amino 
acid analysis: Asx 2 2.07, Ser 2 1.70, Pro 4 4.74, G1y 2 1.901  
Ala, 0.96, Cys1 0.42, Va1 5 5.04, Met, 0.96, lie 1 0.96, 
Leu1 1.01, Phe1 1.14, Arg 1 1.09; m/z (FAB) 2344.0; HPLC 
(Aquapore C18, 220 x 4.6 mm, 7 m; A = H 20, B = CH 3CN, 
0.1% TFA, 10-90% B over 25 main.), Rt = 17.1 main., 67% B. 
The t-butyithio cysteine protection was removed by 
sonication of the peptide (54) (35 mg, 0.015 mmol) in a 
trifluoroethanol (2.5 ml), water (1.0 ml) and Bu 3P 
(150 jl, 0.6 mmol) mixture for one hour. 	The solvents 
were removed in vacuo to give a white residue which was 
dissolved in 10% aqueous acetic acid and applied to a 
Sephadex GlO column (30 x 1.5 cm). The column was eluted 
with 10% acetic acid at 30 ml h 	and the product was 
eluted in fraction 4 (22-30 ml). The solvent was removed 
by lyophilisation to give the title compound (55) (30 mg, 
89%); amino acid analysis: Asx 2 2.07, Ser 2 1.63, Pro 4 
3.60, G1y 2 1.93, Ala, 1.01, Cys1 0.58, Val 5 4.64, Met, 
0.89, lie 1 1.00, Leu 1 0.99, Phe 1 1.00, Arg 1 0.96; mn/z 
(FAB) 2255.1 (M), HRMS C101H 165N 26028S 2 requires 
2255.17607 found 2255.17619 	< 1 ppm; HPLC (Aquapore C18  
reverse phase column, 220 x 4.6 nun, 7 ian; A = H 20, B = 
CH 3CN, 0.1% TFA, 10-90% B over 25 main.), Rt = 16.3 main., 
64.5% B. 




The synthesis was carried out using the functionalised 
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resin FmocGiy-(OCH 2 C 6 H 4OR) (29d) on a 0.5 nunol scale. The 
arginine, cysteine, glutainic acid, lysine and serine side 
chains were protected as described previously while 
asparagine and glutainine were unprotected and the 
histidine protected with the trityl group. Couplings were 
carried out in a 1:1 mixture of DMF/1,4-dioxan using a 
double coupling cycle (2 equivalents). 	The Finoc 
deprotection was monitored at 302 mu. Half (0.25 minol) of 
the resin (56) was removed before the final Fmoc 
deprotection, for use in the preparation of the 
Na_cysteinyl sequence. The peptide was cleaved from the 
resin (0.3 g) and the side-chain protection was removed by 
sonication with TFA/H 2 0/anisole (95:5:5, 9 ml) at room 
temperature for 2 hours. 	The resin was removed by 
filtration and was washed with TFA (1 ml) and CHC13  
(6 ml). 	The combined washings and filtrate were 
concentrated in vacuo and the peptide (161 lug) was 
precipitated with diethyl ether. The peptide (160 mg) was 
dissolved in a water/acetonitrile mixture (1:1) containing 
0.1% TFA and purified by semi-preparative HPLC on a vydac 
column (280 x 25 nun) with a linear gradient 25-60% B over 
20 minutes, where A = H 20, B = CH 3CN, both containing 0.1% 
TFA. A flow rate of 10 ml min' was used, monitoring at 
229 nm. The solvents were removed by lyophilisation to 
give the title compound (58) (56.1 mg, 35%); amino acid 
analysis: Asx2 1.99, Ser i  0.96, G1x3 3.12, Pro 3 3.38, G1y 1 
1.05, Ala, 0.91, Va13 2.74, lie1 0.70, Leu 2 1.99, Phe 2 
2.08, His1 0.73, Trp1 1.51, Lys, 0.86, Ar92 1.89; m/z 
(FAB) 2833.6 (M), 1417.2 (M2+), HRNS C132H 202N 370 33  
requires 2834.52982, found 2834.52983 	< 1 ppm; HPLC 
(Aquapore C18 reverse phase column, 220 x 4.6 nun, 7 pun; A 
= H 2 0, B = CH 3 CN, 0.1% TFA, 10-90% B over 25 mm.), Rt = 
13.5 mm., 55% B. 
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oH [600 MHz, 90% H 2 0, 10% D 2 03 
Amino Acid NH aCH OH's )'H's Others 
Ala 269 8.63 4.56 1.31 
Arg 281 8.27 4.21 1.67,1.76 1.51 63.10 
NH 7.10 
Arg273 8.45 4.30 1.63,1.71 1.48,1.54 63.07 
NH 7.10 
Asn 289 8.39 4.60 2.62,2.76 NH 2 	6.88,7.56 
Asn 278 8.28 4.44 2.60,2.74 NH 2 6.91,7.57 
Glu 8.28 4.23 1.87,2.05 2.35 
Glu 8.25 4.24 1.94,2.00 2.39 
Gin 280 8.34 4.25 1.92,2.03 2.28 NH 2 	6.80,7.46 
Gly 291 8.22 3.88 
His 272 8.59 4.70 3.06,3.14 4F! 	7.18 
2H 8.52 
Ile 271 8.20 4.01 1.69 1.09,1.36 0.77 
Leu 284 8.15 4.56 1.53 1.43 60.86,0.88 
Leu 290 8.31 4.30 1.30,1.57 1.22 60.79,0.85 
Lys 275 8.31 4.22 1.56,1.64 1.21 61.30,2.86 
£NH 3 	7.49 
Phe 286 7.98 4.45 2.94 4H 7.24 
2,6H 7.13 
3,5H 7.09 
Phe 287 7.94 4.52 2.90,2.96 4H 7.28 
2,6H 7.15 
3,5H 	7.11 
Pro 285 4.28 1.64,2.09 1.90 63.51,3.72 
Pro 270 4.35 1.73,2.20 1.97 63.57,3.75 
Ser 283 8.31 4.39 3.77 






Val 277 7.89 3.92 1.85 0.75 
Val 288 7.90 3.92 1.88 0.82,0.84 
Val 274 8.23 4.03 1.89 0.75,0.81 
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ROESY cross peak coordinates and assignments 
8.63 Ala(269) NH 4.32 Pro(268) cxCH 
8.58 His(272) NH 4.00 Ile(271) aCH 
8.42 Arg(273 NH 4.70 His(272) aCH 
8.31 Leu(290 NH 4.60 Asn(289) aCH 
8.34 Gln(282 NH 4.20 Arg(281) aCH 
8.39 Asn(289) NH 3.91 Val(288) aCH 
8.30 Lys(275) NH 4.02 Val(274) aCH 
8.28 Asn(278) NH 3.93 Val(277) aCH 
8.22 Val(274) NH 4.29 Arg(273) aCH 
8.18 Ile(271) NH 4.35 Pro(270) crCH 
8.14 Leu(284) NH 4.39 Ser(283) aCH 
8.14 Leu(284) NH 3.78 Ser(283) OCH 2 
8.18 Trp(276) NH 4.20 Lys(275) aCH 
7.96 Phe(286) NH 4.27 Pro(285) aCH 
7.94 Phe(287) NH 4.45 Phe(286) aCH 
7.90 Val(277) NH 4.62 Trp(276) aCH 
7.90 Val(288) NH 4.53 Phe(287) aCH 
7.54 Trp(276) 4H 4.63 Trp(276) aCH 
7.16 Phe(287) 2,6H 4.52 Phe(287) aCH 
7.16 Phe(287 2,6H 2.92 Phe(287) 3CH 2 
7.12 Phe(286) 2,6H 4.45 Phe(286) aCH 
7.12 Phe(286) 2,6H 2.93 Phe(286) 3CH 2 
7.54Trp(276) 4H 3.93 Val(277) aCH 
7.54 Trp(276) 4H 3.15 Trp(276) 3CH 2 
7.18 Trp(276) 6H 3.15 Trp(276) 
7.57 Asn 276/289 NH 2 2.75 Asn 276/289 OCH 
7.57 Asn 276/289 NH 2 2.60 Asn 276/289 3'CH 
7.46 Gln(280) NH 2 2.26 Gln(280) 7CH 2 
8.64 Ala(269) NH 2.38 Pro(268) 19CH 2  
8.64 Ala(269) NH 1.98 Pro(268) 7CH 2 
8.58 His(272) NH 1.69 Ile(271) OCH 2  
8.58 His(272) NH 0.76 Ile(271) 6CH 3  
8.38 Asn(289) NH 1.88 Val(288) 13CH 2  
8.38 Asn(289 NH 0.80 Val(288) yCH 3  
8.22 Val(274) NH 1.56 Lys(275) 13CH 2  
7.54 Trp(276) 4H 0.76 Val(277) -yCH 3 
7.30 Phe(287) 4H 0.83 Val(288) 'yCH 3  
7.22 His(272) 4H 0.76 Ile(271) 6CM 3  
7.15 Phe(287) 2,6 H 0.82 Val(288) yCH 3 
7.12 Phe(287) 3,5 H 0.82 Val(288) yCH 3 
7.16 Trp(276) 6H 0.75 Val(277) 7CH 3  
8.27 Glu(279) NH 4.44 Asn(278) aCH 
8.27 Glu(280) NH 4.23 Glu(279) aCH 
8.27 Arg(281) NH 4.23 Glu(280) aCH 
8.31 Ser(283) NH 4.25 Gln(282) aCH 
8.32 Gly(291) NH 4.30 Leu(290) aCH 
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N°-Cysteiny1 Isopenicillin N Svnthase (268-291) 
Cys-IPNS(268-291) (60) 
H-Cys-Pro-A1 a-Pro-I le-His-Arg-Vai -Lys-Trp-Val-Asn-Glu-
Glu-Arg-Gln-Ser-Leu-Pro-Phe-Phe-Val-ASfl-LeU-G1Y-OH 
The Fmoc group was removed from the resin-bound 
peptide (56) by treatment with 20% piperidine in DMF for 
20 mm. to give the free amino resin-bound IPNS(268-291) 
(57) 
Cys(t-butyithio)OH was then coupled to the resin- 
bound peptide (57). 	A double coupling cycle (4 
equivalents) was employed with 1:1 DMF/1,4-dioxan as 
solvent. The peptide was detached from the resin (0.3 g) 
with simultaneous acid-labile side-chain protection 
removal by treatment with TFA/H 20/anisoie (95:5:5, 9 ml) 
with sonication at room temperature for 2 hours. 	The 
resin was filtered off, washed with TFA (1 ml), CHC1 3  
(6 ml) and the combined washings and filtrate were 
concentrated in vacuo. 	The crude peptide (182 mg) was 
obtained by trituration of the residue with diethyl ether. 
The peptide (180 mg) was purified by semi-preparative HPLC 
on a vydac column (280 x 25 mm) with a linear gradient of 
25-60% B over 20 minutes where A = H 20, B = CH 3CN, 
containing 0.1% TFA. A flow rate of 10 ml min was used 
with UV monitoring at 229 nm. The solvent was removed by 
lyophilisation to give the cysteine protected peptide (59) 
(0.60 g, 34%); amino acid analysis: Asx 2 2.11, Ser1 0.94, 
G1x 3 3.35, Pro 3 3.44, G1y1 1.09, Ala, 0.89, Cys1 0.00, 
Va1 3 2.85, lie 1 0.69, Leu 2 2.11, Phe 2 2.22, His1 0.76, 
Trp1 1.61, Lys, 0.93, Ar92 1.96; m/z (FAB) 3026.9 (MH), 
1513.6 (M2+), HPNS C139H215N 38034S 2 requires 3025.57367, 
found 3025.57360 	< 1 ppm; 	HPLC (Aquapore C18, 220 x 
4.6 mm, 7pm; A = H 20, B = CH 3CN, 0.1% TFA, 10-90% B over 
25 mm.), Rt = 14.2 mm., 57.5% B. 
Peptide (59) (30 mg, 10 jun01) was dissolved in TFE 
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(3 ml) and water (1.2 ml), BU 3P (99 i, 0.4 mmol) were 
added and the solution was sonicated for 1 hour. 	The 
solvent was removed in vacuo and the resulting residue was 
dissolved in 10% aqueous acetic acid. Following several 
extractions with ether the solution was applied to a 
Sephadex GlO column (30 x 1.5 cm). The column was eluted 
with 10% acetic acid at a flow rate of 30 ml h 1. The 
product was eluted in fraction 5 (30-38 ml) from which the 
solvent was lyophilised to give the title compound (60) 
(15 mg, 51%); amino acid analysis: Asx 2 1.981  Ser 1 0.98, 
G1x 3 3.15, Pro 3 4.48, G1y1 1.05, Ala, 0.92, Cys1 0.00, 
Va1 3 2.70, lie 1 0.67, Leu 2 1.92, Phe 2 1.88, His, 0.74, 
Trp 1 1.48, Lys, 0.89, Ar92 2.05; m/z (FAB) 2938.8, HRNS 
C135H 202N 380 34S 1 requires 2937.53900, found 2937.53915 
1 ppm; HPLC (Aquapore C18, 220 x 4.6 mm, 7 m; A = H 20, B 
= CH 3CN, 0.1% TFA, 10-90% B over 25 mm.), Rt = 13.5 mm., 
55.5% B. 
11- (9' -FluorenylmethoxvcarbOflvlaTlliflO) undecanoic Acid 
FmocAua0H (61) 
11-Aminoundecanoic acid was suspended in H 20 (120 ml), 
and a solution of triethylamine (6.3 ml, 45 mmol) in 
1,4-dioxan (120 ml) was added. 	N-(9-Fluorenylmethoxy- 
carbonyloxy)succinimide (11.1 g, 33 mmol) was then added 
and the solution was stirred overnight. 	The reaction 
mixture was diluted with H 20 (500 ml) and was acidified to 
pH 3 with 2M KHSO 4. A white precipitate was formed which 
was extracted with DCM (250 ml x 4), the DCM extract was 
washed with H 2  0 (250 ml x 4) and dried over MgSO 4 . 
Removal of the DCM in vacuo followed by recrystallisation 
from DCM/petrol (b.p. 40-60°C) gave the required compound 
(61), (10.8 g, 85%); m.p. 125-126°C (Lit.89 108-109°C); 
(Found: C, 73.48; H, 7.84; N, 3.52, calc. for C26H 33N0 4 : 
C, 73.73; H, 7.85; N, 3.31%); 	t.1.c. (A) Rf 0. 52, (C) Rf 
0.55; 'max (KBr) 3340 (NH), 1685 (urethane and acid CO), 
1530 cm' (urethane amide i) 	Xmax (MeOH) 264 (E 23000 
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din 3 mo1 1 cm-1 ), 288 (5700), 299 nm (7200); bH  [CDC1 3 , 200 
MHz] 7.30-7.78 (8H, in, aromatic), 4.76 (1H, S, NH), 4.40 
(2H, d, J 6.8 Hz, Fmoc CH 2 ), 4.25 (1H, t, J 6.8 Hz, Fmoc 
CH), 3.13-3.19 (2H, in, CH 2 NH), 2.34 (2H, t, 3 7.4 Hz, 
CH 2 CO 2 H), 1.28-1.66 (16H, in, CH 2 x 8); & 	[CDC1 3 , 50 MHz] 
179.0 (acid CO), 156.4 (urethane CO), 143.9, 141.2 (Fmoc 
quaternaries) , 	127.5, 	126.9, 	124.9, 	119.8 	(Fmoc 
aromatics), 66.4 (Fmoc Cl 2 ), 47.2 (Fmoc CH), 41.0, 33.8, 
30.4, 29.8, 29.2, 29.0, 28.9, 26.6, 24.6 (CH 2 1s); m/z 
(FAB) 424(MH+), 210, HRMS found 424.24876, C26 H 34N0 4 
requires 424.24877 	< 1 ppm. 
11- (9' -FluorenylmethoxycarbonylamiflO)UndeCanOYl-11-amflinO-
undecanoyl-li-aminoundecanoic Acid 
Fmoc (Aua) 30H (67) 
The compound was synthesised in a stepwise manner onto 
a p-alkoxybenzyl alcohol resin. 
The first Fmoc NH (CH 2 ) 100O 2H (61) was coupled to the 
resin in the presence of DMAP (38 mg, 0.3 mnmol) to give 
Fmoc Aua-(OCH 2 C 6 H 40R) (62). 
Diphenylphosphinic anhydride coupling 
FmocNH(CH 2 ) 10CO 2H (61) (5.28 g, 12.5 mnxnol) was 
dissolved in DMF (50 ml), diphenyiphosphinic anhydride 
(5.10 g, 12.5 nmiol) and NMM (1.4 ml, 12.5 inmol) were added 
and the solution was sonicated for 10 minutes. The mixed 
anhydride was then added to the p-alkoxybenzyl alcohol 
resin (4.0 g, 3.12 mrnol). 	NMM (1.4 ml, 12.5 nunol) and 
2,6-lutidine (2.7 ml, 25 mmol) were added and the resin 
was sonicated overnight. 	The resin was filtered and 
excess reagents were removed by washing with DMF and 
1, 4-dioxan. 
Acid chloride coupling 
FmocNH(CH 2 ) 10CO 2H (61) (5.28 g, 12.5 mnxnol) was 
suspended in DCM (40 ml) and thionyl chloride (9.3 ml, 125 
mnmnol) was added. The reaction was heated under reflux for 
30 minutes after which the solvent was removed in vacuo. 
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The resulting residue was washed with DCM (3 x 15 ml) with 
subsequent removal of the DCM in vacuo. The white solid 
was then dissolved in DCM (25 ml) and added to the 
p-alkoxybenzyl alcohol resin (4.0 g, 3.12 nunol) previously 
swollen in DMF (25 ml). Pyridine (1.2 ml, 12.5 nunol) was 
added and the resin was sonicated overnight. The resin 
was filtered and was washed well with DCM. 
(C) Diisopropylcarbodiilnide/l-HydroxybenZOtriaZOle 
coupling 
FmocNH(CH 2 ) 10 CO 2H (61) (5.28 g, 12.5 ininol) was 
dissolved in DMF (50 ml). 	Diisopropylcarbodiimide 
(2.0 ml, 12.5 ininol) and HOBt (1.68 g, 12.5 mmol) were 
added and the solution was sonicated for 10 minutes. The 
reaction was then added to the p-alkoxybenzyl alcohol 
resin and sonicated overnight, after which excess reagents 




Coupling FmocAuaOH Coupling % Resin 
method used time loading 
a 2 overnight 50 
a 4 overnight 84-90 
b 2 overnight 26-52 
b 4 overnight 36-74 
Table (9). 	Fmoc NH(CH 2 ) 10CO 2H Coupling to a p-Alkoxy- 
benzyl Alcohol Resin 
The resin loading was measured by a small scale Fmoc 
deprotection. The Fmoc group was cleaved from the main 
portion of resin-bound Aua (62) by sonication with 20% 
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piperidine in DMF for 30 minutes to give Aua-(OCH 2C 6H 40R) 
(63). 	The liberation of the amine was checked by a 
qualitative Kaiser test and the resin was washed well with 
DMF and 1,4-dioxan. The second FmocAuaOH was then coupled 
to (63) using coupling procedure a, b or c. The coupling 
was monitored by qualitative Kaiser tests. The Fmoc group 
was removed from Fmoc(Aua) 2-(OCH 2C 6H 40R) (64) as described 
for 	(62) to give the free amine compound (Aua) 2 
(OCH 2C 6H 4OR) (65). The final FmocAuaOH was then coupled 
in an analogous fashion to give Fmoc(Aua) 3-(OCH 2C 6H 4OR) 
(66) 
Molar Excess 
Time Required for Negative Kaiser 
Coupling to Coupling to 
Coupling of FmocAuaOH Aua-(OCH 2C6H 40R) (Aua) 2-(OCH 2C6H 4OR) 
Method used (63) (65) 
a 4 overnight overnight 
b 2 5h + overnight overnight 
b 4 overnight overnight 
C 4 5h + overnight overnight 
Table (10). 	Fmoc NH(CH 2 ) 10CO 2H coupling to (Aua)-(O-- 
CH 2C 6H 40R) 
The resin-bound product (66) (4g, 3.12 mmol) was 
sonicated in TFA (38 ml) and H 2  0 (2 ml) for 3 hours. The 
resin was removed by filtration and was washed with TFA 
(1 ml). 	The washings and filtrate were combined and 
diluted with DCM (40 ml). 	The TFA was removed by 
extraction with H 20 until a precipitate was just observed. 
The remaining solvent was removed in vacuo to give a white 
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residue. 	The product was then purified by flash 
chromatography, eluting with CHC1 3/MeOH/AcOH (9:1:0.5). 
The solvent was removed in vacuo to give the title 
compound (67) (1.17 g, 68% from the resin loading); m.p. 
129-137°C (transition from white to transparent granules), 
155-158°C (melt); t.1.c. (C) Rf 0.67; umax (KBr disc), 
3420-3140 (NH), 3000, 2800 (CH), 1725 (acid CO), 1690 
(urethane CO), 1635 (amide I), 1530 cm-1  (amide II); Xinax 
(NNP) 267 (c 21000 din3 inol' cm'), 289 (6900), 300 nm 
(7700); oH  [CDC13 , 200 MHz] 7.26-7.77 (8H, In, aromatics), 
5.56 (2H, in, NH's), 4.85 (lH, in, NH), 4.39 (2H, d, J 
6.9 Hz, Fmoc CH 2 ), 4.21 (1H, in, Fmoc CH), 3.13-3.27 (6H, 
M, 3 x CH 2 NHCO), 2.32 (2H, t, J 6.8 Hz, CH 2CO 2H), 
2.06-2.20 (4H, in, 2 x CH 2CONH), 1.27-1.60 (48H, in, CH 2 x 
24); bc [TFA/(CD3 ) 2 CO 3 50 MHz]., 181.3 (amide CO), 178.9 
(acid CO), 142.9, 140.9 (Fmoc quaternaries), 127.3, 126.6, 
124.2, 119.3 (Fmoc aromatic CH's), 67.5 (Fmoc CH2 ), 46.5 
(Fmoc CH), 42.1-23.9 (CH 2 ); m/z (FAB) 790 (M), 607 (Fmoc 
Aua 2 ), 568 (Aua 3 ), 385 (Aua 2 ) 1  179 (dibenzofulvene), HRNS 




The compound was prepared by the method of Bodanszky 
et a190. 	FmocMetOH (3.5 g, 9.5 inmol) was dissolved in 
ethyl acetate (35 ml) and p-nitrophenol (1.6 g, 11.4 rnxnol) 
was added. The stirred solution was cooled to 4°C on a 
water/ice bath during the addition of 1,3-dicyclohexyl- 
carbodlimide (DCCI) (2.0 g, 9.5 iiunol). 	The solution was 
stirred at 4°C for 30 minutes and a further 2 hours at 
room temperature. 	The disappearance of the DCCI was 
monitored by IR (2120 cm-1, nujol). 	The precipitate of 
1,3-dicyclohexylurea was removed by filtration and the 
ethyl acetate removed in vacuo. 	Recrystallisation from 
95% ethanol containing 1% acetic acid gave the required 
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compound (68) as a pale yellow powder (2.9 g, 62%); in.p. 
123-126°C (lit90. 125-127°C); (Found: C, 63.13; H, 4.88; N, 
5.66 Calc. for C 26H24N 206S: C, 63.40; H, 4.91; N, 5.69%); 
[a] 5 -48.7° (C = 1, DMF with 1% AcOH) (Lit90. -51.6°); 
t.l.c. (A) Rf 0.78, (B) Rf 0.29; umax  (KBr disc) 3330 
(NH), 1765 (ester CO), 1695 (urethane CO), 1595 cm-1  
(aromatic); Xmax (MeOH) 265 (c 23000 din 3 mo1 1 cm-1), 289 
(9600), 300 (11000), 388 nm (3400); bH [CDC1 3, 200 MHz] 
7.25-8.30 (12H, in, aromatics), 5.51 (1H, d, J 8.9 Hz, Met 
NH), 4.74 (1H, in, Met aCH), 4.47 (2H, d, J 6.8 Hz, Fmoc 
CH 2), 4.23 (1H, t, J 6.6 Hz, Fmoc CH), 2.64 (2H, t, Met 
yCH 2), 2.10-2.31 (5H, in, Met (3CH 2, Met S-CH3); 6c  [CDC 1 3 , 
50 MHz] 169.9 (ester CO), 155.8 (urethane CO), 154.8, 
145.5 	(ONp 	quaternaries), 	143.5, 	141.2 	(Fmoc 
quaternaries), 127.7, 	127.0, 125.2, 119.9 (Fmoc 
aromatics), 124.8, 122.1 (ONp aromatics), 67.0 (Fmoc CH 2)1 
53.2 (Net cxCH) , 47.0 (Fmoc CH), 30.9 (Met 3CH 2), 29.8 (Met 
)/CH 2), 15.4 (Met S-CH 3); in/z (FAB) 493 (Mt), HRNS found 
493.14335, C26H 25N 206S requires 493.14332 .. < 1 ppm. 
N-9 -F1uoreny1methoxycarbonvl-L-methiOfly11VCifle 
Fmoc-L-MetGlyOH (69) 
The compound was prepared by the method of Bodanszky 
et a191. Glycine (0.75 g, 10 mmol) was dissolved in H 20 
(10 ml) and the pH was adjusted to 9.0 with 1 M NaOH. 
Pyridine (20 ml) was added, followed by FmocMetONp (68) 
(2.5 g, 5 mmol). The pH of the solution was maintained at 
9.0 by the addition of 2 M NaOH. The solution was stirred 
for 4 hours after which it was cooled on an ice bath and 
the pH was adjusted to 7.0 with conc. HC1. The solvents 
were removed in vacuo and the resulting residue was 
dissolved in water. Acidification to pH 2.0 with 2 M HC1 
afforded a white solid which was filtered and dried. 
Recrystallisation from ethyl acetate/n-hexane gave the 
required compound (69) as a white powder (1.6 g, 74%); 
m.p. 163-165°C (Lit.91 111-112°C (gel)); (Found: C, 61.48; 
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H, 5.71; N, 6.66 Calc. for C 22H 24N 20 5S: C, 61.66; H, 5.65; 
N, 6.54%); [a] 	-14° (C = 1 in DMF) (Lit.91  -13°C); t.1.c. 
(C) Rf 0.54, (D) Rf 0.78; Pmax (KBr disc) 3200-3400 (NH), 
1760 (acid CO), 1690 (urethane CO), 1650 (amide CO), 1540 
cm-1  (amide); Xmax (MeOH) 266 (E 19000 din 3 mo1 	cm 1 ), 
290 (4800), 301 nm (5900); 6H [(CD3 ) 2 CO 3 200 MHz] 
7.29-7.88 (8H, in, Fmoc aromatics), 4.24-4.41 (4H, in, Fmoc 
CH, Met aCH, Gly CH 2 ), 4.00 (2H, d, J 5.9 Hz, Fmoc CH 2 ), 
2.57-2.65 (2H, in, Met 7CH2)1 6H [(CD3 ) 2 S0, 200 MHz] 
1.6-2.35 (5H, in, Met 13CH 2 , Met S-CH 3 );bc [(CD3 ) 2 CO 3 50 
MHz] 170.9 (acid CO), 169.5 (amide CO), 155.3 (urethane 
CO), 143.3, 140.4 (Fmoc quaternaries), 126.8, 126.3, 
124.5, 119.1 (Fmoc aromatic CH's), 65.5 (Fmoc CH 2 ), 53.2 
(Met CH), 46.4 (Fmoc CH), 39.6 (Gly CH 2 ), 31.3 (Met 
3CH 2 ), 29.0 (Met yCH 2 ), 13.5 (Met S-CH 3 ); m/z (FAB) 429 
(M+), 207, 179, HRNS found 429.14839, C 22H 25N 2 0 5 S requires 
429.14841 :. < 1 ppm; amino acid analysis: Gly, 1.00, Met, 
0.92; HPLC (Aquapore C8 , 220 x 4.6 mm, 7 m; A = H 2 0, B = 





The compound was prepared by the general method of 
Bodanszky et a190. 	FmnocPheOH (3.9 g, 10 mnmol) was 
dissolved in THF (40 ml) and p-nitrophenol (1.7 g, 
12 mninol) was added. 	The stirred solution was cooled to 
4°C on a water/ice bath during the addition of DCCI 
(2.1 g, 10 miunol). The reaction was stirred for 30 minutes 
at 4°C and for a further 2.5 hours at room temperature. 
The precipitate of 1,3-dicyclohexylurea was removed by 
filtration and the THF was removed in vacuo. 
Recrystallisation from THF/petrol (b.p. 40-60°C) gave the 
required compound (70) as a white powder (3.7 g, 83%); 
mn.p. 206-208°C (Lit. 90 207-209°); (Found, C, 70.68; H, 
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4.69; N, 5.30, Calc. for C 30H 24N 20 6 : C, 70.85; H, 4.76; N, 
5.51%); [a]5 = _43.0 0  (C = 1, DMF with 1% AcOH) (Lit. 90  
_43.00); t.1.c. (A) Rf 0.81, (B) Rf 0.11; umax (KBr disc) 
3330 (NH), 1765 (ester CO), 1690 (urethane CO), 1595 cm-1  
(aromatic); Xmax  (MeOH) 265 (E 26000 din 3 inol' cm 1 ), 290 
(11000), 301 (13000), 390 nm (6600); 6H  (CDC1 3 , 200 MHz] 
7.08-8.27 (17H, in, aromatic), 5.28 (1H, d (broad), NH), 
4.88 (1H, in, Phe aCH), 4.48 (2H, in, Fmoc CH 2 ), 4.22 (1H, 
t, J 7.0 Hz, Fmoc CH), 3.27 (2H, d (broad), Phe 3CH 2 ); bc 
[(CD 3 ) 2S0, 50 MHz] 170.2 (ester CO), 156.1 (urethane CO), 
155.1, 145.2 (ONp quaternaries), 143.7, 140.8 (Fmoc 
quaternaries), 137.0 (phenyl quaternary), 129.3, 128.4, 
126.7 (phenyl aromatic CH's), 127.7, 127.1, 125.4, 120.1 
(Fmoc aromatics), 125.2, 122.9 (ONp aromatics), 65.7 (Fmoc 
CH 2 ), 55.7 (Phe oCH), 46.7 (Fmoc CH), 36.1 (Phe 13CH 2 ); in/z 
(FAB) 509 (M+), HRNS found 509. 17128, C 30H 25N 20 6 requires 
509.17125 	< 1 ppm. 
N-9 -Fluorenvlmethoxycarbonvl-L-phenylalanylglvcine 
Fmoc-L-PheGlyOH (71) 
The compound was prepared by the general method of 
Bodanszky91 as described for FxnocMetGlyOH (69). 
Recrystallisation from ethyl acetate/petrol (b.p. 40-60°C) 
gave the title compound (71) as a white powder (1.6 g, 
74%); m.p. 189-190°C; (Found: C, 70.10; H, 5.59; N, 6.12, 
C 26 H 24N 2 0 5 requires: C, 70.28; H, 5.44; N, 6.30%); [a] 5 
-4 0 (C = 1 in DMF); t.1.c. (C) Rf 0.54, (D) Rf 0.79; "max 
(KBr disc) 3300 (NH), 1730 (acid CO), 1690 (urethane CO), 
1660 (amide CO), 1540 cm-1  (amide); Xmax  (DCM) 266 (E 
24000 din 3 mo1 1 cm- 1 ), 290 (6900), 310 nm (7800); 6  
[(CD 3 ) 2 CO 3 200 MHz] 7.18-7.87 (13H, in, aroinatics), 6.72 
(1H, d, J 8.8 Hz, NH), 4.53 (lH, in, Phe aCH, (Hc)), 
3.98-4.31 (5H, in, Fmoc CH, Cl!2 , Gly CH 2 ), 3.27 (1H, dxd, 
a,b 13.9 Hz, Ja,c  4.5 Hz, Phe f3CH 2 , (Ha)),  2.97 (1H, dxd, 
a,b 13.9 HZ, Jb,c  9.4 Hz, Phe PCH 2 , (Hb)); ac [(CD 3 ) 2 S0, 
50 MHz] 172.1 (acid CO), 171.2 (amide CO), 155.9 (urethane 
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CO), 143.9, 140.8 (Fmoc quaternaries), 138.3 (Phe 
quaternaries), 129.3, 128.1, 127.7 (Phe aromatics), 127.2, 
126.3, 125.4, 120.2 (Fmoc aromatics), 65.8 (Fmoc CH2), 
56.2 (Phe aCH) , 46.7 (Fmoc CH), 40.9 (Gly CH2), 37.4 (Phe 
f3CH2); in/z (FAB) 445 (N&), 223, 179, HRNS found 445.17634 
C26H25N205 requires 445.17633 	< 1 ppm; HPLC (Aquapore 
C8, 220 x 4.6 mm, 7 m; A = H20, B = CH 3CN, 0.1% TFA, 




The compound was prepared by the general method of 
Bodanszky et a190.  as described for FmocMetoNp (68). 
Recrystallisation from 95% ethanol containing 1% acetic 
acid/petrol (b.p. 40-600 ) gave the required compound (72) 
as a pale yellow powder (4.9 g, 69%); m.p. 117-118°C 
(Lit.90 115-116°C); (Found: C, 68.42; H, 5.46; N, 5.46, 
Caic. for C22H26N206 C, 68.34; H, 5.52; N, 5.90%); [a] 
-52.90 (C = 1, DMF with 1% AcOH) (Lit.90 -50.0°); t.1.c. 
(A) Rf 0.79, (B) Rf 0.85; umax  (KBr disc) 3330 (NH), 1765 
(ester CO), 1690 cnr' (urethane CO); Xmax (DCM) 266 (E 
40000 din 3 mo1 1 cm'), 288 (18000), 299 nm (14000); oH 
[CDC1 31' 200 MHz] 7.17-8.27 (12H, in, aromatics) , 5.23 (lH, 
d, J 8.0 Hz, NH), 4.60 (1H, in, Leu aCH), 4.47 (2H, d, J 
6.7 Hz, Fmoc CH2), 4.23 (1H, t, J 6.7 Hz, Fmoc CH), 1.83 
(3H, in, Leu 3C}!21  'yCH), 1.02 (6H, d, 3' 4.4 Hz, Leu 6CH 3 X 
2); o 	[CDC1 3, 50 MHz] 170.9 (ester CO), 155.9 (urethane 
CO), 155.0, 145.4 (ONp quaternaries), 143.5, 141.2 (Fmoc 
quaternaries), 	127.6, 	126.9, 	125.1, 	119.9 	(Fmoc 
aromatics), 124.8, 122.1 (ONp aromatics), 67.0 (Fmoc CH2), 
52.7 (Leu aCH), 47.0 (Fmoc CH), 41.0 (Leu j3CH2), 24.8 (Leu 
'yCH), 22.7, 21.6 (Leu 6d!3 x 2); m/z (FAB) 475 (MW), 355, 
308, 253, HRMS found 475.18688, C22H27N206 requires 
475.18690 	< 1 ppm. 
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N_ 9 -Fluorenylmethoxycarbonyl -L-1 eucvl -L-rthenyl al anine 
Finoc-L-Leu-L-PheOH (73) 
The compound was prepared by the general method of 
Bodanszky et ail. as described for Fmoc-L-MetGlyOH (69). 
Recrystallisation from ethyl acetate/petrol (b.p. 40-60°C) 
gave the title compound (73) as a white powder (3.1 g, 
63%); in.p. 175.5-177°C; (Found: C, 71.99; H, 6.46; N, 
5.65, C30H 32N 205 requires: C, 71.98; H, 6.44; N, 5.60%); 
[o]-14.5° (C = 1, DMF); t.l.c. (C) Rf 0.54, (D) Rf 
0.90; "max (KBr disc) 3340 (NH), 1735 (urethane CO), 1635 
(amide I), 1535 (amide II); Xmax (MeOH) 264 (c 21000 dm 3 
mo1 1 cm-1), 289 (5400), 299 rim (6800); oH [CDC1 3 , 
200 MHz] 7.08-7.78 (13H, m, aromatics), 6.86 (1H, d, J 7.4 
Hz, NH), 5.56 (1H, d, J 8.5 Hz, NH), 4.82 (111, dxd, J 6.5 
Hz, Leu aCH), 4.15-4.33 (4H, in, Finoc CH, CH 2, Phe cCH, 
(Hc)), 3.19 (111, dxd, Ja,b  13.9 Hz, Ja,c  5.1 Hz, Phe 3CH 21  
(Ha)), 2.97 (lH, dxd, Ja,b  13.9 Hz, Jb,c  6.7 Hz, Phe 3CH 21  
(Hb)), 1.45-1.61 (3H, in, Leu 3CH 2 , yCH), 0.84-0.89 (6H, in, 
Leu 6CH 3 x 2); o 	[CDC1 3, 50 MHz] 173.9 (acid CO), 172.2 
(amide CO), 156.2 (urethane CO), 143.5, 141.1 (Fmoc 
quaternaries), 135.6 (Phe quaternary), 129.2, 128.3 (Phe 
aromatic CH's), 127.6, 126.9, 124.9, 119.9 (Finoc aromatic 
CH's), 67.1 (Finoc CH 2 ) 1  53.1 (Leu aCH), 46.9 (Fmoc CH), 
41.0 (Leu 3CH 2), 37.3 (Phe 0 CH 2), 24.4 (Leu -1CH), 22.6, 
21.8 (Leu 6CH 3 x 2); In/z (FAB), 501 (MH+),  279, HRNS found 
501. 23895, C30H33N 205 requires 501.23893 	< 1 ppm; HPLC 
(Aquapore C8, 220 x 4.6 mm, 7 m; A = H 20, B = CH 3CN, 0.1% 
TFA, 10-90% B over 25 mm.), Rt = 20.5 mm., 77% B. 
Ncg -Fluorenvlmethoxvcarbonvl -L-1 eucyl -D-phenyl a 1 anine 
Fmoc-L-Leu-D-PheOH (74) 
The compound was prepared by the general method of 
Bodanszky et al.91 as described for Fmnoc-L-MetGlyOH (69). 
Recrystallisation from ethyl acetate/petrol (b.p. 40-60°C) 
gave the title compound (74) as a white powder (0.93 g, 
37%); m.p. (151-153°C); (Found: C, 72.01; H, 6.48; N, 
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5. 61, C30H32N205 requires C, 71.98; H, 6.44; N, 5.60%); 
[a] 5 -8.71, (C = 1, DMF); t.1.c. (A) Rf 0. 11, (C) Rf 0.59; 
"max (DCM) 1730 (urethane CO), 1675 (amide I), 1550 cm 
(amide II); Xlnax (MeOH) 264 (E 14000 din 3 mo1 1 cm-1), 289 
(3600), 299 rim (4400); 6H  CDC1 3, 200 MHz] 7.12-7.73 (13H, 
in, aromatics), 6.97 (lii, d, J 7.2 Hz, NH), 5.78 (lH, d, J 
9.1 Hz, NH), 4.83 (1H, q, J 6.6 Hz, Leu aCH), 4.07-4.47 
(4H, in, Fmoc CH, CH2, Phe aCH, (Hc)),  3.22 (lH, dxd, Ja,b 
14.0 Hz, Ja,c  5.7 Hz, Phe PCH21 (Ha)), 3.04 (1H, dxd, Ja,b 
14.0 Hz, Jb,c  6.4 Hz, Phe 3CH 21 (Hb)),  1.25-1.51 (3H, in, 
Leu 3CH21  yCH), 0.86 (6H, d, J 5.8 Hz, Leu 6CH 3  x 2); bc  
[CDC1 31  50 MHz] 173.6 (acid CO), 172.5 (amide CO), 156.4 
(urethane CO), 143.5, 141.1 (Fmoc quaternaries), 135.7 
(Phe quaternary), 129.3, 128.3 (Phe aromatic CH's), 127.6, 
126.9, 124.9, 119.8 (Fmoc aromatic CH's), 67.2 (Fmoc CH2), 
60.0 (Leu cxCH), 46.8 (Fmoc CH), 42.0 (Leu CH2),  37.5 (Phe 
3CH2), 24.4 (Leu -1CH), 22.8, 21.7 (Leu 6CH 3x2); m/z (FAB) 
501 (M+),  179, HRNS C 30H 33N205 requires 501.23893, found 
501.23895 	< 1 ppm. 
N-9-F1uoreny1methoxycarbonYl-L-1eUCV1-L-prO1 me 
Fmoc-L-Leu-L-ProOH (75) 
The compound was prepared by the general method of 
Bodanszky et a191. Proline (0.69 g, 6 nunol) was dissolved 
in H20 (6 ml) and the pH adjusted to 9.0 by the addition 
of 1M NaOH. Pyridine (12 ml) was added followed by Fmoc 
LeuONp (72) (1.42 g, 3 nunol). The pH of the solution was 
maintained at 9.0 with 2M NaOH and was stirred overnight 
at room temperature. 	The pH of the solution was then 
adjusted to 7.0 with conc. HC1, cooling on an ice bath. 
The solvents were removed in vacuo and the resulting 
orange oil was dissolved in ethyl acetate (30 ml). The 
organic layer was washed with 2N HC1 (3 x 30 ml), H20 (3 x 
30 nil) and dried over MgSO 4. The solvent was removed in 
vacuo to give an orange oil which was redissolved in a 
small volume of ethyl acetate and added dropwise to a 
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large volume of petrol (b.p. 40-600C). The title compound 
(75) was collected by filtration (1.08 g, 80%); m.p. 
75-91°C; (Found: C, 67.50; H, 6.56; N, 6.34, C 26H 30N 205 
requires C, 69.33; H, 6.66; N, 6.22%); t.l.c. (A) Rf 0.24, 
(C) Rf 0.56; "max (DCN) 1755 (acid CO), 1720 (urethane 
CO), 1645 (tertiary amide), 1595 (aromatic), 1510 cm-1  
(secondary amide II); Xmax (NeOH) 265 (c 16000 din 3 mo1 1 
cm-1), 289 (5600), 300 (7300), 310 nm (2600); oH [CDC1 31  
200 MHz] 7.25-7.70 (8H in, aromatics), 5.8 (1H, d, J 8.9 
Hz, NH), 4.2-4.6 (5H, in, Fmoc CH, CH 2, Leu aCH, Pro aCH), 
3.6-3.8 (2H, rn, Pro 6CH 2 ) 1  1.5-2.3 (7H, rn, Pro f3CH 21  1CH 2 . 
Leu 3CH 21  yCH), 0.9 (6H, 2 x d, Leu 6CH 3 x 2); O 	[CDC1 31  
50 MHz] 174.8 (acid CO), 172.9 (amide CO), 156.4 (urethane 
CO), 143.6, 143.5, 141.1 (Fmoc quaternaries), 127.6, 
126.9, 125.0, 119.8 (Fmoc aromatic CH's), 67.0 (Fmoc CH 2), 
59.2 (Pro aCH), 50.8 (Leu aCH), 47.0 (Fmoc CH), 46.9 (Pro 
CH 2), 41.0 (Leu 3CH 2), 28.4 (Pro CH 2), 24.7 (Pro CH 2), 
24.3 (Leu 'yCH), 23.1, 21.5 (Leu 6CH 3 x 2); m/z (FAB) 451 
(MIFF), 179, HRNS found 451.22329, C26H 31N 205 requires 
451.22328 	< 1 ppm. 
DiphenvllDhosphinic Anhydride 
Ph 2PO 2POPh 2 (76) 
The compound was prepared by the method of Gray92. 
Diphenylphosphinic chloride (54.3g, 0.23 minol) was 
dissolved in dry benzene (400 ml) and cooled to 0°C. A 
solution of sodium ethoxide (Na, 5.3 g, 0.23 minol) in dry 
ethanol (100 ml) was added over 30 minutes. The reaction 
was allowed to warm to room temperature and stirred for 24 
hours. Filtration through celite followed by removal of 
the solvent in vacuo afforded the ethyldiphenylphosphinate 
as a clear oil (53.8 g, 95%). To this was added diphenyl-
phosphinic chloride (51.7 g, 0.22 minol) and the reaction 
was heated to 200°C under reflux for 2 hours in an 
atmosphere of argon. The solution was allowed to cool to 
55°C, toluene (100 nil) was added and the resulting 
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solution cooled on an ice/salt bath. 	Trituration 
encouraged the formation of a white precipitate which was 
collected by filtration, washed with a small volume of 
cold toluene and dried to give the required compound (76) 
(78.9 g, 92%); m.p. 136-143°C (Lit.92 138-140°C); 31p 




The compound was prepared using automated solid phase 
peptide synthesis. 	The functionalised resin Fmoc 
Gly-(OCH 2C 6H 4OR) (29e) was used on a 0.3 minol scale. 
Single HOBt couplings (3 equivalents) were employed with a 
1:1 mixture of DMF/1,4-dioxan as solvent. 	The Fmoc 
deprotection was monitored at 302 nm. The Fmoc 
derivatised peptide was cleaved from the resin by 
sonication in TFA/H 20 (95:5, 4 ml) for 1 hour. The resin 
was removed by filtration and washed with TFA (1 ml) and 
CHC1 3 (5 ml). The washings and filtrate were combined and 
the solvent was removed in vacuo. The resulting residue 
was dissolved in H 20/CH 3CN and lyophilised to give the 
title compound (77) (100.3 mg, 60%); amino acid analysis: 
G1y1 1.05, Leu 1 0.44, Phe 1 1.00; m/z (FAB) 558 (M+), 179 
(dibenzofulvene); [cj 	-28.00 (C = 1 in DMF); HPLC 
(Aquapore Cl ,,, 220 x 4.6 mm, 7 m; A = H 20, B = CH 3CN, 
0.1% TFA), isocratic 34% B, Rt = 87.5 mm, isocratic 32% 
B, Rt = 130 mm. 
N-9 -Fluorenylmethoxycarbonyl -L-1 eucyl -L-phenyl a 1 anyl -L-
prol me 
Fmoc-L-Leu-L-Phe-L-ProOH (78) 
The synthesis of this compound was attempted using 
automated solid phase synthesis. The functionalised resin 
FmocPro-(OCH 2C6H 40R) (31b) was employed with analogous 
coupling procedures as described for (77). A deprotection 
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peak for the phenylalanine was observed, however, no 
peptide was detected on the resin after the coupling of 
FinocProOH. 
The title compound (78) was successfully synthesised 
by coupling FmocLeuPheOH (73) to the functionalised resin 
(31b); xn/z (FAB) 598 (M+). 
N-9 -Fluorenylmethoxvcarbonyl-L-leucyl-L-PrOlylqlvCifle 
Fmoc-L-Leu-L-ProGlyOH (79) 
The synthesis was carried out using the functionalised 
resin FrnocGly-(OCH 2 C 6 H 40R) (29e) on a 0.2 mmol scale. 
Single HOBt couplings (5 equivalents) were used with a 1:1 
mixture of DMF/1,4-dioxan as solvent. 	The Fmoc 
derivatised peptide was cleaved from the resin as 
described for (77) to give the title compound (79) (95 rig, 
94%); amino acid analysis: G1y1 1.05, Leu1 0.44, Pro1 
1.00; in/z (FAB) 508 (W), 286 (M-Fmoc), 179 
(dibenzofulvene); HPLC (Aquapore C18 , 220 x 4.6 mm, 7 zm; 
A = H 2 0, B = CH 3 CN, 0.1% TFA), isocratic 27% B, Rt = 145 
min. 	[a]S_55.40 (C = 1 in DMF). 
Coupling Procedures for Dipeptide Couplings 
The dipeptides were coupled to the required 
functionalised resin using the following general coupling 
procedures: 
DIC/HOBt activation 
The Frioc protected dipeptide (0.36 mmol), DIC (0.36 
mmol) and HOBt (0.36 mmol) were dissolved in DMF (1.5 ml). 
The solution was sonicated for 5 minutes then added to the 
resin (0.09 mmol). The resin was sonicated for 3 hours, 
filtered and washed well with DMF and 1,4-dioxan. 
Diphenyiphosphinic anhydride activation 
The Finoc protected dipeptide (0.36 mmol), Ph 2 PO 2 POPh 2 
(0.36 mmol) and NMM (0.36 mmol) were sonicated in DMF (1.5 
ml) for 5 minutes. The solution was then added to the 
resin (0.09 mmol). NHM (0.36 mmol) and 2,6-lutidine (0.72 
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mmol) were added and the resin was sonicated for 3 hours. 
The resin was filtered and washed well with DMF and 
1, 4-dioxan. 
(c) Symmetrical anhydride activation 
The Finoc protected dipeptide (0.72 mmol) and DIC (0.36 
mmol) were sonicated in DMF (1.5 ml) for 15 minutes. The 
solution was added to the resin (0.09 mmol) and sonicated 
for 3 hours. The resin was filtered and washed well with 
DMF and 1,4-dioxan. 
The coupling efficiency was measured by a small scale 
quantitative Fmoc cleavage. The peptide was cleaved from 
the resin by TFA/H 20 treatment (95:5, 4 ml), sonicating 
for 1 hour. 	The resin was removed by filtration and 
washed with TFA (1 ml) and CHC1 3 (5 ml). 	The combined 
washings and filtrate were reduced in vacuo then diluted 
with H 20/CH 3CN 1.1, 0.1% TFA and lyophilised. 
HPLC Conditions for the Separation of the di and tn- 
peptide Racemates 
The peptides were dissolved in a 1:1 mixture of H 20/ 
CH 3CN containing 0.1% TFA (2 mg m1'). The solution was 
analysed using an Aquapore reverse phase C 18 column, 220 x 
4.6 mm, 7gm; A = H 20, B = CH 3CN, 0.1% TFA. An isocratic 
gradient of 32% or 34% B was employed. The peaks were 
integrated using an LKB 220 Recording Integrator. 




C) Symmetrical anhydride 24 




Resin Activation Conditions 
Coupling 
% 
ee from HPLC 
peak height 
integration (a) 
Gly-(OCH 2C 6H 4OR) a r.t. 100,100 99% -26.9' 
b r.t. + DMAP 89 67% -18.3° 
b r.t. 96,97,100 74% -19.3° 
b 5°C 72 67% -20.9° 
Pro-(OCH 2C 6H 4OR) a r.t. 79 99.4% -38.3' 
b r.t. + DMAP 91 23.4% -36.1' 
b r.t. 93,96 78.8% -36.2' 
b 5°C 91 30.6% -36.61  
HO-(CH 2CH 4OR) a r.t. + DMAP 9 12.6% - 
b it 58 3.8% - 
r.t.: room temperature 
Table (12). Coupling FmocLeuPheOH (73) 









Table (13). Coupling FmocLeuProOH to Gly-(OCH2C 6H 4OR) 
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9-Fluorenylmethyl Acetate (80) 
9-Fluorenylmethanol (3.0 g, 15.3 ininol) was dissolved 
in acetic anhydride (70 ml). 	H2SO4 (214, 3 drops) was 
added and the solution was stirred for 3 hours at room 
temperature. The solution was then poured into ice cooled 
water to give a pale yellow solid. 	The solid was 
collected by filtration and recrystallised from DCM/petrol 
(b.p. 40-60°C), to give the required compound (80) (2.9 g, 
81%); m.p. 84-86°C (Lit.93 87°); (Found: C, 80.40; H, 5.83; 
N, 0. 00, Caic. for C 16 H 140 2 : C, 80.67, H, 5. 88, N, 0.00); 
t.l.c. (E) Rf = 0.42, (F) Rf 0.69; umax (KBr) 2900-3100 
(CH), 1730 (ester CO), 1595 cin' (aromatic); Xinax  (DCM) 
266 (E 24000 dm 3 ]no1 1 cm'), 289 (6500), 300 nm (7800); 
oH [CDC1 3 , 80 MHz] 7.27-7.81 (8H, m, aromatics), 4.16-4.44 
(3H, m, CH, CH 2 ), 2.13 (3H, 5, CH 3 ); o 	[CDC1 3 , 50 MHz] 
170.8 (CO) , 143.7, 141.1 (Finoc quaternaries) , 127.6, 
126.9, 124.9, 119.9 (aromatic CH's), 66.3 (CH 2 ), 46.6 
(CH), 	20.8 	(CH 3 ); 	m/z 	(FAB) 	239 	(MH+), 	179 
(dibenzofulvene), HPNS C 16H 15 0 2 requires 239.10720, found 
239.10721 	< 1 ppm. 
2 .2-Bis(4'-nitrophenvl)ethyl Acetate 
Bnpe-OAc (81) 
2,2-Bis(4'-nitrophenyl)ethanol (5.0 g, 17.4 inmol) was 
dissolved in acetic anhydride (70 ml), H2SO4  (214, 5 drops) 
was added and the solution was stirred at room temperature 
for 30 minutes. The reaction was then poured into water 
(300 ml) and the resulting yellow solid was collected by 
filtration. 	The product was recrystallised from 
DCM/petrol (b.p. 40-60°C) to afford the required compound 
(81) 	(5.0g, 	87%) ; m.p. 	111-115°C 	(Lit. 92  110-111°C) ; 
(Found: C, 58.00; H, 4.27; N, 8.42, Caic. for C 16 H 14N 2 0 6 , 
C, 58.20; H, 4.24; N, 8.48%); t.1.c. (A) Rf 0.71, (D) Rf 
0.78; umax  (DCM), 1740 cm-1  (ester CO); Xmax  (DCM) 276 nm 
(E 18000 dm 3 mo1 1 cm); 6H  CDCl 3 , 80 MHz) 7.3-8.2 (4H, 
m, aromatics), 4.63 (3H, in, CH, CH 2 ), 1.96 (3H, s, CH 3 ); 
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c 	[CDC1 31 	50 	MHz] 	170.4 	(CO), 	147.0, 	146.7 
(quaternaries), 129.0, 123.9 (aromatic CH's), 65.1 (Cu 2), 
49.2 (Cu), 20.5 (CH 3). 
Dibenzofulvene (82 
Using flash vacuum pyrolysis apparatus devised by 
McNab9411 9-fluorenylmethyl acetate (80) (800 mg, 3.3 minol) 
was pyrolised [Tf 800°C, Ti  100°C, P 5 x 10 	Torr, t 1 
hour] to give the required compound (82); m.p. 49-50.5°C, 
(Lit.95 46-48°C); Xmax 307 (E 9400 din 3 mol' cm 1), 296 fin 
(11000); oH [CDC1 3, 60 MHz] 7.17-7.93 (8H, in, aromatics), 
6.05 (2H, s, CH 2). 
The piperidine adduct (84) was formed by the addition 
of the pyrolysis product to 20% piperidine in DMF. Xmax 
300 (E 9200 din 3 mol' cm-1), 289 nm (6800). 
1. 1-Bis (4 '-nitrophenyl) ethene (83) 
Pyrolysis of 2, 2'-bis(4 '-nitrophenyl)ethyl acetate 
(81) (50 mg, 0.2 inmol) [Tf 800°C, Ti200°C, P 1 x 10 
Torr, t 1 hour] produced an intractable brown solid. 
2,2'-Bis(41-nitrophenyl)ethyl acetate (81) (1.4g, 
2.8 inmol) was dissolved in chloroform (15 ml). 	DBU (4 
drops) was added and the solution stirred for 15 minutes. 
The reaction mixture was diluted with chloroform (10 ml) 
and washed with 2M HC1 (2 x 20 ml), water (2 x 20 ml), 1M 
NaOH (2 x 20 ml) and brine (1 x 20 ml). The solution was 
dried over Na 2SO 4 and evaporated to give a yellow solid. 
The material was recrystallised from chloroform/ petrol 
(b.p. 40-600C), to give the required compound (83) (0.47 
g, 62%); m.p. 175-176°C (Lit.92 175-1760C); t.l.c. (E) Rf 
0.42, (F) Rf 0.73; Xmax (DCM) 303 nm (E 21000 din 3 mol' 
CM-1); 0H  (CDC1 3, 60 MHz), 8.27 (4H, d, aromatics), 7.50 
(4H, d, aromatics), 5.80 (2H, s, CH 2). 
The piperidine adduct (85) was formed by addition of 
(83) to a 20% piperidine/DMF solution. 	>max = 280 fin (E 
14000 din 3 mo1 1 cm-1). 
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Studies on IPNS(243-267)-(Aua)-IPNS(92-120) 
HPLC Assay 
Buffer A : 
	
	50 mM Tris HC1, pH 7.1, containing 2.8 mM 
ascorbic acid and 70 VM FeSO 4 . 
Buffer B : 	50 mM Tris HC1, pH 7.1, containing 2.8 mM 
ascorbic acid, 70 pM FeSO4 and 70 ItM 
L-histidine. 
The peptides used were IPNS(243-267)-(Aua)-
IPNS(92-120) where n = 1 (43), or n = 3 (48). 
(a) -(L--a-aminoadipy1)-L-cysteinvl-D-Valifle (LLD-ACV) 
The ACV (1 mg) was incubated in 66.7 mM dithiothreitol 
(DTT) (125Al) for 2 hours at 25°C prior to use. 
The peptide (0.2 mg, 28 nmoles) was dissolved in the 
two phase system of the required buffer (0.4 ml) and 
n-octane (0.4 ml). 	The ACV/DTT solution (1.3 tl, 28 
ninoles) was added and the aqueous phase (20 l) was 
analysed by reverse phase HPLC at time t=0. The reaction 
was then incubated at 200 or 40°C for 1-5 hours after which 
methanol (0.4 ml) was added and a 30 ul aliquot injected 
on HPLC. A zBondapak column (300 x 3.9 nm, C 8 , 125 A, 10 
1) was employed with a flow rate of 1 ml minl and UV 
monitoring at 214 nm. The column was eluted with 50 mM 
KH 2 PO 41  pH 7.0 for 25 minutes. The methanol content was 
then increased from 0 to 13% over 5 minutes and held 
isocratic at 13% for 10 minutes. Washing was achieved by 
increasing the methanol content from 13 to 20% over 5 
minutes and eluting isocratically at 20% for 10 minutes 
before returning to 0% over 5 minutes. 	The retention 
times of the compounds involved were established to be 
Isopenicillin N (15 min.), DTT-reduced (21 mm.), 
DTT-oxidised (31 mm.), ACV-monomer (33 mm.) and 
ACV-dimner (42 mm.). The results obtained are summarised 
in Table (14). 
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Appearance of a Peak with Rt=15 mm 
+I4eOH 
Peptide Buffer Temp/°C t=O, Peak st/h 	Peak st/h 	Peak 
- A 20 - 1.5 	small 3.5 	small 
- B 20 - 2.5 - 
43 A 20 - 2.5 	small 3.0 	- 
43 B 20 small 1.5 medium 2.5 medium 
48 A 20 - 2.0 	- 3.5 	- 
48 B 20 - 2.0 small 3.0 small 
- A 40 - 3.0 	- 
- B 40 - 3.0 - 
43 A 40 - 3.0 	- 
43 B 40 - 1.5 	- 2.5 - 
48 A 40 - 3.0 	large 
48 B 40 - 2.5 - 
At = Incubation period 
Table 14. 
(b) Bis-phenylacetyl-L-cvsteinyl-D-Valine (PCV) 
The PCV (10 mg) was suspended in water (80 ml) and 1M 
NaOH was added until the PCV just dissolved. The solution 
was made up to 0.5 ml with 66.7 mM DTT and incubated at 
25°C for 2 hours prior to use. 
The reactions were carried out as described for ACV 
and analysed using the described HPLC system. The column 
was eluted with 70% 50mM KH 2PO 41  pH 7.0, 30% methanol for 
30 minutes. The methanol content was then increased from 
30 to 60% over 5 minutes then back down to 30% over 5 
minutes. The retention times of the components involved 
were established to be: DTT (7 mm.), PCV-monomer (18.5 
mm.), Penicillin C (22 mm.), PCV-diiner (42 mm.). The 
results are summarised in Table (15). 
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Pepide Buffer Temp/°C 
Appearance of a Peak with Rt=22 min 
t = 0 st/h + 0.4 ml MeOH 
- A 20 - 1.5 	 - 
- B 20 - 2.0 - 
43 A 20 - 2.0 	 - 
43 B 20 - 2.5 - 
48 A 20 - 2.5 	 - 
48 B 20 - 2.0 - 
- A 40 - 2.0 	 - 
- B 40 - 2.0 - 
43 A 40 - 2.0 	 - 
43 B 40 - 2.0 - 
48 A 40 - 2.0 	 - 
48 B 40 - 2.0 - 
Table 15. 
Biological Assays 
1. Inhibition of B. Calidolactis 
(a) ACV 
Buffer C : 
	
	50ntM Tris HC1, pH 7.1, containing 
5.6 mM ascorbic acid and 140 1zM FeSO 4 . 
The ACV (1 mg) was incubated with 66.7 inN DTT (125 1) 
for 1 hour at 20°C prior to use. 
The peptide (0.2 mg, 28 ninoles) was dissolved in the 
two phase system of buffer C (200 Al) and n-octane 
(200 p1). 	The reaction was incubated at 20°C for 2.5 
hours. Isopeniciulin N formation was assayed using a hole 
plate assay with B. Calidolactis as the indicator 
organism. 	80 pl of each reaction was assayed in 
duplicate. The reactions were as follows: 




Peptide (48) (0.2 mg, 28 nmoles) + ACV (1.3 Al, 
28 nmoles). 
Peptide (43) (0.2 mg, 28 nmoles). 
Peptide (48) (0.2 mg, 28 nmoles). 
ACV (1.3 !L1, 28 nmoles). 
Standard isopenicillin N solutions containing 10, 15, 
20, 25, 30, 35, 40 and 50 ng of isopenicillin N were also 
incubated on the plate. The plate was incubated overnight 
at 48°C then examined for zones of inhibition. A faint 
zone was observed around sample 2, approximating to an 
equivalent of about 15 ng of isopenicillin N. 
(b) Peptide (48) with ACV 
Peptide (48) was incubated with the ACV monomer for 3 
hours in buffer C (200 jl) and n-octane (200 Al), in the 
conditions described below. 
Peptide (0.2 mg, 28 nmoles) + ACV (1.3 pl, 28 nmoles), 
20°C 
Peptide (0.2 mg, 28 nmoles), 20°C 
Peptide (0.2 mg, 28 nmoles) + ACV (1.3 pl, 28 nmoles), 
40°C 
Peptide (0.2 mg, 28 nmoles), 40°C 
Peptide (0.2 lug, 28 nmoles) +ACV (1.3 pl, 28 nmoles), 
shaken at 20°C 
Peptide (0.2 mg, 28 nmoles), shaken at 20°C 
Peptide (0.4 mg, 56 mmoles) + ACV (2.6 pl, 56 nmoles), 
20°C 
Peptide (0.4 mg, 56 nmoles), 20°C 
80 jtl of each reaction was assayed in duplicate using 
a B. Calidolactis hole-plate assay. 	Standard iso- 
penicillin N solutions containing 10, 15, 20, 25 and 30 ng 
of isopenicillin N were also assayed. 	The plate was 
incubated overnight at 48°C. No zones of inhibition were 




The PCV dimer was reduced to the monomer as described 
for the HPLC assay, prior to use. The peptide (1 mg, 160 
nmoles) was dissolved in the two phase system of buffer C 
(2 ml) and n-octane (2 ml). 	The reactions were as 
follows: 
Peptide (43) (1 mg, 150 nmoles) + PCV (5 Al, 
300 nmoles). 
Peptide (43) (1 mg, 150 nmoles). 
Peptide (48) (1 mg, 150 nmoles) + PCV (5 Al, 
300 nmoles). 
Peptide (48) (1 mg, 150 nmoles). 
PCV (5 Al, 300 nmoles). 
Reactions 1 to 5 were shaken at 20°C for 2.5 hours. 
The n-octane layer was then removed and the pH of the 
aqueous layer was adjusted to 5.5 with phosphoric acid. 
The aqueous layer was then extracted with methyl isobutyl 
ketone (3m1 x 2). The methyl isobutyl ketone was back 
extracted with 0.5M potassium phosphate, pH 7.0 (300 izl). 
The two phases were separated by centrifugation and 80 Al 
aliquots of the aqueous phase were assayed in duplicate, 
on a B. Calidolactis hole-plate assay. 	Standard 
penicillin G solutions were also placed on the plate, 
containing 10, 15, 20, 25, 30, 40 and 50 ng of penicillin 
G. The plate was incubated overnight at 48°C. No zones 
of inhibition were observed around samples 1-5. 
(d) Assay in the presence of IPNS 
Reactions 1 to 4 were prepared in buffer C (200 izl) 
and n-octane (200 Al). 
ACV (2.8 Al, 63 nmoles). 
Peptide (43) (0.4 mg, 63 nmoles) + ACV (2.8 Al, 
63 nmoles). 
Peptide (48) (0.4 mg, 63 nmoles) + ACV (2.8 Al, 
63 nmoles). 
ACV (2.8 jul, 63 nmoles) - no octane. 
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The solutions were shaken at 20°C for 1 hour after 
which 2 t1 of an IPNS containing solution was added. The 
reactions were then shaken at 25°C for 1 hour. Aliquots 
(2 x 80 l) of each reaction were assayed on a B. 
Calidolactis hole-plate assay, standard 80 jil solutions 
containing 10, 15, 20, 30, 40 and 50 ng of isopenicillin N 
were also included. The plate was incubated overnight at 
48°C. 	The zones of inhibition around each sample were 
measured and found to be as shown in table (16). 
Diameter of Standard Diameter of 
inhibition zone/ solution inhibition zone, 
Sample mm Isopenicillin mm 
N/ng 
1 30.3,30.8 10 - 
2 trace,trace 15 trace (- 11) 
3 20.4,20.9 20 12.7 




Table 16. Inhibition Zone Diameters. 
2. 8-Lactamase Induction Assay 
Reactions 1 to 10 were prepared in buffer C (200 zl) 
and n-octane (200 p1). 
Peptide (43) (0.2 mg, 28 nmoles) + ACV (1.3 tl, 
28 nmoles). 
Peptide (48) (0.2 mg, 28 nmoles) + ACV (1.3 pl, 
28 nmoles). 
ACV (1.3 pl, 28 nmoles). 
Peptide (43) (0.2 mg, 28 nmoles). 
Peptide (48) (0.2 mg, 28 nmoles). 
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Peptide (43) (0.2 mg, 28 nmoles) + PCV (1 pl, 
56 nmoles). 
Peptide (48) (0.2 mg, 28 nmoles) + PCV (1 z1, 
56 nmoles). 
PCV (1 t1, 56 nmoles). 
Peptide (43) (0.2 mg, 28 nmoles). 
Peptide (48) (0.2 mg, 28 nmoles). 
The reactions were shaken at 25°C for 2.5 hours then 
incubated at 37°C for 2.5 hours on a B. lichenitorrais 
hole-plate assay. 	Discs of Rifampicin and Cloxacillin 
(5 g) were placed on the plate as negative and positive 
controls respectively. 	After incubation the plate was 
flooded with nitrocephin (500 Ag m1 1). 	No red 
colouration indicative of the presence of a 3-lactarnase 
was observed around the wells containing reactions 1 to 
10. 
Polyclonal Antibodies to IPNS(1-21)96 (53) 
Anti-sera against BSA-Cys-IPNS(1-21) conjugate were 
raised in seven rabbits. These anti-sera were studied in 
ELISA tests and on Western blots. 
ELISA - to determine the IC., 
Microtitre plates were coated with IPNS(1-21)cys-
ovalbumin conjugate (20ng/100l well) by passive 
adsorption. 	Non-specific binding sites were saturated 
with (250 jl, 0.5% ovalbumin in tris-buffered saline, pH 
7.4/well) . 	IPNS(1-21) (53) or cysIPNS(1-21) (55) was 
incubated with 50 V1 of anti-serum (diluted in 0.5% 
ovalbumin, TBS pH 7.4) for 60 minutes at 37°C. 	The 
microtitre plates were then flushed with this solution. 
The inicrotitre plates were washed and bound rabbit IgG was 
detected by sequential incubation with biotinylated 
anti-rabbit IgG, streptavidin-alkaline phosphatase and 
p-nitrophenyl phosphate. From the readings of 0D405, the 
concentration of peptide giving 50% inhibition of the 
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response to each anti-serum (IC..) was determined. 
Rabbit serum 
IC50 vs IPNS(1-21) 
ng/ml 
IC50 vs cysIPNS(1-21) 
ng/xnl 
6233 400 15 
6383 > 10,000 > 3,000 
6479 > 10,000 3,000 
6796 200 10 
6426 2,000 3,000 
6271 1,000 300 
6454 500 200 
Table 17. 
ELISA - to determine the titre 
Microtitre plates were coated with IPNS(1-21)cys-
ovalbumin conjugate (20 ng/lOO t1 well) by passive 
adsorption. After saturating non-specific binding sites 
(250 yl , 0.5% ovalbuinin in tris-buffered saline, pH 
7.4/well) and washing, 50 pl anti-serum (0.5% ovalbumin in 
TBS pH 7.4) was added and incubated for 60 min at 37°C. 
The microtitre plates were washed and bound rabbit IgG was 
detected as described for the previous ELISA. From the 
readings of 0D405 the dilution of anti-serum giving a 
4-fold higher response compared with the non-specific 
binding control (primary antibody omitted) was determniend 
(= titre), see Table 18. 
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Antigen from IPNS-producing strains was subjected to 
SDS-PAGE followed by electrotransfer onto a PVDF 
(Immobilon) membrane. 	The antigen-bearing membrane was 
probed with the rabbit anti-sera (diluted 1/500 in 0.5% 
BSA, 0.25% bovine gamma-globulin, TBS pH 7.4) raised 
against BSA-Cys-IPNS(1-21). Bound rabbit IgG was detected 
by a sequential incubation with biotinylated anti-rabbit 
IgG, streptavidin and silver enhancer. 
A major band was detected at 40 kDa, with four minor 
bands at approximately 30 kD. 	The intensity of these 
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FmocGly-(OCH2C6H4OR) 	 95 
FmocTyr(t-Bu)-(OCH2C6H4OR) 	 95 
FniocPro-(OCH2C6H4OR) 	 95 
FmocLys(Boc)-(OCH2C6H4OR) 	 95 
IPNS(92-120) 	 97 
IPNS(243-267) 99 
FmocAua-IPNS (92-120) (t-butylthio) 	 100 
IPNS (243-267) -Aua-IPNS (92-120) 102 
IPNS(243-267)-(Aua) 3 -IPNS(92-120) 	 114 
IPNS(1-21) 	 117 
Cys-IPNS(1-21) 	 123 
IPNS(268-291) 	 124 
Cys-IPNS(268-291) 	 128 












Fmoc-L-Leu-L--PheGlyOH 	 141 
Finoc-L-Leu-L-Phe-L-ProOH 	 141 
Fxnoc-L--Leu-L--ProGlyOH 	 142 
Ph 2 PO 2 POPh 2 	 140 
9-Fluorenylinethyl Acetate 	 145 
2,2-Bis(4 '-nitrophenyl)ethyl Acetate 	 145 
Dibenzofulvene 	 146 
1, 1-Bis (4' -nitrophenyl) ethene 	 146 
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